{
    "1": {
        "question": "<div class=\"qtext\"><p>A 52-year-old man with CKD stage 3 is referred for outpatient evaluation of recurrent nephrolithiasis. He has a past medical history of hypertension, type 2 diabetes, and class 3 obesity status post Roux-en-Y gastric bypass 2 years ago. He has passed an occasional stone in the past, but for the last 6 months, the frequency has increased, and he is now passing stones every few weeks</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>4.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>24 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>1.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Calcium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>9.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>    </strong>Phosphorus </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>4.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    PTH, intact</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>55 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>10–65</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    25-Hydroxyvitamin D</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>31 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>30–60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24-Hour urine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>   </strong>Calcium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>380 mg </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>&lt;300, male</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>   </strong>Oxalate </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>95 mg </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>&lt;40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>   </strong>Uric acid </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>812 mg </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>250–750</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>    </strong>pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>5.0</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px; vertical-align: top; width: 29.8722%;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound shows multiple, bilateral, non-obstructing stones and increased echogenicity.</p>\n<p><strong> Which ONE of the following is the MOST likely cause of this patient’s recurrent stone disease?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Primary hyperoxaluria"
            },
            {
                "label": "B.",
                "text": "Hypercalciuria"
            },
            {
                "label": "C.",
                "text": "Hyperuricosuria"
            },
            {
                "label": "D.",
                "text": "Gastric bypass"
            },
            {
                "label": "E.",
                "text": "Excess vitamin C intake"
            }
        ],
        "correct_answer": "Gastric bypass",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient likely has recurrent nephrolithiasis caused by enteric hyperoxaluria from his prior Roux-en-Y gastric bypass.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gastric bypass, specifically the Roux-en-Y procedure, has been associated with enteric hyperoxaluria and increased risk of calcium oxalate kidney stones.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are two major sources of oxalate: exogenous food intake and endogenous hepatic metabolism. Enteric hyperoxaluria occurs as a result of fat malabsorption, often caused by inflammatory bowel disease, short gut syndrome, or Roux-en-Y gastric bypass surgery. In healthy intestines, enteric calcium binds to enteric oxalate, chelating it and preventing oxalate from being absorbed into the systemic circulation. When fatty acids and bile acids remain in the intestinal lumen, they bind to calcium, preventing the chelation of enteric oxalate. This unbound oxalate can be absorbed and excreted, leading to hyperoxaluria and stone formation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperoxaluria is caused by several possible mutations in hepatic enzymes, leading to accumulation of oxalate in the blood and urine. Primary hyperoxaluria is predominantly a pediatric disease, with high rates of ESRD in childhood. This condition is often accompanied by liver failure, and liver-kidney transplantation is curative.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient’s 24-hour urine calcium and uric acid levels are slightly elevated, they are not the major causative factors in nephrolithiasis, whose incidence increased after bypass surgery consistent with enteric hyperoxaluria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vitamin C is metabolized to oxalate, and some cases of nephrolithiasis and nephrocalcinosis have been attributed to heavy vitamin C intake, but the clinical history suggests enteric hyperoxaluria as a more likely diagnosis.</p>\n</div>",
        "references": [
            "Duffey BG, Alanee S, Pedro RN, et al: Hyperoxaluria is a long-term consequence of Roux-en-Y gastric bypass: a 2-year prospective longitudinal study.J Am Coll Surg211(1): 8‒15, 2010",
            "Duffey BG, Pedro RN, Makhlouf A, et al: Roux-en-Y gastric bypass is associated with early risk factors for development of calcium oxalate nephrolithiasis.J Am Coll Surg206(6): 1145‒1153, 2008",
            "Upala S, Jaruvongvanich V, Sanguankeo A: Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis.Surg Obes Relat Dis12(8): 1513‒1521, 2016",
            "Cochat P, Rumsby G: Primary hyperoxaluria.N Engl J Med369(7): 649‒658, 2013"
        ]
    },
    "2": {
        "question": "<div class=\"qtext\"><p>A 32-year-old man with CKD stage 3a presents to nephrology clinic to discuss his disease prognosis and family planning. He was diagnosed with bilateral cystic kidney disease by ultrasound at age 17 after presenting with hypertension. He reports that his mother started HD at age 50, but he does not know any further details. </p>\n<p>On examination, his BP is 145/98 mm Hg, and his abdomen is distended. The remainder of the examination is unremarkable. </p>\n<p>CT scan of the abdomen and pelvis is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m1b1q10.png\" width=\"75%\"/><br/>\n<figcaption><em>Image courtesy of <span>J Am Soc Nephrol</span> 11(9): 1767‒1775, 2000</em></figcaption>\n</figure>\n<p><strong> Which ONE of the following gene products is MOST likely abnormal in this patient? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Polycystin-1"
            },
            {
                "label": "B.",
                "text": "Polycystin-2"
            },
            {
                "label": "C.",
                "text": "Uromodulin"
            },
            {
                "label": "D.",
                "text": "Tuberin"
            },
            {
                "label": "E.",
                "text": "Fibrocystin"
            }
        ],
        "correct_answer": "Polycystin-1",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has ADPKD caused by abnormal polycystin-1<em>.</em></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ADPKD is most commonly caused by mutations in the <em>PKD1 </em>and <em>PKD2 </em>gene loci, with approximately 78% of patients exhibiting <em>PKD1</em> mutations and abnormal polycystin-1 function. Polycystin-1 is a transmembrane mechanosensor located on primary cilia in renal tubule cells. Polycystin-2 is the gene product encoded by <em>PKD2</em> and is a calcium channel closely associated with polycystin-1<em>. </em>Patients with <em>PKD1</em> mutations are more likely to have earlier-onset disease than those with <em>PKD2 </em>mutations. Studies have shown that having a family member who developed ESRD by age 55 had a positive predictive value of 100% for a <em>PKD1</em> mutation. Although most patients with ADPKD remain asymptomatic until the fourth decade of life, childhood-onset ADPKD has been increasingly commonly diagnosed and may be incidentally discovered.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Abnormal tuberin function is implicated in tuberous sclerosis complex (TSC). Patients with TSC have a number of systemic manifestations. In the kidney, TSC frequently manifests as angiomyolipomas. Because the <em>TSC2</em> and <em>PKD1</em> genes are adjacent, patients with deletions involving both genes may present with manifestations of both TSC and ADPKD. In this case, the patient has no other clinical manifestations of TSC.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A mutation in the <em>UMOD</em> gene, encoding uromodulin, is the most common cause of autosomal dominant tubulointerstitial kidney disease (ADTKD), a disease that also causes slowly progressive cystic kidney disease, but kidney size is smaller and not marked by the large cysts of ADKPD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mutations in <em>PKHD1</em> genes lead to defects in fibrocystin and cause autosomal recessive polycystic kidney disease (ARPKD), which usually presents in children and adolescents. Although this patient presented at age 6, his CT scan shows large cysts in the kidneys and liver. Although ARPKD is also associated with liver involvement, this more commonly manifests as cystic dilation of biliary ducts (Caroli disease), with hepatobiliary fibrosis, recurrent cholestasis, and portal hypertension, rather than overt cystic liver. Additionally, patients with ARPKD typically demonstrate large, echogenic kidneys on ultrasound without discrete cysts.</p>\n</div>",
        "references": [
            "Gimpel C, Bergmann C, Bockenhauer D, et al: International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.Nat Rev Nephrol15(11): 713‒726, 2019",
            "Avni FE, Guissard G, Hall M, et al: Hereditary polycystic kidney diseases in children: changing sonographic patterns through childhood.Pediatr Radiol32(3): 169‒174, 2002",
            "Eckardt KU, Alper SL, Antignac C, et al: Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—a KDIGO consensus report.Kidney Int88(4): 676‒683, 2015",
            "Barua M, Cil O, Paterson AD, et al: Family history of renal disease severity predicts the mutated gene in ADPKD.J Am Soc Nephrol20(8): 1833‒1838, 2009",
            "Crino PB, Nathanson KL, Petri Henske E: The tuberous sclerosis complex.N Engl J Med355(13): 1345‒1356, 2006"
        ]
    },
    "3": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with a history of ESRD, treated with HD for the last 1.5 years, presents with painful lesions on his calves. His past medical history includes type 2 diabetes, hypertension, and atrial fibrillation. His medications include fosinopril, apixaban, insulin, multivitamins, sevelamer, and calcitriol. He is diagnosed with calciphylaxis. He is prescribed sodium thiosulfate (STS) thrice weekly with HD, and his calcitriol is discontinued. Despite these measures, he reports worsening of his pain and ulceration of the lesions on his calves.</p>\n<p>On skin examination, he has multiple large, stellate, ulcerated plaques on both medial calves, covered by thick black eschar and without surrounding erythema or purulence.</p>\n<p>Laboratory data are as follows:</p>\n<table></table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.9 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Phosphorus</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.7 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–4.5 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Albumin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.2 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">PTH, intact</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">132 pg/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">130–585 (dialysis patients)</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25-Hydroxyvitamin D</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">18 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">30–60</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Kt/V </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.7 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≥1.2</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Parathyroidectomy"
            },
            {
                "label": "B.",
                "text": "Change apixaban to warfarin"
            },
            {
                "label": "C.",
                "text": "Hyperbaric oxygen"
            },
            {
                "label": "D.",
                "text": "Cholecalciferol"
            },
            {
                "label": "E.",
                "text": "Surgical debridement"
            }
        ],
        "correct_answer": "Hyperbaric oxygen",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best treatment for this patient with calciphylaxis that has not improved with STS therapy is hyperbaric oxygen (HBO) treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Managing calciphylaxis, or calcemic uremic arteriolopathy (CUA), remains challenging in patients with ESRD. The cause of CUA remains obscure and may be multifactorial, but the pathophysiology consists of calcium phosphate deposition in the walls of dermal and subcutaneous arterioles, resulting in exquisitely painful, ischemic skin necrosis. Lesions typically begin as indurated purple plaques or livedo reticularis, often in areas of subcutaneous fat and/or repetitive trauma or irritation. Some of the risk factors for CUA in patients with ESRD include warfarin, female sex, obesity, hypercoagulability, connective tissue disorders, diabetes, liver disease, and exposure to various other medications (corticosteroids, iron, calcium-containing phosphate binders, and possibly vitamin D and its analogues). Changing anticoagulation from apixaban to warfarin is contraindicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Management focuses mainly on risk factor management, wound care, and analgesia. Intensive dietary counseling should be given to control hyperphosphatemia in combination with non–calcium-based phosphate binders. STS is often trialed for 4‒6 weeks despite contradictory meta-analysis data for this off-label use. Ongoing wound care is essential, and surgical debridement may be necessary for control of infection but is reserved for refractory cases or those with concurrent active infection, because any surgical wound is likely to heal poorly. In this case, the findings of intact eschar do not warrant debridement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Concurrent management of hyperparathyroidism is recommended. Vitamin D and activated vitamin D analogues are typically avoided in the setting of calciphylaxis as they can result in higher serum calcium and phosphorus concentrations or, in some cases, may trigger calciphylaxis. Surgical parathyroidectomy (or medical parathyroidectomy with cinacalcet) is often used in the setting of severe hyperparathyroidism, but the role of such therapy in a patient whose PTH level is at or below goal is not established.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Additional medical management strategies used in some cases include intensification of dialysis, bisphosphonates, vitamin K, systemic thrombolysis with a plasminogen activator, endothelin antagonists, and pentoxifylline.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although randomized controlled trials are lacking, case reports and case series suggest that HBO can have a favorable impact on most patients with CUA who can tolerate the treatment. HBO would be a reasonable approach to managing this patient, who has nonhealing lesions despite good control of identifiable risk factors.</p>\n</div>",
        "references": [
            "Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, et al: Treatment of calciphylaxis in CKD: a systematic review and meta-analysis.Kidney Int Rep4(2): 231‒244, 2018",
            "An J, Devaney B, Yang Ooi K, et al: Hyperbaric oxygen in the treatment of calciphylaxis: a case series and literature review.Nephrology (Carlton)20(7): 444‒450, 2015",
            "McCarthy JT, El-Azhary RA, Patzelt MT, et al: Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis.Mayo Clin Proc91(10): 1384‒1394, 2016",
            "Velasco N, MacGregor MS, Innes A, MacKay IG: Successful treatment of calciphylaxis with cinacalcet—an alternative to parathyroidectomy?Nephrol Dial Transplant21(7): 1999‒2004, 2006",
            "Santos PW, He J, Tuffaha A, Wetmore JB: Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.Int Urol Nephrol49(12): 2247‒2256, 2017",
            "Don BR, Chin AI: A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies.Clin Nephrol59(6): 463‒470, 2003"
        ]
    },
    "4": {
        "question": "<div class=\"qtext\"><p>A 35-year-old woman presents to the emergency department after a fall complicated by a fracture of her distal tibia. Her past medical history includes HIV and acne vulgaris. Her HIV has been well controlled with bictegravir, emtricitabine, and tenofovir\n    for the last 2 years. On review of systems, she reports polyuria and polydipsia.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Results</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5 .0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                116 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                110 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong><b>Which ONE of the following is the MOST likely\ndiagnosis?</b> </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Fanconi syndrome"
            },
            {
                "label": "B.",
                "text": "Diabetes mellitus"
            },
            {
                "label": "C.",
                "text": "Distal renal tubular acidosis"
            },
            {
                "label": "D.",
                "text": "Vitamin D deficiency"
            },
            {
                "label": "E.",
                "text": "Hyperparathyroidism"
            }
        ],
        "correct_answer": "Fanconi syndrome",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with electrolyte derangements and a non-anion gap metabolic acidosis most likely has Fanconi syndrome due to tenofovir.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fanconi syndrome, or a proximal tubulopathy, presents with numerous signs and symptoms of proximal tubular dysfunction. Patients with Fanconi syndrome typically have hypokalemia and hypophosphatemia from potassium and phosphorus wasting, respectively. Polyuria results from impaired sodium and water reabsorption. Loss of bicarbonate and glucose reabsorption in the proximal tubule result in a proximal renal tubular acidosis (RTA) and glucosuria despite euglycemia (note that the other common cause of glucosuria with euglycemia is the use of sodium-glucose cotransporter 2 inhibitors).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To categorize the renal response to hypophosphatemia, the fractional excretion of phosphorus (FEphos) can be calculated as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEphos = [phosphorus (urine) × creatinine (serum)] ÷ [phosphorus (serum) × creatinine (urine)] × 100%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEphos = [40 × 1] ÷ [1.8 × 100] × 100% = 22%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEphos greater than 5–20% suggests a renal etiology of hypophosphatemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fanconi syndrome can be genetic or acquired. This patient has a history of long-standing tenofovir use, which can cause acquired Fanconi syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has polyuria, polydipsia, and glucosuria, she has a random blood glucose level &lt;200 mg/dL without symptoms, which is not consistent with a diagnosis of diabetes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A type 1 (distal) RTA would present with hypokalemia and a non-anion gap metabolic acidosis, but renal phosphate or glucose wasting is not seen in distal RTA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a fracture and osteomalacia in settings of a low phosphorus level from increased urinary phosphate wasting, but vitamin D deficiency would not cause renal glucose wasting or non-anion gap metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyperparathyrodism also presents with hypophosphatemia and a high FEphos, but the remainder of the findings, as previously discussed, are not consistent with hyperparathyroidism.</p>\n</div>",
        "references": [
            "Ansermet C, Moor MB, Centeno G, et al: Renal Fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytrophic retroviral receptor in the nephron.J Am Soc Nephrol28(4): 1073–1078, 2017",
            "Hall AM, Bass P, Unwin RJ: Drug-induced renal Fanconi syndrome.QJM107(4): 261–269, 2014",
            "Linn BS, Vandiver JW, Ren D, Shassetz J: Fanconi syndrome induced by concomitant HIV PrEP and tacrolimus.J Investig Med High Impact Case Rep9:23247096211050207, 2021"
        ]
    },
    "5": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man is admitted to the hospital with confusion and hypoxic respiratory failure. He has a long history of alcohol use disorder and untreated hepatitis C. He was subsequently diagnosed with COVID pneumonia and was treated with steroids and remdesivir. His respiratory symptoms have improved during his hospital course, but on hospital day 3, he developed abdominal distension and pain and was noted to have an ileus. His medications include dexamethasone, heparin, and pantoprazole.</p>\n<p>On examination, his BP is 117/52 mm Hg, and heart rate is 80/min. He is afebrile, and oxygen saturation is 100% on 2 L of oxygen by nasal cannula. His lungs have bilateral coarse breath sounds. His abdomen is distended and tympanic. He has no lower extremity edema. </p>\n<p>Laboratory data are as follows:</p>\n<table>\n</table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                111 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2<s> </s></sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.96 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                85 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.0 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Phosphorus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Magnesium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                34.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                125.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals no protein or blood. Specific gravity is 1.020.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of hypomagnesemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Chronic alcohol use"
            },
            {
                "label": "B.",
                "text": "Hyperparathyroidism"
            },
            {
                "label": "C.",
                "text": "Gitelman syndrome"
            },
            {
                "label": "D.",
                "text": "Pantoprazole"
            },
            {
                "label": "E.",
                "text": "Chronic diarrhea"
            }
        ],
        "correct_answer": "Chronic alcohol use",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with alcohol use disorder and renal magnesium wasting, chronic alcohol use is the most likely etiology of his hypomagnesemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypomagnesemia is common in hospitalized patients with a history of heavy alcohol use. A study of patients with chronic alcohol use and hypomagnesemia demonstrated excess urinary excretion of magnesium caused by alcohol-induced tubular dysfunction. In this study, abstinence from alcohol led to a reversal of this finding.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Differentiating between hypomagnesemia from gastrointestinal (GI) losses and kidney losses may be done by measuring a 24-hour urine for magnesium excretion or calculating the fractional excretion of magnesium (FEMg) on a random urine specimen. The serum magnesium is multiplied by 0.7 because only ~70% of the magnesium in the serum is unbound to albumin or other anions and, consequently, freely filtered at the glomerulus. Patients with hypomagnesemia caused by GI losses will have FEMg &lt;2%, and patients with hypomagnesemia caused by renal wasting will have FEMg &gt;4%.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEMg = (Mg (U) <span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>×</span> Cr (S)) ÷ (0.7 <span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>×</span> Mg (S) <span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>×</span> Cr (U)) <span style='color: rgb(0, 0, 0); font-family: \"Times New Roman\"; font-size: medium; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;'>×</span> 100%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEMg = 38%, which indicates renal wasting.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypomagnesemia is a common finding in hospitalized patients and is frequently attributable to GI losses or cell shift (refeeding syndrome). GI-associated magnesium depletion may occur because of diarrhea, malabsorption, steatorrhea, and small bowel bypass surgery. Proton-pump inhibitors also may cause hypomagnesemia. However, the high FEMg suggests a renal, not GI, cause.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A challenge in measuring the relevant parameters in a hospitalized patient is timing sampling around the administration of magnesium supplementation, which could transiently affect findings. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperparathyroidism may be associated with hypomagnesemia in some patients. The increased filtered calcium load in hypercalcemic states will deliver more calcium to the loop of Henle; the ensuing rise in calcium reabsorption will diminish that of magnesium. However, this patient does not have hyperparathyroidism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gitelman syndrome is a form of familial renal magnesium wasting and associated with hypokalemic metabolic alkalosis, which is not seen in this patient. </p>\n</div>",
        "references": [
            "Topf JM, Murray PT: Hypomagnesemia and hypermagnesemia.Rev Endocr Metab Disord4(2): 195–206, 2003",
            "DeMarchi S, Cecchin E, Basile A, et al: Renal tubular dysfunction in chronic alcohol abuse—effects of abstinence.N Engl J Med329(26): 1927–1934, 1993",
            "Agus ZS: Mechanisms and causes of hypomagnesemia.Curr Opin Nephrol Hypertens25(4): 301–307, 2016"
        ]
    },
    "6": {
        "question": "<div class=\"qtext\"><p>A 77-year-old man was admitted to the hospital 5 days ago for AKI and hypercalcemia. He has a history of CKD stage 3b with a baseline creatinine level of 1.4 mg/dL, bladder cancer with bone metastases, type 2 diabetes, and coronary artery disease. He complained of lightheadedness upon standing, nausea, and weakness. Outpatient medications include atorvastatin, gabapentin, glipizide, and insulin.</p>\n<p>BP is currently 101/48 mm Hg, heart rate is 105/min, and temperature is 37.6°C. On examination, he is lethargic but arousable. He is cachectic with dry oral mucosa and skin tenting. Heart and lung examinations are unremarkable. He has an indwelling urinary catheter, and recorded urine output has been 2.5–3 L/day.</p>\n<p>Laboratory data are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Day 1</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Day 2</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16.3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p>The patient has been initially managed with 0.9% normal saline IV and has received 2 doses of calcitonin 300 units intramuscularly and pamidronate 90 mg IV on the day of admission.</p>\n<p><strong> Which ONE of the following is the MOST appropriate next step in medical management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Calcitonin"
            },
            {
                "label": "B.",
                "text": "Sevelamer"
            },
            {
                "label": "C.",
                "text": "Furosemide"
            },
            {
                "label": "D.",
                "text": "Denosumab"
            },
            {
                "label": "E.",
                "text": "Hydrocortisone"
            }
        ],
        "correct_answer": "Denosumab",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best next step in management of this patient with humoral hypercalcemia of malignancy, who has not responded adequately to IV fluid, bisphosphonate, and calcitonin is denosumab.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypercalcemia in this patient with metastatic cancer is due to excessive osteoclast activation. The receptor activator of nuclear factor-κB (RANK) on osteoblasts binds to and activates RANK ligand (RANK-L) on osteoclast precursors, leading to osteoclast maturation, bone resorption, and hypercalcemia. Denosumab is a fully human monoclonal antibody that binds to RANK-L, blocking osteoclast activation. Denosumab is not cleared by the kidneys, so its use is not restricted in patients with AKI or CKD. Hypocalcemia is observed in approximately 5% of patients receiving this medication.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although calcitonin may lower the serum calcium within several hours, patients tend to develop a tolerance or tachyphylaxis to this medication after 24–48 hours. Given the severity of hypercalcemia and its refractoriness to previous doses of calcitonin, redosing would not be the next best step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sevelamer HCl or carbonate is a non-calcium-based phosphate binder used to manage chronic hyperphosphatemia in patients with advanced CKD or ESRD. In this case, hyperphosphatemia is attributable to AKI and should improve as AKI resolves with successful treatment of hypercalcemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with severe hypercalcemia are frequently hypovolemic at presentation due to nausea, vomiting, and hypercalcemia-mediated diuresis and aquaresis. This patient had orthostatic symptoms and continues to be hypotensive and tachycardic, so ongoing volume resuscitation rather than diuresis would be recommended.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Corticosteroids have been used successfully to treat hypercalcemia mediated by extrarenal calcitriol production from monocytes/macrophages, which is important for patients with lymphoma or sarcoidosis but is less relevant in this patient, who has humoral hypercalcemia of malignancy. Corticosteroids inhibit the 1-α hydroxylation of 25-hydroxyvitamin D, decreasing intestinal absorption of ingested calcium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is worthwhile to note that, although long-term administration of bisphosphonates is generally discouraged in patients with advanced CKD or ESRD because of concerns for progression of CKD and lack of efficacy, among others, the acute use of these drugs in AKI caused by hypercalcemia is appropriate. Pamidronate, which is shorter-acting, is preferred by some in this setting.</p>\n</div>",
        "references": [
            "Qi WX, Lin F, He AN, et al: Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.Curr Med Res Opin29(9): 1067–1073, 2013",
            "Zagzag J, Hu MI, Fisher SB, Perrier ND: Hypercalcemia and cancer: differential diagnosis and treatment.CA Cancer J Clin68(5): 377–386, 2018",
            "Hu MI: Hypercalcemia of malignancy.Endocrinol Metab Clin North Am50(4): 721–728, 2021",
            "Robinson DE, Sanni Ali M, Strauss VY, et al: Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.Health Technol Assess25(17): 1–106, 2021"
        ]
    },
    "7": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman with CKD stage 5 secondary to IgA nephropathy presents for follow-up. She notes progressive fatigue, decreased appetite, and nausea over the last few months. She has lost 4 kg over the last month. She takes furosemide and reports a urine output of 1.5 L/day.</p>\n<p>On examination, BP is 154/86 mm Hg, and heart rate is 85/min. She has 1+ lower extremity edema bilaterally. Heart and lung examinations are unremarkable. She does not have a pericardial rub. She has a mild bilateral hand tremor but no asterixis.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                16 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                450 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585 (dialysis patients only)\n            </td>\n</tr>\n</tbody>\n</table>\n<p>She is an emergency medicine physician and frequently works an erratic schedule. Lately, work has been difficult due to her symptoms. She is interested in starting PD, and she is concerned that her work schedule may cause her to miss 1–2 days of PD per week but would like to continue working as long as possible. She has a potential living kidney donor undergoing evaluation, but her transplant center has informed her that it will likely be at least 6 months until she can receive a kidney transplant. </p>\n<p><strong> Which ONE of the following is the MOST appropriate plan for renal replacement therapy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Start home HD 4–5 days per week"
            },
            {
                "label": "B.",
                "text": "Start in-center HD 3 days per week"
            },
            {
                "label": "C.",
                "text": "Await pre-emptive transplantation"
            },
            {
                "label": "D.",
                "text": "Start PD 4–5 days per week"
            }
        ],
        "correct_answer": "Start PD 4–5 days per week",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with CKD stage 5 with uremic symptoms but good residual kidney function, incremental PD (IPD) is the most appropriate initial plan for renal replacement therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This individual would benefit from dialysis due to her uremic symptoms. She is interested in PD, but daily dialysis is not currently feasible. IPD should be considered as her starting modality in a patient-centered approach to dialysis.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IPD is a strategy in which less than “standard” PD is prescribed to account for the contribution of residual kidney function (RKF). Peritoneal clearance is frequently less than the goal weekly Kt/V, but the combination of peritoneal and RKF clearance meets or exceeds the weekly Kt/V goal. This modality should be prescribed with the intent to increase the dose of PD as RKF wanes or symptoms worsen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potential benefits of IPD include a less onerous prescription initially, less anxiety in starting PD, more time to build confidence in the therapy, and better ability to continue work and other daily activities, which is important to this physician.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thus far, data support IPD as an initial dialysis modality in those with significant RKF. One randomized trial comparing an initial prescription of 3 versus 4 exchanges showed no difference in eGFR, urine volume, anuria-free survival, mortality, or technique failure after 1 year. There was a nonsignificant trend to less peritonitis in the group performing 3 daily exchanges. Twelve of 70 patients needed to increase from 3 to 4 exchanges. Cohort studies show no differences in outcomes between IPD and a traditional prescription. Some studies show an association between IPD and preservation of RKF.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Given this patient’s interest in PD and the data suggesting that IPD is an acceptable initial prescription, there is no urgency to initiate RRT with a nonpreferred modality (in-center or home HD) or daily PD, all of which would interfere with her quality of life and life goals. Given uremic symptoms, weight loss, and low albumin, waiting at least 6 months for a pre-emptive kidney transplant would not be the next best step in management.</p>\n</div>",
        "references": [
            "Brown EA, Blake PG, Boudville N, et al: International Society for Peritoneal Dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis.Perit Dial Int40(3): 244–253, 2020",
            "Yan H, Fang W, Lin A, et al: Three versus 4 daily exchanges and residual kidney function decline in incident CAPD patients: a randomized controlled trial.Am J Kidney Dis69(4): 506–513, 2017",
            "Ankawi GA, Woodcock NI, Jain AK,et al: The use of incremental peritoneal dialysis in a large contemporary peritoneal dialysis program.Can J Kidney Health Dis3: 2054358116679131, 2016",
            "Sandrini M, Vizzardi V, Valerio F, et al: Incremental peritoneal dialysis: a 10 year single-centre experience.J Nephrol29(6): 871–879, 2016",
            "Lee Y, Chung SW, Park S, et al: Incremental peritoneal dialysis may be beneficial for preserving residual renal function compared to full-dose peritoneal dialysis.Sci Rep9(1): 10105, 2019",
            "Yan H, Abreu Z, Bargman JM: Incremental peritoneal dialysis in incident end-stage kidney disease patients [published online ahead of print, 2021 Aug 9].Perit Dial Int, 2021"
        ]
    },
    "8": {
        "question": "<div class=\"qtext\"><p>A 65-year-old woman with a history of breast cancer metastatic to the liver presents with 2 weeks of shortness of breath, fatigue, anorexia, weight loss, and back pain. She has received zoledronic acid monthly in an attempt to improve bone pain and prevent fractures.</p>\n<p>BP is 130/80 mm Hg, heart rate is 82/min, and oxygen saturation is 98% while breathing room air. Physical examination is significant for dry oral mucosa, clear lungs, and no peripheral edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Magnesium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6–2.6</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   PTH, intact</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>32 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–65</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>43 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>62 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following is the MOST LIKELY cause of hypophosphatemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Falsely low phosphorus measurement caused by interference of\ntumor-related proteins"
            },
            {
                "label": "B.",
                "text": "Urinary phosphorus wasting from proximal tubulopathy"
            },
            {
                "label": "C.",
                "text": "Increased production of fibroblast growth factor-23 (FGF-23)"
            },
            {
                "label": "D.",
                "text": "Decreased dietary phosphorus intake"
            },
            {
                "label": "E.",
                "text": "Bisphosphonate-mediated calcium and phosphorus deposition in bone"
            }
        ],
        "correct_answer": "Increased production of fibroblast growth factor-23 (FGF-23)",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with metastatic breast cancer and symptoms of severe hypophosphatemia is most likely presenting with tumor-induced osteomalacia (TIO) from overproduction of FGF-23.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypophosphatemia results in the inability to replenish ATP, which produces several clinical consequences. Insufficient ATP impairs muscle relaxation, which can cause diaphragmatic muscle weakness with respiratory distress, as seen in this case, as well as rhabdomyolysis. Hemolysis may result from insufficient cellular energy to stabilize RBC membranes. Lastly, colonic ischemia may occur as 2,3-bisphosphoglycerate is depleted, impairing release of oxygen from hemoglobin into tissues susceptible to watershed arterial supply.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The initial evaluation of hypophosphatemia requires assessment of the renal response. The urine phosphorus and creatinine may be used to calculate a tubular reabsorption of phosphorus (TRP) or fractional excretion of phosphorus (FEphos), similar to the fractional excretion of sodium. In the setting of hypophosphatemia, TRP &lt;80% or FEphos greater than 5–20% suggests inappropriate urinary phosphate wasting. In this case:</p>\n<p>FEphos = [(urine phosphorus × serum creatinine) ÷ (serum phosphorus × urine creatinine)] × 100%</p>\n<p>= (43 × 0.6) ÷ (1.0 × 62) × 100%</p>\n<p>= 41%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thus, the low serum phosphorus is likely attributable to renal losses rather than inadequate dietary intake or bisphosphonate-mediated bone deposition.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TIO is a well-recognized oncologic cause of urinary phosphate wasting and has been reported with sarcomas and breast and colon carcinomas. TIO is caused by tumoral overproduction of FGF-23, a phosphatonin that causes internalization of tubular sodium-phosphate cotransporters and inhibits calcitriol production by 1α-hydroxylase. Although hypophosphatemia is the predominant manifestation, hypocalcemia and elevated PTH levels may also occur. Tumor tissue staining for FGF-23 and high plasma levels of FGF-23 are consistent with a diagnosis of TIO. TIO is associated with an increased risk of bone fractures and mortality, so early and aggressive supplementation of phosphorus, calcium, and activated vitamin D may be required, as well as treatment of the underlying malignancy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohyperphosphatemia has been described in patients with multiple myeloma and has been attributed to interference of free light chains with the phosphomolybdate ultraviolet assay for phosphorus. The result is a spuriously high serum phosphate, which normalizes after ex vivo removal of the paraprotein. GFR and PTH levels are usually normal in these patients.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinary phosphate wasting may also occur in patients with multiple myeloma and light chain proximal tubulopathy (Fanconi syndrome). This condition occurs when a heavy load of filtered light chains are reabsorbed by proximal tubule cells, eventually damaging or destroying these cells and their ability to reabsorb phosphorus and other electrolytes and to reabsorb bicarbonate. Histopathology shows crystalline or non-crystalline proximal tubular deposits that may require pronase/proteinase digestion for diagnosis. This diagnosis would be unusual in this patient with metastatic breast cancer, although can be a rare complication of bisphosphonate use. However, patients with proximal tubulopathy will also have hypokalemia and a proximal renal tubular acidosis. The normal potassium and total CO<sub>2 </sub>levels in this case make proximal tubulopathy much less likely.</p>\n</div>",
        "references": [
            "Abramson M, Glezerman IG, Srinivasan M, et al: Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.Clin Nephrol95(2): 104–111, 2021",
            "Aligail K, Dave JA, Ross IL: Tumor-induced osteomalacia: a case report.J Med Case Rep16(1): 22, 2022",
            "Leaf DE, Pereira RC, Bazari H, Juppner H: Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.J Clin Endocrinol Metab98(3): 887–891, 2013",
            "Lee Y, Koo T, Yi JH, et al: Pseudohyperphosphatemia in a patient with multiple myeloma.Electrolyte Blood Press5(2): 131–135, 2007",
            "Stokes MB, Valeri AM, Herlitz L, et al: Light chain proximal tubulopathy: clinical and pathological characteristics in the modern treatment era.J Am Soc Nephrol27(5): 1555–1565, 2016",
            "Liamis G, Milionis HJ, Elisaf M: Medication-induced hypophosphatemia: a review.QJM103(7): 449–459, 2010"
        ]
    },
    "9": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man is referred to nephrology clinic for evaluation of hypokalemia. He has a past medical history of hypertension, hyperlipidemia, and Crohn disease, treated 10 years ago with a partial small bowel resection and ileostomy creation. Ostomy\n    output is moderately heavy but stable. The patient says that his diet rarely includes fruits or vegetables, and he has recently started eating black licorice. His medications include losartan and atorvastatin.</p>\n<p>On examination, he is a healthy-appearing man who looks his stated age. His blood pressure is 142/74 mm Hg, and his pulse is 68/min. He has an ostomy on abdominal examination with abundant liquid stool.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>140 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>105 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Aldosterone, supine, 8 AM</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;3 ng/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤10</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Renin activity, supine, normal diet, 8 AM</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11 ng/mL/hr</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–2.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine, random</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>   </strong>pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>218 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>166 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely etiology of his hypokalemia? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Low oral intake"
            },
            {
                "label": "B.",
                "text": "Ostomy output"
            },
            {
                "label": "C.",
                "text": "Distal renal tubular acidosis"
            },
            {
                "label": "D.",
                "text": "Syndrome of apparent mineralocorticoid excess"
            },
            {
                "label": "E.",
                "text": "Renal artery stenosis"
            }
        ],
        "correct_answer": "Ostomy output",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s hypokalemia is attributable to potassium loss through the ostomy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypokalemia can be attributed to renal or extrarenal losses or transcellular shift. A study in 180 Chinese patients with hypokalemia addressed accuracy of various spot urine tests for distinguishing renal from extrarenal potassium loss. This study compared fractional excretion of potassium (FEK), urine potassium-to-creatinine ratio (UK/UCr), transtubular potassium gradient (TTKG), and spot urine potassium values with 24-hour urine potassium and found that the FEK was most highly correlated with 24-hour urine potassium and most predictive of renal versus extrarenal loss. A cut-off value for FEK 9.3% was found to be 81% sensitive and 86% specific. Of note, the TTKG was previously found to rely on invalid assumptions and is no longer recommended to evaluate hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEK is calculated as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FEK = [(UK × SCr) × 100%]/[SK × UCr] = [(27 ×1.1) × 100%]/[3.2 × 218] = 4.3%.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An FEK of 4.3% suggests appropriate renal conservation of potassium and extrarenal potassium loss. Similarly, UK/UCr = (27 mEq/L)/(2.18 g/L) = 12.4 &lt;15 mEq/g, which also suggests extrarenal potassium loss. Extrarenal losses are most likely occurring through the ileostomy. Except in cases of critical malnutrition, insufficient PO potassium intake by itself is an uncommon cause of hypokalemia, as upregulation of gastrointestinal absorption and renal reabsorption of potassium will keep serum potassium within the normal range.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If this patient had renal potassium losses, the next step would be evaluation of hypertension with hypokalemia by measuring morning serum aldosterone level and plasma renin activity or concentration. Of note, hypokalemia should be corrected before these measurements, as low potassium levels would be expected to inhibit aldosterone secretion. Renovascular disease would be expected to cause high renin and aldosterone levels. Black licorice contains glycyrrhizic acid, whose metabolite (glycyrrhetinic acid) blocks the intracellular detoxification of cortisol and causes excess mineralocorticoid receptor stimulation. Both these conditions would be associated with suppressed aldosterone and renal potassium wasting. The elevated renin is likely attributable to negative feedback from losartan on the juxtaglomerular apparatus.</p>\n</div>",
        "references": [
            "Grams ME, Hoenig MP, Hoorn EJ: Evaluation of hypokalemia.JAMA325(12): 1216–1217, 2021",
            "Li J, Ma H, Lei Y, Wan Q: Diagnostic value of parameters from a spot urine sample for renal potassium loss in hypokalemia.Clin Chim Acta511: 221–226, 2020",
            "Kamel KS, Halperin ML: Intrarenal urea recycling leads to a higher rate of renal excretion of potassium: an hypothesis with clinical implications.Curr Opin Nephrol Hypertens20(5): 547–554, 2011",
            "Chhabria M, Portales-Castillo I, Chowdhury M, et al: A case of severe hypokalemia.Am J Kidney Dis76(1): A9–A12, 2020",
            "Wu KL, Cheng CJ, Sung CC, et al: Identification of the causes for chronic hypokalemia: importance of urinary sodium and chloride excretion.Am J Med130(7): 846–855, 2017"
        ]
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman with ESRD due to ADPKD is evaluated in the HD center for excess interdialytic weight gain. Her past medical history includes hypertension and bilateral nephrectomy. She has been counseled about restricting sodium and fluid intake but\n    acknowledges increased salt consumption over the past weekend. She is anuric. Her estimated dry weight is 61 kg, and her HD prescription is 4.5 hours using dialysate containing 138 mEq/L sodium, 3 mEq/L potassium, and 35 mEq/L bicarbonate.</p>\n<p>On examination, her BP before dialysis is 172/88 mm Hg. Pre-dialysis weight is 66 kg, and the most recent post-dialysis weight was 61 kg. She is overweight and in no acute distress. Heart sounds are normal, and lungs reveal fine, bibasilar crackles. She has 2+ pitting\n    edema to her mid-shins bilaterally and sacral edema.</p>\n<p>At the end of treatment, she develops severe cramping. Her post-dialysis weight is 61 kg.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>After Dialysis, Previous Treatment</strong> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Before Dialysis,<br/> Current Treatment</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>137 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>132</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.2 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.7</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5 .0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>107 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>102</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong> Which ONE of the following is the BEST estimate of the interdialytic dietary sodium intake?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "360 mEq"
            },
            {
                "label": "B.",
                "text": "600 mEq"
            },
            {
                "label": "C.",
                "text": "720 mEq"
            },
            {
                "label": "D.",
                "text": "180 mEq"
            },
            {
                "label": "E.",
                "text": "410 mEq"
            }
        ],
        "correct_answer": "180 mEq",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The interdialytic sodium intake in patients receiving HD may be estimated by the change in the total body sodium between the end of one HD session to the beginning of another. The total body sodium at any time may be estimated by the formula:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Total body sodium = SNa × V,</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">where SNa is the serum sodium concentration and V is the total body water, which may be estimated by the weight in kg multiplied by 0.5.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This value may be compared from the end of one dialysis treatment to the beginning of the next to estimate the interdialytic sodium intake as follows: </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Estimated sodium intake = pre-dialysis total body sodium (time #2) –<br/>   post-dialysis total body sodium (time #1)</p>\n<p>   = SNa<sub>2</sub>V<sub>2</sub> – SNa<sub>1</sub>V<sub>1</sub></p>\n<p>   = (132 mEq/L × 66 L × 0.5) – (137 mEq/L × 61 L × 0.5)</p>\n<p>   = 4356 – 4178 mEq</p>\n<p>   = 177 mEq</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s interdialytic weight gain of 5 kg exceeds the recommended threshold of 13 mL/kg/h (13 mL/kg/h × 66 kg × 4.5 h = 3.9 L), and she is at increased risk of major cardiovascular events.</p>\n</div>",
        "references": [
            "Panzetta G, Bianco F, Ianche M, et al: Validation of a simple method for assessing sodium intake in dialysis patients.Blood Purif19(1): 15–20, 2001",
            "Santos SF, Peixoto AJ: Sodium balance in maintenance hemodialysis.Semin Dial23(6): 549–555, 2010",
            "Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.Kidney Int79(2): 250–257, 2011"
        ]
    },
    "11": {
        "question": "<div class=\"qtext\"><p>A 45-year-old woman with no medical history is admitted to the cardiac care unit because of increasingly severe shortness of breath, without chest pain, cough, or fever. Her review of systems is positive for hand swelling and stiffness, as well as Raynaud syndrome.</p>\n<p>BP is 200/110 mm Hg and heart rate is 95/min. She has jugular venous distension to the angle of the jaw when sitting at 45°. An S4 gallop is present. There are no abdominal bruits. Crackles are present at the lung bases, and there is trace lower extremity edema. There is no synovitis present. Her skin is normal.</p>\n<p>Laboratory results:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Admission</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Two Days Later</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11,500/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelets </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">250,000/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">250,000</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Troponin I</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.01 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≤0.04</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Brain-type natriuretic peptide</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1000 pg/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;100</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine protein-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7 mg/mg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2</td>\n</tr>\n</tbody>\n</table>\n<p>The peripheral smear shows occasional schistocytes. Serologic studies, including antinuclear antibody, anti-topoisomerase antibody, anti-RNA polymerase III antibody, and anticentromere antibody are pending.</p>\n<p>Chest x-ray shows bilateral pulmonary edema. EKG shows normal sinus rhythm with nonspecific ST- and T-wave changes in the lateral leads. Echocardiogram reveals normal left ventricular size and function with evidence of diastolic dysfunction. Kidney ultrasound reveals normal size and echogenicity. Duplex examination is negative for renal artery stenosis.</p>\n<p>The patient is treated with an infusion of nitroglycerine and bumetanide 1 mg IV twice daily. Two days later, she has not improved. BP is 160/90 mm Hg, heart rate is 74/min, and pulmonary edema persists; urine output has decreased to 800 mL/day despite doubling her diuretic dose.</p><strong>Which of the following is the next BEST step in management? </strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Sodium nitroprusside"
            },
            {
                "label": "B.",
                "text": "Captopril"
            },
            {
                "label": "C.",
                "text": "Labetalol"
            },
            {
                "label": "D.",
                "text": "Plasmapheresis"
            },
            {
                "label": "E.",
                "text": "Nicardipine"
            }
        ],
        "correct_answer": "Captopril",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should be treated with captopril for presumptive scleroderma renal crisis (SRC).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SRC is a life-threatening complication of scleroderma affecting 10% of patients with systemic sclerosis. SRC is characterized by the abrupt onset of hypertension and AKI. Pulmonary edema and hypertensive encephalopathy may also occur. Typically, SRC manifests within 5 years of onset of systemic sclerosis, and most patients already have the characteristic skin features. However, SRC may be the presenting manifestation in as many as 20% of patients. A high index of suspicion is needed to identify these patients. The initial manifestations of systemic sclerosis often include Raynaud syndrome, as well as swelling and stiffness of the hands. The presence of anti-RNA polymerase III antibodies is associated with an increased risk of SRC. This patient has new-onset hypertension, AKI, pulmonary edema, bland urine sediment, and modest proteinuria, with hand stiffness, swelling, and Raynaud phenomenon; this presentation is consistent with SRC. Treatment of SRC is directed toward the normalization of BP with ACEIs. ACEI therapy should be maintained even if a patient becomes dialysis-dependent, as up to 55% may eventually recover kidney function. ARBs are often substituted in patients intolerant of ACEIs, but there is less experience with these agents. ACEIs remain the preferred primary treatment option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The addition of other agents to control BP, such as nicardipine or labetalol, may be necessary but should not be substituted for primary therapy with ACEIs. Endothelin dysregulation is suspected of playing a central role in the pathogenesis of SRC, and endothelin antagonists are being studied for treatment of this disorder, but there is insufficient evidence as yet to recommend their use outside of a clinical trial. The use of sodium nitroprusside is discouraged in the setting of AKI due to the risk for accumulation of toxic thiocyanate and cyanide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasmapheresis is used to treat thrombotic thrombocytopenia purpura (TTP), a disorder that shares some features with SRC, including AKI and microangiopathic hemolytic anemia, and distinguishing between them may be difficult. TTP is usually characterized by significant and progressive thrombocytopenia, whereas SRC more commonly is associated with severe hypertension. In this case, the stable and relatively high platelet count favors the diagnosis of SRC.</p>\n</div>",
        "references": [
            "Logee KM, Laksminarayanan S: Scleroderma renal crisis as an initial presentation of systemic sclerosis: A case report and review of the literature. Clin Exp Rheumatol 33(4 Suppl 91): S171–S174, 2015",
            "Bhavsar S, Carmona R: Anti–RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. J Clin Rheumatol20(7): 379–382, 2014",
            "Cozzi F, Marson P, Cardarelli S, et al: Prognosis of scleroderma renal crisis: A long term observational study.Nephrol Dial Transplant27(12): 4398–4403, 2012",
            "Keeler E, Fioravanti G, Samuel B, et al: Scleroderma renal crisis or thrombotic thrombocytopenic purpura: Seeing through the masquerade.Lab Med46(2): e39–e44, 2015",
            "Felker GM, Lee KL, Bull DA, et al: Diuretic strategies in patients with acute decompensated heart failure.N Engl J Med364(9): 797–805, 2011"
        ]
    },
    "12": {
        "question": "<div class=\"qtext\"><p>A 69-year-old woman presents for evaluation of muscle twitching. She has a history of diabetes mellitus type 2, hypertension, and arthritis of the right hip for which she had a total hip arthroplasty. Her hip arthroplasty became infected and 1 month ago she underwent surgical removal of hardware and began treatment with vancomycin and cefepime based on culture data. A total of 6 weeks of antibiotic therapy was planned. Initial dosing of vancomycin was 1 g daily, and the cefepime was 2 g every 12 hours.</p>\n<p>On the fourth week of treatment, her serum creatinine and a vancomycin trough level were both increased, so the vancomycin dose was decreased, and repeat values 1 week later prompted admission.</p>\n<p>She reports twitching movements of her arms and legs since last night along with fatigue. However, her appetite is normal and she has no nausea, itching, dyspnea, or pain.</p>\n<p>In addition to the antibiotics detailed above, she also takes insulin, amlodipine, and oxycodone as needed. Her most recent dose of oxycodone was several days ago.</p>\n<p>Her BP is 165/95 mm Hg, she is afebrile, and her heart rate is 88/min. She is alert but distressed about the twitching. Myoclonus is evident in the face, jaw, and extremities. There is no asterixis and no focal neurologic deficits.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                After 4 weeks of vancomycin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                1 week after dose reduction\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                Admission the next day\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\">\n                Reference Range\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                63\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                66\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL (baseline 1)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Vancomycin trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 µg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n</tbody>\n</table>\n<p>A CT scan of the head shows an old small subdural hematoma.</p><strong>Which of the following is the MOST likely cause of the neurological findings?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Subdural hematoma"
            },
            {
                "label": "B.",
                "text": "Cefepime toxicity"
            },
            {
                "label": "C.",
                "text": "Vancomycin toxicity"
            },
            {
                "label": "D.",
                "text": "Uremia"
            },
            {
                "label": "E.",
                "text": "Hypocalcemia"
            }
        ],
        "correct_answer": "Cefepime toxicity",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s neurologic symptoms is cefepime-induced neurotoxicity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has developed a movement disorder characterized by myoclonus and involuntary, abrupt muscle jerking. These symptoms developed in the setting of AKI and multiple medications; thus, a toxic/metabolic cause is most likely. Uremia, hypocalcemia, and metabolic alkalosis can all cause myoclonus, but the recent use of cefepime should raise the possibility of cefepime toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cefepime is a fourth-generation, extended-spectrum cephalosporin, which affords coverage of <em>Pseudomonas aeruginosa </em>and ceftazidime-resistant isolates. Cefepime is predominately renally cleared by filtration and excreted unchanged in the urine. Dose reduction is necessary in the setting of impaired kidney function. The pathogenesis of cephalosporin-induced neurotoxicity is believed to be related to antagonism of inhibitory γ-aminobutyric acid (GABA), which leads to an increase in excitatory response. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cefepime neurotoxicity is more common in the setting of decreased kidney function. Symptoms vary and may include altered consciousness, seizures, or myoclonus. Cessation of cefepime usually results in an improvement in symptoms. Because symptoms vary, many believe that this adverse effect is more common than recognized. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Uremia can also cause myoclonus, but this patient does not have other symptoms of uremia, and the BUN is only mildly elevated. If she does not improve with cessation of the cefepime, it would be reasonable to consider dialysis, which is also efficient at removing cefepime. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient’s total calcium is low, the serum albumin is also low, and the ionized calcium is likely to be normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Oxycodone and other narcotic analgesics can cause myoclonus as well, but this patient had not taken oxycodone for several days prior to her presentation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vancomycin toxicity may be the cause of the decline in kidney function but is unlikely to cause neurotoxicity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Subdural hematomas can cause a variety of neurologic signs and symptoms, but myoclonus is more characteristic of a metabolic insult.</p>\n</div>",
        "references": [
            "Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser G: Cefepime-induced neurotoxicity: a systematic review. Crit Care 21:276, 2017",
            "Sonck J, Laureys G, Verbeelen D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure.Nephrol DialTransplant23(3): 966–970, 2008"
        ]
    },
    "13": {
        "question": "<div class=\"qtext\"><p>A 67-year-old man with ESRD due to diabetic nephropathy and hypertension is evaluated for pain and numbness in his right hand. His current hemodialysis access is a right internal jugular tunneled catheter. Previous accesses in the left forearm and left upper arm have failed, and he has no suitable right forearm vessels. Four weeks ago, a right brachiocephalic arteriovenous fistula (AVF) was created. The patient is now experiencing pain, numbness, and weakness of the right hand that are increasing in severity. </p>\n<p>On examination, the AVF incision is well healed, and there is a good thrill and bruit; the right radial pulse is palpable but diminished, and the hand is pale and cool. There is a small ulcer on the tip of the index finger. Grip strength and light touch sensation are diminished. Capillary refill is sluggish. Access flow is 500 mL/min.\n\n</p><strong>Which of the following options represents the MOST appropriate management for this patient?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Refer for urgent arteriography"
            },
            {
                "label": "B.",
                "text": "Refer for urgent banding of AVF"
            },
            {
                "label": "C.",
                "text": "Obtain neurophysiologic studies"
            },
            {
                "label": "D.",
                "text": "Refer for immediate ligation of the\nAVF"
            },
            {
                "label": "E.",
                "text": "Treat with analgesia"
            }
        ],
        "correct_answer": "Refer for urgent arteriography",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has signs and symptoms of distal ischemia, which require urgent evaluation with arteriography.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Placement of an arteriovenous (AV) access creates a shunt that diverts blood flow from the distal extremity. Usually this diversion of blood flow is well tolerated, and the “steal” is insufficient to produce distal ischemia. The most common cause of distal ischemia is vascular disease in the native arterial vessels, compromising inflow to the distal limb. Arterial stenosis located either proximal or distal to the AVF can result in critical ischemia of the distal limb. This is called distal hypoperfusion ischemia syndrome (DHIS). Less common causes of distal ischemia include low cardiac output, hypotension, and/or excessive flow through the AVF. Four percent of upper extremity AVF are complicated by severe DHIS. Upper arm AVF are particularly prone to this complication. Although measurement of access flow and transcutaneous oxygen tension can help, the diagnosis of steal syndrome or DHIS is largely clinical. It is important to recognize signs and symptoms of significant steal and intervene before there is permanent loss of hand function. The precise cause of DHIS will determine the treatment. Thus, the patient should urgently undergo arteriography to evaluate his native arterial vessels. Suitable lesions may be treated with angioplasty. In case of a large anastomosis and high flow fistula, distal revascularization with interval ligation (DRIL) or banding that may be accomplished by a variety of surgical or endovascular techniques can sometimes salvage the access. If no correctable cause of DHIS is identified, the fistula should be ligated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although ligation of access will limit further ischemia and potentially restore limb circulation, it would be premature to sacrifice the AVF without first looking for correctable causes. This is of particular importance in this patient without other upper extremity options.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The symptoms of steal should be differentiated from those of carpal tunnel syndrome or other neuropathic process. In cases of diagnostic uncertainty, nerve conduction studies can be obtained. However, such studies are not necessary in this patient with definitive findings on physical examination. </p>\n<p>Conservative follow-up of this patient with severe ischemia could result in permanent loss of function or even amputation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urgent banding of AVF, while sometimes a treatment for steal, is not indicated without first investigating the cause of ischemia such as arterial stenosis. Banding is usually applied when the AVF flow is considerably higher than the flows measured in this patient.</p>\n</div>",
        "references": [
            "Al-Jaishi AA, Liu AR, Lok CE, Zhang JC, Moist LM: Complications of the arteriovenous fistula: A systemic review.J Am Soc Nephrol28(6): 1839–1850, 2017",
            "Leon C, Asif A: Arteriovenous access and hand pain: The distal hypoperfusion ischemic syndrome.Clin J Am Soc Nephrol2: 175–183, 2007",
            "Tordoir JH, Dammers R, van der Sande FM: Upper extremity ischemia and hemodialysis vascular access.Eur J Vasc Endovasc Surg27: 1–5, 2004",
            "Asif A, Leon C, Merrill D, Bhimani B, Ellis R, Ladino M, Gadalean FN: Arterial steal syndrome: A modest proposal for an old paradigm.Am J Kidney Dis48: 88–97, 2006"
        ]
    },
    "14": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man with ESRD due to hypertension has been hospitalized with a diagnosis of left lower lobe pneumonia. He has received maintenance HD for 3 years. His medications include lisinopril, amlodipine, atorvastatin, aspirin, erythropoietin, sevelamer, and calcitriol. He has no known allergies, smokes one pack of cigarettes per day, and received the influenza vaccination last fall. He has never received a pneumococcal vaccine.</p>\n<p>At his initial presentation with pneumonia, he appeared ill and was febrile and hypoxemic; initial laboratory data included a leukocytosis, a left lower lobe opacity on chest x-ray, and positive blood cultures for <em>Streptococcus pneumoniae</em> sensitive to penicillin. After 72 hours of ceftriaxone, he is afebrile and no longer requires supplemental oxygen. Leukocytosis has improved but not yet normalized.</p>\n<strong>In addition to completing a 10-day course of oral antibiotics and encouraging smoking cessation, which of the following is the MOST appropriate intervention?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer the 13-valent\npneumococcal conjugate vaccine prior to discharge"
            },
            {
                "label": "B.",
                "text": "Plan\nto administer the 23-valent pneumococcal polysaccharide vaccine after\ncompletion of his antibiotic course"
            },
            {
                "label": "C.",
                "text": "Administer\nthe 23-valent pneumococcal polysaccharide vaccine prior to discharge"
            },
            {
                "label": "D.",
                "text": "Administer\nboth the 13-valent pneumococcal conjugate vaccine and the 23-valent\npneumococcal polysaccharide vaccine"
            },
            {
                "label": "E.",
                "text": "Plan to administer the 13-valent pneumococcal conjugate\nvaccine simultaneously with the influenza vaccine next fall"
            }
        ],
        "correct_answer": "Administer the 13-valent\npneumococcal conjugate vaccine prior to discharge",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient should receive one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) prior to discharge from the hospital.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vaccination for common infectious diseases is an important strategy to reduce morbidity in the general population and is even more important for the immunocompromised patient with CKD and ESRD. A review of vaccination rates in CKD patients admitted with infections showed that influenza vaccination rate was 52% and pneumococcal pneumonia vaccination rate was only 13.5%, far lower than target levels. Both CKD and ESRD are associated with an increased risk for major infectious complications of community-acquired pneumonia, including death, bacteremia, secondary infections such as <em>Clostridium difficile</em> colitis, and prolonged hospitalization. Hospitalization for any reason represents an opportunity to initiate or enhance a vaccination program. There is no evidence that delaying such vaccination for completion of antibiotic therapy improves response or reduces complications. Rather, delaying vaccination is more likely to result in a missed opportunity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The sequence of pneumococcal vaccination appears to be important in conferring optimal immunity. The United States Centers for Disease Control (CDC) recommends that patients with ESRD who have never been vaccinated against pneumococci (or patients for whom the vaccination history is unknown or incomplete) receive one dose of PCV13 followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. A second dose of PPSV23 should be administered 5 years later to complete the sequence. The vaccines should not be delivered simultaneously. If the patient has received PPSV23 first, PCV13 vaccination should be delayed 1 year.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adverse reactions include injection site erythema, pain, and swelling.  Systemic reaction such as fever, myalgias, arthralgias, and fatigue are uncommon. Contraindications to pneumococcal vaccines are limited to a history of severe allergic reaction to the vaccine.</p>\n</div>",
        "references": [
            "Advisory Committee on Immunization Practices. CDC. Adult conditions immunization schedule. Available at:http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html.Accessed October 13, 2022",
            "Reddy S, Chitturi C, Yee J: Vaccination in Chronic Kidney Disease.Adv Chronic Kidney Dis26: 72–78, 2019",
            "Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease.Adv Chronic Kidney Dis13:199–204, 2006",
            "James MT, Quan H, Tonelli M, et al: CKD and risk of hospitalization and death with pneumonia.Am J Kidney Dis54: 24–32, 2009",
            "D’Agata EM, Mount DB, Thayer V, Schaffner W: Hospital-acquired infections among chronic hemodialysis patients.Am J Kidney Dis35: 1083–1088, 2000",
            "Lafrance JP, Rahme E, Iqbal S, et al: Trends in infection-related hospital admissions and impact of length of time on dialysis among patients on long-term dialysis: A retrospective cohort study.CMAJ Open2: E109–E114, 2014",
            "Vandecasteele SJ, Ombelet S, Blumental S, Peetersmans WE: The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.Clin Kidney J8: 318–324, 2015",
            "Bratzler DW, Houck PM, Jiang H, et al: Failure to vaccinate Medicare inpatients: A missed opportunity.Arch Intern Med162: 2349–2356, 2002"
        ]
    },
    "15": {
        "question": "<div class=\"qtext\"><p><span style=\"font-size: 13.125px;\">A 75-year-old woman who resides in a skilled nursing facility due to chronic obstructive pulmonary disease and frailty (body weight, 50 kg) presents with fever and hypotension without an apparent source of infection. An infectious disease consultant recommends empiric antibiotic coverage with vancomycin and piperacillin-tazobactam pending culture results. </span></p>\n<p>She is admitted to the ICU, where she requires mechanical ventilation. In addition to the antibiotics, her medications include propofol, omeprazole, bronchodilators, acetaminophen, and low-molecular weight heparin to prevent venous thrombosis. Over the ensuing 96 hours, her total fluid intake is 13 L, and her total urine output is 3 L. Her serum creatinine increases to 1.1 mg/dL (baseline, 0.7; reference range, 0.5–1.1).  Liver function tests are normal except for a reduced serum albumin.<br/></p>\n<p>Urinalysis via a urinary catheter-derived specimen reveals specific gravity 1.010, pH 6, and trace blood and protein. The sediment contains 1–3 RBCs/hpf, 1–3 WBCs/hpf, and occasional granular casts.<br/></p>\n<p><strong>Which of the following studies is MOST likely to yield an explanation for the acute decline in kidney function in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ultrasound of the kidneys and bladder"
            },
            {
                "label": "B.",
                "text": "Serum creatine kinase level"
            },
            {
                "label": "C.",
                "text": "Urine sodium and creatinine levels"
            },
            {
                "label": "D.",
                "text": "Vancomycin trough level"
            },
            {
                "label": "E.",
                "text": "Urine eosinophil stain"
            }
        ],
        "correct_answer": "Vancomycin trough level",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A vancomycin trough level should be obtained in this patient with AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The first step in the evaluation of the AKI in this patient is to recognize the severity of the problem. In this case, marked positive fluid balance has led to expansion of the volume of distribution of serum creatinine, the principal biomarker used to identify AKI. This dilution blunts the rise in creatinine and may “mask” AKI, delaying recognition and contributing to a poor outcome. The creatinine concentration can be corrected for the degree of volume expansion by multiplying by a correction factor that accounts for expansion of total body water:</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2q15eq1.png\" width=\"33%\"/></figure>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TBW represents total body water, estimated as 0.5 × admission weight, and ∑ represents the cumulative daily fluid balance:</p><figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2q15eq2.png\" width=\"33%\"/></figure><p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the correction factor is 1.4, so 1.4 × 1.2 mg/dL results in a corrected creatinine of 1.68 mg/dL, more than double her admission value and consistent with stage 2 AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although sepsis could explain or contribute to AKI, the combination of vancomycin and piperacillin-tazobactam is associated with AKI in up to 16% patients exposed to this combination for more than 48 hours. A trough level exceeding 20 mg/L appears to correlate with vancomycin-induced AKI. Other risk factors include CKD, hypotension, and exposure to other nephrotoxic agents such as radiocontrast or aminoglycoside antibiotics. Acute tubular necrosis is the most commonly attributed mechanism, although acute interstitial nephritis and vancomycin cast nephropathy have also been reported. Careful attention to dosing adjustments for changing kidney function might prevent or ameliorate this complication.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis is a potential explanation for the AKI, but urine eosinophil staining is neither a sensitive nor specific marker for this process.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine sodium and creatinine levels allow calculation of the fractional excretion of sodium (FENa), which can be useful in distinguishing between renal hypoperfusion and acute tubular necrosis in an oliguric patient with AKI. In this non-oliguric patient, the FENa would be less informative.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Creatine kinase (CK) should be measured in cases of suspected propofol infusion syndrome (PRIS), a multisystem failure syndrome that includes metabolic acidosis, AKI, acute liver abnormalities, cardiac dysfunction, hyperlipidemia, and elevated CK. It is associated with propofol infusions lasting &gt;48 hours. In this case, the absence of hematuria by urinalysis, as well as the normal liver tests, argue that measuring CK would be unlikely to identify a cause for the AKI. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney ultrasound is often used in the evaluation of AKI due to its availability and safety, but in the absence of clinical suspicion of urinary obstruction, it rarely contributes to the diagnosis, especially for in-hospital AKI.</p>\n</div>",
        "references": [
            "Luque Y, Louis K, Jouanneau C, Placier S,et al: Vancomycin-associated Cast Nephropathy.J Am Soc Nephrol28(6):1723–1728, 2017",
            "Macedo E, Bouchard J, Soroko S, et al: Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients.Crit Care14(3): R82, 2010",
            "Ricci Z, Cruz D, Ronco C: Classification and staging of acute kidney injury: Beyond the RIFLE and AKIN criteria.Nat Rev Nephrol7(4): 201–208, 2011",
            "Burgess L, Drew R: Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.Pharmacotherapy34(7): 670–676, 2014",
            "Orsini J, Nadkarni A, Chen J, Cohen N: Propofol infusion syndrome: Case report and literature review.Am J Health Syst Pharm66(10): 908–915, 2009",
            "Nguyen M, Maynard S, Kimmel P: Misapplications of commonly used kidney equations: Renal physiology in practice.Clin J Am Soc Nephrol4(3): 528–534, 2009",
            "Perazella M, Bomback A: Urinary eosinophils in AIN: Farewell to an old biomarker?Clin J Am Soc Nephrol8(11): 1841–1843, 2013",
            "Podoll A, Walther C, Finkel K: Clinical utility of gray scale renal ultrasound in acute kidney injury.BMC Nephrol14: 188, 2013"
        ]
    },
    "16": {
        "question": "<div class=\"qtext\"><p>A 45-year-old patient with ESRD from long-standing untreated hypertension is seen during HD. She had been performing PD for the last 2 years but recently developed a peritoneal catheter tunnel infection, and the catheter was removed. During her hospitalization for the tunnel infection and treatment of the resulting peritonitis, a tunneled HD catheter was placed, and she subsequently underwent two HD sessions with a steam-sterilized, polysulfone dialyzer without incident.</p>\n<p>She presents to the outpatient dialysis center appearing well. She is scheduled to receive a 3.5-hour treatment.. Her ultrafiltration goal is set to 2 L, which will bring her to her target weight. Her sitting BP at the start of her treatment is 140/85 mm Hg. The treatment is initiated, and the dialysis catheter is working well with a blood flow of 400 mL/min.</p>\n<p>Within 10 minutes of the treatment onset, she complains of difficulty breathing and feeling dizzy and clammy. She appears cyanotic and restless. Her BP is 80/40 mmHg, heart rate is 100/min, and oxygen saturation is 83% while breathing room air. She has an urticarial rash, diffuse wheezing, and clammy skin.</p>\n<strong>Which ONE of the following is the MOST appropriate intervention for this patient?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Place dialysis machine in bypass mode"
            },
            {
                "label": "B.",
                "text": "Administer IV isotonic saline\nbolus"
            },
            {
                "label": "C.",
                "text": "Administer IV methylprednisolone\nand diphenhydramine"
            },
            {
                "label": "D.",
                "text": "Administer subcutaneous epinephrine"
            },
            {
                "label": "E.",
                "text": "Terminate treatment without returning her\nblood"
            }
        ],
        "correct_answer": "Terminate treatment without returning her\nblood",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the case of a suspected type A dialyzer reaction, the dialysis procedure should be immediately terminated without return of the patient’s blood.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dialyzer reactions are a group of adverse events caused by exposure to some component of the dialysis circuit or by the treatment and are characterized by symptoms that may include dyspnea, sense of impending doom, hypotension, cyanosis, and even cardiac arrest. Milder reactions may include itching, with or without urticaria, coryza, cough, chest pain, back pain, abdominal cramps, and diarrhea.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">“Type A” (acute hypersensitivity) reactions typically occur within 15 minutes of initiation of dialysis and are associated with severe manifestations consistent with anaphylaxis. These are thought to be related to preformed immunoglobulin E (IgE) antibodies. The classic example is an allergy to ethylene oxide sterilant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anaphylactoid reactions (which are not IgE-mediated and do not require initial sensitization) can also occur early in the dialysis procedure. The prototypical example is exposure to the synthetic dialyzer made of acrylonitrile-sodium methallylsulfonate (AN69) in patients taking ACEI. These membranes are thought to increase the rate of bradykinin production, which is generally well tolerated, except in those taking ACEI, because blockade of ACE prevents metabolism of bradykinin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In addition, heparin allergy, contamination of the dialysate or bicarbonate with bacterial products, or reaction to a reuse sterilant can also cause serious symptoms. Often a specific cause cannot be identified, and nonspecific strategies are used to limit symptomatology such as double rinsing of the dialyzer prior to the treatment. Eosinophilia and a history of allergic reactions appear to be predisposing factors, and eosinophilia is occasionally identified following a reaction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The type A reactions are the most serious and can be life-threatening; thus, immediate cessation of the procedure without returning blood to the patient is recommended. If symptoms persist, management of anaphylaxis with epinephrine, corticosteroids, bronchodilators, and antihistamines would be reasonable. Placement of the machine into the bypass mode is not an adequate approach, as there is ongoing exposure of blood to the agent provoking the reaction and this blood returns to the patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">“Type B” reactions tend to be less severe and occur later in the dialysis procedure, often after 20–40 minutes of treatment. Complement activation is believed to play a role. Management is supportive and includes oxygen administration. Myocardial ischemia should be considered in the differential diagnosis. Often it is possible to continue the treatment, as symptoms will abate, usually within 1 hour.</p>\n</div>",
        "references": [
            "Butani L, Calogiuri G:  Hypersensitivity reactions in patients receiving hemodialysis.Ann AllergyAsthma Immunol118(6): 680–684, 2017",
            "Yang R, Lindsay R: Dialyzer reactions in a patient switching from peritoneal dialysis to hemodialysis.Hemodial Int9(2): 120–126, 2005",
            "Daugirdas J, Blake P, Ing T:Handbook of Dialysis, 5th Ed., Philadelphia, Wolters Klewer Health, 2015",
            "Verresen L, Fink E, Lemke HD, Vanreterghem Y: Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes.Kidney Int45(5): 1497-1503, 1994"
        ]
    },
    "17": {
        "question": "<div class=\"qtext\"><p>A 70-year-old woman is referred for evaluation of lower extremity edema and proteinuria. She has had progressive lower extremity edema and a 4-kg weight gain in the last few months. Transthoracic echocardiogram was normal.  </p>\n<p>BP is 146/80 mm Hg, pulse is 78/min, and 3+ lower extremity edema is present, but the remainder of the physical examination is normal.</p>\n<p>Laboratory data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11.6 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelets </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">374,000/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">138 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.4 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">109 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">56 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.78 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Albumin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.3 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine protein-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.2 mg/mg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"100%\">\n<p>Urinalysis: yellow, clear, 4+ protein, moderate blood</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>EM of a kidney biopsy specimen demonstrates randomly arranged 15- to 30-nm fibrils.</p>\n<strong>Which ONE of the MOST likely diagnosis?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Immunotactoid\nglomerulonephritis"
            },
            {
                "label": "B.",
                "text": "Amyloidosis"
            },
            {
                "label": "C.",
                "text": "Cryoglobulinemic\nvasculitis"
            },
            {
                "label": "D.",
                "text": "Fibrillary\nglomerulonephritis"
            },
            {
                "label": "E.",
                "text": "Collagenofibrotic\nglomerulopathy"
            }
        ],
        "correct_answer": "Fibrillary\nglomerulonephritis",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The diagnosis of fibrillary glomerulonephritis is made by finding randomly arranged fibrils, 15- to 30-nm in diameter, on EM. Because the light microscopic findings in fibrillary glomerulonephritis can vary, establishing the diagnosis relies on this pathognomonic EM finding.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glomerular disorders related to non-amyloid fibrillary deposits are rare. Congo red staining is negative in these disorders; instead, characteristic findings on electron microscopy are used to identify these conditions. Of these disorders, fibrillary glomerulonephritis represents the majority of cases, and immunotactoid glomerulonephritis is the second most common. Both typically present with nephrotic syndrome, and more than half of patients have hypertension and hematuria. Most cases appear to be idiopathic; however, malignancy, plasma cell dyscrasias, and autoimmune diseases have also been associated with these disorders, so these diagnoses should be considered when non-amyloid fibrils are identified on EM. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Immunotactoid glomerulonephritis is characterized by parallel arrays of microtubules with a diameter usually &gt;30 nm, which is much larger than the fibrils that characterize fibrillary glomerulonephritis. This diagnosis has a better prognosis than that of fibrillary glomerulonephritis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Light microscopy of renal amyloidosis demonstrates periodic acid Schiff (PAS)-staining amorphous, acellular material. The gold standard for diagnosis of amyloidosis is Congo red positivity. Characteristic electron microscopy findings include randomly distributed small fibrils of 10–12 nm in diameter.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Collagenofibrotic glomerulopathy is a rare glomerulopathy with organized deposits. These deposits are made of type III collagen, and the pathognomonic EM finding is fibers in a transverse band pattern approximately 60 nm in size. Light microscopy shows a nodular appearance of glomeruli that can be confused with Kimmelstiel-Wilson lesions. Immunofluorescence is generally unremarkable. Pathogenesis of this rare disease is unknown. Patients present with hypertension, edema, and proteinuria and progress to ESRD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Deposits of cryoglobulins typically have a clear substructure with curving microtubules that has been likened to a “fingerprint” on EM, rather than the randomly arranged, narrow fibrils seen in amyloidosis or fibrillary glomerulonephritis.</p>\n</div>",
        "references": [
            "Joh K: Pathology of glomerular deposition diseases.Pathol Int579(9): 551–565, 2007",
            "Fogo AB: Amyloid.Am J Kidney Dis32: E1–E2.2, 1998",
            "Alchi B, Nishi S Narita I, Gejyo F: Collagenofibrotic glomerulopathy: Clinicopathologic overview of a rare glomerular disease.Am J Kidney Dis49(4): 499–506, 2007"
        ]
    },
    "18": {
        "question": "<div class=\"qtext\"><p>A 63-year-old woman with chronic hepatitis C infection complicated by cirrhosis and hepatocellular carcinoma underwent elective percutaneous radiofrequency ablation of the hepatic mass. Intra-abdominal bleeding complicated the procedure. CT angiography was performed, followed by conventional angiography and embolization of branches of the right hepatic artery. She was then admitted to the ICU for further management of hemorrhagic shock, respiratory failure, lactic acidosis, and anuric AKI.</p>\n<p>Blood products were transfused and vasopressors initiated. CVVHDF was begun with the following prescription:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Rate</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Fluid Composition/Delivery</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Blood flow</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150 mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Citrate infusion</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  90 mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5% pre-filter</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Replacement solution  </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> <br/>1800 mL/h  <br/>  200 mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">HCO<sub>3</sub> 32 mEq/L, K 2 mEq/L<br/>pre-filter<br/>post-filter</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Dialysate</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1000 mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">HCO<sub>3</sub> 32 mEq/L, K 2 mEq/L</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Net ultrafiltration target</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      0 mL/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n</tbody>\n</table>\n<p>Despite calcium chloride infusion titrated by sliding scale to maintain a normal ionized calcium level, the patient's ionized calcium to total calcium ratio falls below normal, consistent with citrate toxicity.</p>\n<strong>After temporarily discontinuing the citrate infusion, which of the following is the BEST approach to prevent filter thrombosis in this patient?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase the pre-filter replacement fluid\nrate"
            },
            {
                "label": "B.",
                "text": "Reduce the blood flow rate"
            },
            {
                "label": "C.",
                "text": "Infuse heparin pre-filter"
            },
            {
                "label": "D.",
                "text": "Increase\nthe ultrafiltration target"
            },
            {
                "label": "E.",
                "text": "Increase the post-filter replacement\nfluid rate"
            }
        ],
        "correct_answer": "Increase the pre-filter replacement fluid\nrate",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best approach to prevent filter thrombosis in this patient during CVVHDF is to increase the pre-filter replacement fluid rate, which serves to dilute the blood in the hemofilter and thereby reduce the viscosity and the concentration of clotting factors, reducing the tendency to thrombosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with acutely or chronically impaired liver function may be unable to metabolize citrate to bicarbonate. As a result, citrate can accumulate in the systemic circulation and chelate free calcium. This problem will lead to a decline in the ionized calcium and an increase in the anion gap. This phenomenon may be recognized by an increased ratio of total to ionized calcium. The low ionized calcium can result in prolonged repolarization of the myocardium and increase the risk of polymorphic ventricular tachycardia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the blood flow rate may also help to prevent thrombosis related to stasis, but only if the vascular access can support the higher flows. If the vascular access is inadequate to support higher blood flow, machine alarms can cause interruption of the treatment and enhance the risk of system thrombosis. Heparin would be contraindicated in a patient with hemorrhage because it is not cleared by passage of blood through the dialysis filter. Increasing the ultrafiltration target would increase hemoconcentration and increase the risk of filter thrombosis. Increasing the post-filter fluid replacement would not address thrombosis in the filter and would require additional ultrafiltration in order to maintain net even fluid balance.</p>\n</div>",
        "references": [
            "Schneider AG, Journois D, Rimmelé T: Complications of regional citrate anticoagulation: accumulation or overload?Crit Care21: 281, 2017",
            "Joannidis M and Oudemans-van Straaten HM: Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 11(4): 218, 2007",
            "Davies H, Leslie G: Maintaining the CRRT circuit: Non-anticoagulant alternatives.Aust Crit Care19(4): 133–138, 2006"
        ]
    },
    "19": {
        "question": "<div class=\"qtext\"><p>A 38-year-old man is admitted with shortness of breath 3 months after starting PD for ESRD attributed to hypertension.</p>\n<p>He has significant residual renal function and is adherent to his therapy and medications, which include furosemide 40 mg twice daily, lisinopril 40 mg daily, calcitriol 0.25 μg daily, and calcium acetate 1334 mg with meals. His BP and volume status improved within a few weeks after initiating PD. His regimen includes 4 manual exchanges of 2500 mL of 1.5% dextrose dialysate. Review of the patient’s flowsheets reveals that his ultrafiltration volume has decreased over the past 2 weeks. He is active on the transplant list, and his sister has completed her donor evaluation and living-donor kidney transplantation is anticipated to occur within the next few months.</p>\n<p>His BP is 128/82 mm Hg, heart rate is 72/min, and respiratory rate is 24/min. Lung exam reveals dullness to percussion and absent breath sounds over the right lower lung field. The left lung is normal. The jugular venous pressure is normal, and no murmurs or gallops are appreciated. The abdomen is soft and nontender, with no palpable hernias, and the catheter exit site is normal in appearance. There is no peripheral edema.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8400/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                270,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.6 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                101 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                46 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                91 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                164 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Chest radiograph reveals a large right-sided pleural effusion. Thoracentesis with removal of 1 L of fluid is performed. The fluid is clear and colorless. Laboratory analysis of the fluid reveals protein 1 g/dL, lactate dehydrogenase 53 U/L, glucose 365 mg/dL, and no cells or bacteria.</p>\n<strong>Which of the following is the NEXT best step in management?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change to low-volume cycler-assisted PD"
            },
            {
                "label": "B.",
                "text": "Increase furosemide to 80 mg twice daily"
            },
            {
                "label": "C.",
                "text": "Refer for thoracoscopy with pleurodesis"
            },
            {
                "label": "D.",
                "text": "Increase dialysate dextrose concentration to\n2.5%"
            },
            {
                "label": "E.",
                "text": "Transition to HD"
            }
        ],
        "correct_answer": "Change to low-volume cycler-assisted PD",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a right-sided pleural effusion associated with PD should transition to low-volume, cycler-assisted PD until he is able to undergo kidney transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Right-sided, transudative pleural effusion, or hydrothorax, is an early complication of PD attributed to an acquired or congenital diaphragmatic defect. This pathophysiology is thought to be similar to that of hepatic hydrothorax in patients with cirrhosis and ascites. PD-associated hydrothorax is often mistaken for congestive heart failure. The pathognomonic finding in a patient who is using dextrose-containing dialysate is the high-glucose concentration in the effusion (“sweet effusion”). Low-volume exchanges, performed with a cycler while the patient is supine, may minimize reaccumulation of pleural fluid and allow this patient to continue PD until he receives a transplant within the next few months.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment depends on the severity and acuity of the effusion and may require transitioning to HD with an attempt to return to PD at a later time. If hydrothorax recurs and PD is still desired, thoracoscopy with chemical pleurodesis or surgical correction of the diaphragmatic defects can be attempted. These procedures are not required at this time because this is a first occurrence and the patient is close to receiving a kidney transplant. Transitioning to HD would require tunneled catheter placement, and this would confer an increased risk for infection. Such risk should be avoided unless other alternatives have proved unsuccessful.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing furosemide dose or dextrose concentration would be appropriate measures for a patient receiving PD with evidence of volume overload, but this patient’s BP and volume status are appropriate, so increased diuresis or ultrafiltration is not necessary. Moreover, either of these measures could cause hypovolemia with symptomatic hypotension if instituted in an attempt to reduce the size of the pleural effusion.</p>\n</div>",
        "references": [
            "García Ramón R, Carrasco AM: Hydrothorax in peritoneal dialysis.Perit Dial Int18: 5-10, 1998",
            "Bargman JM: Noninfectious complications of peritoneal dialysis. In:Nolph and Gokal’s Textbook of Peritoneal Dialysis, 3rded., edited by Khana R and Krediet R, Springer 2018, pp 2734",
            "Christidou F, Vaonas G: Recurrent acute hydrothorax in a CAPD patient: Successful management with small volumes of dialysate.Perit Dial Int15(8): 389, 1995"
        ]
    },
    "20": {
        "question": "<div class=\"qtext\"><p>A 21-year-old man is evaluated in the emergency department for a possible concussion during a football game. He has no known medical history but notes having episodes of muscular weakness associated with some lightheadedness and headache over the last several months. </p>\n<p>His physical examination is remarkable for a BP of 170/98 mm Hg (similar in both arms), pulse of 68/min, and body mass index of 20 kg/m<sup>2</sup>. He is alert and oriented with no deficits on neurological exam. The remainder of the examination is normal.</p>\n<p>Laboratory data reveal the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                140 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                108 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–30\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99 (fasting)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Plasma renin activity (PRA)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.15 ng/mL per hour\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–2.5, normal diet, supine\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Plasma aldosterone concentration (PAC)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2 ng/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–10, normal diet, supine\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Arterial blood gas </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.37\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mmHg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                pO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                88 mmHg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                75–100\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>24-hour urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                95 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Complete blood count, creatine kinase level, and liver function tests are normal. EKG demonstrates mildly peaked T waves. CT scan of the brain demonstrates no acute intracranial abnormality.</p>\n<p>Treatment with fludrocortisone does not increase urinary potassium excretion; however, when fludrocortisone is combined with isotonic sodium bicarbonate in doses large enough to sustain a serum bicarbonate level greater than 25 mEq/L and a urinary pH greater than 8, then urinary potassium concentration increases to 80 mEq/L.</p>\n<strong>Which one of the following is the MOST likely cause of this patient’s laboratory abnormalities?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hyporeninemic\nhypoaldosteronism"
            },
            {
                "label": "B.",
                "text": "A\nmutation in either WNK1 or WNK4 (with no lysine) kinases in the distal\nconvoluted tubule"
            },
            {
                "label": "C.",
                "text": "Primary adrenal insufficiency (Addison disease)"
            },
            {
                "label": "D.",
                "text": "A point mutation in the gene for the α-subunit of the skeletal muscle cell sodium channel"
            },
            {
                "label": "E.",
                "text": "A loss of function mutation in the gene encoding the\nprincipal cell mineralocorticoid receptor"
            }
        ],
        "correct_answer": "A\nmutation in either WNK1 or WNK4 (with no lysine) kinases in the distal\nconvoluted tubule",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The combination of hyperkalemia, hypertension, and mild metabolic acidosis in a young individual is characteristic of pseudohypoaldosteronism type II (Gordon syndrome), which is caused by either a gain of function mutation in WNK1 (with no lysine kinase-1) or a loss of function mutation in WNK4. Both abnormalities result in increased function of the NaCl cotransporter and the epithelial Na channel, as well as profound inhibition of the renal outer medullary potassium channel (ROMK) channels in the cortical collecting duct. The net effect is decreased Na and K excretion. In addition, there is likely a reduction in the luminal electrical gradient secondary to a chloride shunt (increase in paracellular chloride permeability leading to electroneutral sodium chloride reabsorption). Renin and aldosterone are typically suppressed due to volume expansion from the enhanced sodium reabsorption at the distal nephron. Administration of fludrocortisone alone will not substantially increase the rate of potassium excretion given that there is still a marked inhibition of ROMK. However, when combined with sodium bicarbonate administration sufficient to cause bicarbonaturia, there will be an increase in K trapping in the lumen from more proximal sites, thereby resulting in kaliuresis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary adrenal insufficiency also leads to hyperkalemia and a mild metabolic acidosis; however, patients tend to be hypotensive rather than hypertensive. For this reason, the PRA is high, whereas the PAC is low.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyporeninemic hypoaldosteronism is most commonly seen in patients with diabetes and CKD or in patients who have pharmacologic inhibition of the renin-angiotensin-aldosterone axis. Although the PRA and PAC are low in this case, hyporeninemic hypoaldosteronism is an unlikely diagnosis because the patient does not have diabetes or CKD.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A point mutation in the gene encoding the α-subunit of the skeletal muscle cell sodium channel leads to hyperkalemic periodic paralysis. The abnormal sodium channel closes slowly and the muscle can become desensitized; this results in paralysis of the muscle and release of potassium. Precipitants may include cold exposure, rest after exercise, fasting, ingestion of even small amounts of potassium, and anesthesia. Potassium levels may be normal or only modestly elevated during attacks. The mechanism involved in hyperkalemia is one of transcellular shift rather than reduced renal clearance, which makes this choice unlikely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Autosomal dominant pseudohypoaldosteronism type I results when there is a loss of function mutation in the gene encoding the mineralocorticoid receptor. The defect is limited to the kidney and produces sodium wasting. Patients may present in infancy with hyperkalemia, hypovolemia, and failure to thrive; however, symptoms may remit over time. Hypertension with a low PRA and low PAC would be unexpected.</p>\n</div>",
        "references": [
            "Proctor G, Linas S: Type 2 pseudohypoaldosteronism: New insights into renal potassium, sodium, and chloride handling.Am J Kidney Dis48(4): 674–693, 2006",
            "Geller DS, Rodriguez-Soriano J, Boado AV, et al: Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I.Nat Genet19(3): 279–281, 1998",
            "Yang CL, Angell J, Mitchell R, Ellison DH: WNK kinases regulate thiazide-sensitive Na-Cl cotransport.J Clin Invest111(7): 1039–1045, 2003"
        ]
    },
    "21": {
        "question": "<div class=\"qtext\"><p>A 61-year-old woman with ESRD caused by diabetic nephropathy and congestive heart failure is seen during HD. This is her first outpatient dialysis treatment since being discharged from the hospital after treatment for pneumonia. While hospitalized, declining platelet counts were observed, and she experienced thrombosis of her arteriovenous graft, prompting suspicion for heparin-induced thrombocytopenia (HIT). She underwent successful thrombectomy. Exposure to heparin was eliminated and testing for HIT was ordered, the results of which remained pending at the time of discharge. </p>\n<p>The patient reports that she is feeling back to baseline. She is currently dialyzing with a heparin-free circuit. The nurse reports that she clotted her dialyzer earlier in the treatment, and the circuit was replaced. Her current medications include lisinopril, atorvastatin, and insulin glargine.</p>\n<p>Her BP is 135/72 mm Hg and heart rate is 90/min. Breath sounds are diminished at the right base. Cardiovascular examination reveals regular rate and rhythm. Mild bilateral lower extremity edema is present.</p>\n<p>Laboratory data: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6100/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                54 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Antibodies against platelet factor-4 (PF4)–heparin complex return positive.</p>\n<strong>Which one of the following is the next BEST STEP in management of this patient? </strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Apixaban"
            },
            {
                "label": "B.",
                "text": "Enoxaparin during dialysis"
            },
            {
                "label": "C.",
                "text": "Citrate regional anticoagulation during dialysis"
            },
            {
                "label": "D.",
                "text": "Isotonic saline flushes during dialysis"
            },
            {
                "label": "E.",
                "text": "Argatroban during dialysis"
            }
        ],
        "correct_answer": "Apixaban",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Apixaban should be initiated to prevent systemic thrombosis in this patient with ESRD, HIT, and previous thrombosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HIT is a relatively uncommon disorder that may occur after exposure to either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). There are two forms of HIT. Type 1 HIT is related to non-immune platelet aggregation that results in a mild, transient decrease in platelet count. The platelet count nadir is typically &gt;100,000/µL, occurring 24–48 hours after exposure to heparin, followed by gradual recovery to baseline. Type 1 HIT is not associated with bleeding or thrombosis, and heparin therapy may be continued. Type 2 HIT results from antibody formation targeting PF4 complexed to heparin, leading to platelet activation and thrombosis. It is defined by decline in platelet count with absolute thrombocytopenia or a ≥50% in platelet count occurring approximately 5 days after exposure to heparin, although faster onset can be seen in cases in which there has been previous exposure. Platelet count nadirs are typically in the range of 50,000–80,000/µL. Type 2 HIT, which carries up to a 30% mortality rate, occurs in 2–3% of patients exposed to UFH and &lt;1% of patients exposed to LMWH. All heparin therapy must be discontinued, including devices that may be heparin-coated, such as IV catheters. Because patients remain at increased risk for thrombosis despite discontinuation, systemic anticoagulation with an alternative to heparin is mandatory. Up to 50% of patients may develop thrombosis within 30 days after diagnosis, so systemic anticoagulation is usually continued for at least 1 month in the absence of a thrombotic event and for ≥3 months if an event has occurred. Critically ill patients and those with limb or life-threatening thromboembolism should be treated initially with parenteral agents such as argatroban or bivalirudin. Warfarin and direct oral anticoagulants (DOACs) are options for stable patients. However, warfarin is contraindicated until the platelet count has recovered and requires overlap with a suitable agent to avoid transient thrombophilia. In this patient, who does not require hospitalization for IV therapy, apixaban is a reasonable alternative. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thrombosis of the dialysis circuit can occur even in the absence of a thrombophilic condition such as HIT, and many patients with ERSD receiving HD receive anticoagulation during dialysis to prevent clotting. Both UFH and LMWH are acceptable agents for dialysis circuit anticoagulation in the absence of HIT type 2. Typically, a weight-based bolus dose is given at the beginning of treatment, followed by a continuous infusion, which is discontinued 30–60 minutes before the end of the treatment. LMWH has a longer half-life than UFH and is becoming a preferred agent for circuit anticoagulation in Europe and parts of Asia and Australia. Dosing may vary depending on the agent used. Enoxaparin has a longer half-life than other LMWHs and therefore is not recommended for daily dialysis because of risk of dose accumulation. It may be dosed 0.5 mg/kg as a single bolus at the beginning of dialysis through the venous limb of the circuit. Studies have shown no significant differences between bleeding complications or thrombosis between UFH and LMWH. In this patient with HIT type 2, enoxaparin must be avoided.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Because patients with HIT type 2 require systemic anticoagulation for 1–3 months after diagnosis, anticoagulation options that only address circuit thrombosis, such as saline flushes and regional citrate anticoagulation, are not adequate for this patient. Either could be considered once patients have completed therapy. Isotonic saline boluses of 100–200 mL can be given at intervals to flush blood from the dialyzer and dialysis circuit to reduce the likelihood of thrombosis. There are limited data supporting this practice, but it is safe provided that the ultrafiltration goal is adjusted to account for the additional saline. Anticoagulation of the dialysis circuit with citrate can be accomplished with either an infusion of citrate or dialysate containing citrate, which forms a complex with calcium, thus interfering with the calcium-dependent aspects of the coagulation cascade. This strategy may increase the efficiency of HD with less circuit thrombosis compared to HD without heparin. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Argatroban is a direct thrombin inhibitor that is dosed by continuous infusion and is indicated for the management of HIT type 2. Although argatroban may be used during outpatient HD, the logistical problems of a continuous infusion, the close monitoring required, and the increased costs incurred make this method of anticoagulation more suited to hospitalized patients bridging to PO anticoagulation. Furthermore, this patient requires continuous anticoagulation for 1–3 months, so argatroban provided just during dialysis treatments would be inadequate.</p>\n</div>",
        "references": [
            "Ashby D, Borman N, Burton J, et al: Renal association clinical practice guidelines on haemodialysis.BMC Nephrol20: 379, 2019",
            "Shen JI, Winkelmayer WC: Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.Am J Kidney Dis60(3): 473–486, 2012",
            "Kossmann RJ, Gonzales A, Callan R, Ahmad S: Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study.Clin J Am Soc Nephrol4(9): 1459–1464, 2009",
            "Cuker A, Arepally GM, Chong BH, et al: American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.Blood Adv2(22): 3360–3392, 2018",
            "Davenport A: Review article: Low molecular weight heparin as an alternative to unfractionated heparin for routine outpatient haemodialysis treatments.Nephrology(Carlton)14(5): 455–461, 2009"
        ]
    },
    "22": {
        "question": "<div class=\"qtext\"><p>A 77-year-old woman is referred for decreased kidney function that was recognized at her annual examination. She had no interval illness or symptoms and was unaware of any kidney problems until informed of her results (below). Her medical history includes hypertension, obesity, sleep apnea, hyperlipidemia, stable coronary artery disease, depression, and osteoarthritis affecting her knees. Eight months ago, she complained of muscle aches, prompting substitution of fenofibrate for simvastatin. Her current medications include amlodipine, fenofibrate, aspirin, fluoxetine, acetaminophen, and glucosamine. She is adherent to her prescription for continuous positive airway pressure (CPAP).</p>\n<p>She appears well. BP is 134/67 mm Hg, heart rate is 76/min, and body mass index is 32 kg/m<sup>2</sup>. Other than trace edema of the legs and degenerative arthritis of her knees, the examination is normal.</p>\n<p>Investigations include normal electrolytes and complete blood count, along with the data below:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">Result </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">Reference Range</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.2 mg/dL (1.1 six months ago)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Albumin </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.8 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.5–9.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">C-reactive protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.8</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine protein-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.3 mg/mg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.2</td>\n</tr>\n<tr>\n<td colspan=\"3\" style=\"border: 1px solid rgb(0, 0, 0);\" valign=\"top\" width=\"100%\">\n<p>Urinalysis: specific gravity 1.010, 1+ protein, otherwise negative. Urine sediment: rare hyaline cast.</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound reveals bilateral 10-cm kidneys with mildly increased echogenicity but no other abnormalities. </p>\n<strong>Which of the following is the MOST likely explanation for her decline in kidney function? </strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Chronic\ninterstitial nephritis"
            },
            {
                "label": "B.",
                "text": "Analgesic\nnephropathy"
            },
            {
                "label": "C.",
                "text": "Hypertensive nephrosclerosis"
            },
            {
                "label": "D.",
                "text": "Fenofibrate nephrotoxicity"
            },
            {
                "label": "E.",
                "text": "Ischemic\nnephropathy"
            }
        ],
        "correct_answer": "Fenofibrate nephrotoxicity",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has a subacute rise in serum creatinine, bland urine sediment, and minimal proteinuria, as well as chronic exposure to fenofibrate, all of which are most consistent with a diagnosis of fenofibrate nephrotoxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fenofibrate is a synthetic fibric acid derivative that is utilized for the treatment of dyslipidemia, as it can lower triglycerides and low-density lipoprotein and raise high-density lipoprotein levels. The impact of fenofibrate (and other fibric acid derivatives) on cardiovascular outcomes is unclear, with some studies failing to demonstrate clinical improvement despite a favorable effect on lipid profile. Fenofibrate appears to exert its effect by activating peroxisome proliferator-activated receptor-α (PPAR-α). Most patients appear to tolerate fenofibrate well, but multiple case series have demonstrated that some patients will experience a rise in serum creatinine. This rise in creatinine typically occurs after 6 months of therapy or more. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The majority of patients recover to baseline creatinine levels after discontinuation of the drug, but approximately 30% will have persistent CKD. The sediment is bland, and there is usually no significant proteinuria. Kidney biopsies have been infrequently reported in the literature, but when performed, have not demonstrated any specific pathology. One hypothesis regarding the pathophysiology is that fenofibrate (and other fibric acid derivatives) impairs the production of renal vasodilatory prostaglandins. Other studies have suggested that there is direct interference with creatinine excretion or an increase in creatinine production. Fibrates, when combined with statins, may cause rhabdomyolysis that can be associated with AKI, but this is a distinct phenomenon. Kidney transplant recipients treated with calcineurin inhibitors appear to be at particular risk of AKI or CKD with these agents. The propensity to cause CKD appears to be a class effect for fibrates, although there is some suggestion that gemfibrozil may be less problematic than fenofibrate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic interstitial nephritis can present with a subacute decline in kidney function and a relatively bland urinary sediment, but often there may be pyuria or at least mild proteinuria to suggest the diagnosis. None of the patient's current medications is commonly associated with chronic interstitial nephritis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ischemic nephropathy can present with a subacute decline in kidney function and bland urine sediment, but this patient has normal kidney size without evidence of atrophy on ultrasound.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Analgesic nephropathy can be caused by years of exposure to acetaminophen, NSAIDs, and caffeine, often in combination, but it has a characteristic appearance on imaging including atrophy, irregular kidney contours, and calcifications of the papillae.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertensive nephrosclerosis would be unlikely to explain a doubling of the serum creatinine over 1 year in a patient whose BP is well controlled on a single agent.</p>\n</div>",
        "references": [
            "Polanco N, Hernandez E, Gonzalez E, et al: Fibrate-induced deterioration of renal function.Nefrologia29(3): 208–213, 2009",
            "Broaders N, Knoop C, Antoine M, et al: Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent?Nephrol Dial Transplant15(12): 1993–1999, 2000",
            "Attridge R, Frei C, Ryan L, et al: Fenofibrate-associated nephrotoxicity: A review of current evidence.Am J Health-Syst Pharm70(14): 1219–1225, 2013",
            "De Broe M, Elseviers M: Analgesic nephropathy.NEngl J Med338(7): 446–452, 1998"
        ]
    },
    "23": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with ESRD due to type 2 diabetes presents to clinic for follow-up 6 weeks after deceased donor kidney transplant. His transplant surgery was uncomplicated and required placement of an indwelling double-J ureteral stent. His calculated\n    panel of reactive antibodies was 58%, and he received alemtuzumab induction therapy. Four days ago, his ureteral stent was electively removed. Today, he reports generalized fatigue and decreased urine output, but denies fevers, dysuria, or hematuria.\n    His medications include tacrolimus, mycophenolate, prednisone, insulin, and trimethoprim-sulfamethoxazole.</p>\n<p>On examination, he is afebrile and normotensive but is ill-appearing. He has no edema, and his allograft is nontender.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>1 Week Ago</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Current</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>138 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>132 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.4 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.4 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5 .0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>104 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>104 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>19 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>32 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>48 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.3 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.4 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Tacrolimus, whole blood trough</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.8 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.8 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.0–15.0</p>\n<p>(0–3 months post-transplant)</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows 1+ protein, specific gravity 1.010, and negative nitrite, blood, and leukocyte esterase.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Transplant kidney ultrasound"
            },
            {
                "label": "B.",
                "text": "BK polyomavirus DNA levels"
            },
            {
                "label": "C.",
                "text": "Indwelling urinary catheter"
            },
            {
                "label": "D.",
                "text": "Transplant kidney biopsy"
            },
            {
                "label": "E.",
                "text": "Decrease tacrolimus dose"
            }
        ],
        "correct_answer": "Transplant kidney ultrasound",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this kidney transplant recipient with AKI 4 days after double-J ureteral stent removal, the most appropriate next step is to obtain a transplant kidney ultrasound.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s AKI is post-transplant ureteral stricture causing obstructive uropathy. Transplant ureteral strictures are most commonly seen &gt;1 month after kidney transplant. During the transplant surgery, surgeons will often place a ureteral stent at the ureteroneocystostomy site to prevent stenosis and strictures that may be complications of ureteral ischemia. These stents are associated with increased risk of urinary tract infection (UTI), and timing of stent removal should balance the risk of UTI with the risk of recurrent stenosis in the healing ureter. Ultrasound is the preferred method for diagnosis, with most patients showing hydronephrosis of the allograft. Management includes stent replacement and/or percutaneous nephrostomy tube placement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BK polyomavirus is a viral infection that may cause graft dysfunction. Most patients with BK viremia and allograft involvement are asymptomatic. BK infection is unlikely in this patient with symptoms suggesting obstruction in the setting of recent stent removal. Additionally, BK virus-associated nephropathy is most likely to occur 2–6 months after transplant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Indwelling urinary catheters are used to treat urinary obstruction caused by bladder outlet obstruction. In this patient, ureteral stricture due to stent removal is a more likely cause of obstruction than bladder outlet obstruction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney biopsy is useful to diagnose AKI when the etiology is unknown. Likely causes of AKI should be evaluated with the least invasive methods first before proceeding to kidney biopsy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcineurin inhibitor (CNI) toxicity should always be considered as a cause of AKI in kidney transplant recipients. AKI in patients with therapeutic CNI trough levels is rare.</p>\n</div>",
        "references": [
            "Gil-Sousa D, Oliveira-Reis D, Teves F, et al: Ureteral stenosis after renal transplantation—a single-center 10-year experience.Transplant Proc49(4): 777–782, 2017",
            "Sarier M, Yayar O, Yavuz A, Turgut H, Kukul E: Update on the management of urological problems following kidney transplantation.Urol Int105(7–8): 541–547, 2021"
        ]
    },
    "24": {
        "question": "<div class=\"qtext\"><p>A 32-year-old man with sickle cell anemia and type 1 diabetes presents to the emergency department with 3 days of diffuse pain, fever, chest pain, and shortness of breath. He is intubated for respiratory distress and admitted to the ICU. His current medications\n    include insulin, ceftriaxone, azithromycin, and morphine. He is receiving tube feeding with 250 mL of free water flush every 4 hours via nasogastric tube. Urine output is 3.2 L/24 h. </p>\n<p>On examination, his temperature is 38.1°C, BP is 100/50 mm Hg, heart rate is 124/min, and oxygen saturation is 94% while ventilated with 40% oxygen. He is sedated, with coarse breath sounds and tachycardia. He has an indwelling urinary catheter draining abundant,\n    clear yellow urine.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>148 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.1 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5 .0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>20 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>76 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.2 mg/dL (baseline 0.5)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>289 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Urea</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>      Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>89 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely etiology of his polyuria?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Excess water intake"
            },
            {
                "label": "B.",
                "text": "Hypocalcemia"
            },
            {
                "label": "C.",
                "text": "Hyperglycemia"
            },
            {
                "label": "D.",
                "text": "Sickle cell disease"
            },
            {
                "label": "E.",
                "text": "Excess protein intake"
            }
        ],
        "correct_answer": "Sickle cell disease",
        "abim_content_category": "Tubular, Interstitial, and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of polyuria is sickle cell disease (SCD).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SCD commonly causes urinary concentrating defects (hyposthenuria). As hemoglobin traverses the renal medulla, the relative hypoxia within the vasa recta leads to increased sickling and vascular occlusion followed by capillary rarefaction and distal tubular dysfunction. This can cause decreased sodium reabsorption in the renal medulla at the loop of Henle and the inability to generate the normal medullary concentration gradient required for maximal water reabsorption. Moreover, distal tubular dysfunction may cause an inability to absorb water appropriately (concentrating defect, nephrogenic diabetes insipidus). Early manifestations of urinary concentrating defects include nocturnal enuresis, which is reported to occur in 60% of children with SCD. Other manifestations of distal tubule failure include distal renal tubular acidosis and impaired potassium excretion. One consequence of this pathophysiology is proximal tubular hypertrophy, which can result in increased creatinine secretion at the proximal tubule and overestimation of creatinine-based eGFR in SCD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Excess water intake (primary polydipsia) results in a dilute urine, but patients with polydipsia and excess water consumption will tend to have normal or low, not high, serum sodium in AKI. Patients with hypercalcemia may be polyuric and hypernatremic due to nephrogenic diabetes insipidus caused by hypercalcemia; this effect is reversible with normalization of plasma calcium levels. Hypocalcemia does not cause polyuria or hypernatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increased solute intake, such as from urea with excess protein administration during tube feeding or from glucose during diabetes-associated hyperglycemia, can cause an osmotic diuresis and polyuria. However, the polyuria caused by an osmotic diuresis will lead to a high (frequently &gt;300 mOsm/kg H<sub>2</sub>O), not low, urine osmolality.</p>\n</div>",
        "references": [
            "Payan-Pernia S, Ruiz Llobet A, Remacha Sevilla AF, et al: Sickle cell nephropathy. Clinical manifestations and new mechanisms involved in kidney injury. Nefrologia 41(4): 373–382, 2021",
            "Ataga KI, Orringer EP: Renal abnormalities in sickle cell disease.Am J Hematol63(4): 205–11, 2000",
            "Hatch FE, Culbertson JW, Diggs LW:  Nature of the renal concentrating defect in sickle cell disease.J Clin Invest46(3): 336–345, 1967",
            "Palmer BF, Clegg DJ: The use of selected urine chemistries in the diagnosis of kidney disorders.Clin J Am Soc Nephrol14(2): 306–316, 2019",
            "Silva Junior GB, Vieira AP, Couto Bem AX, et al: Renal tubular dysfunction in sickle cell disease.Kidney Blood Press Res38(1): 1–10, 2013"
        ]
    },
    "25": {
        "question": "<div class=\"qtext\"><p>A 70-year-old man with ESRD treated with thrice-weekly in-center HD requests evaluation for a kidney transplant. He has received HD for 1 year. His past medical history includes ANCA vasculitis, unsuccessfully treated with cyclophosphamide; Gleason score 7 prostate cancer 8 years ago, treated with radiation therapy and now in remission; hypertension; atrial fibrillation; and heart failure with preserved ejection fraction. Screening colonoscopy 4 years ago was unremarkable. He is a lifetime nonsmoker.</p>\n<p>He tolerates his dialysis sessions well, with excellent adherence to dietary restrictions, and he achieves his dry weight without hypotension or cramping. He reports no extrarenal symptoms of ANCA vasculitis, palpitations, chest pain, or shortness of breath, and his only current complaint is exhaustion after HD treatments. He has had a 7-kg unintentional weight loss over the last year and reports he only leaves his home to attend HD sessions.</p>\n<p>On examination, his BP is 145/80 mm Hg, and heart rate is 84/min. His body mass index (BMI) is 24 kg/m<sup>2</sup>. His cardiac examination is remarkable for an irregularly irregular rhythm, his lungs are clear bilaterally, and he has symmetric 3/5 hand grip strength. He has no edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                299 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585, dialysis patients\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Prostate-specific antigen\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.1 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                no specific normal or abnormal level\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Erythrocyte sedimentation rate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 mm/h\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–15\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in his pre-transplant evaluation? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "ANCA serology"
            },
            {
                "label": "B.",
                "text": "Urologic oncology referral"
            },
            {
                "label": "C.",
                "text": "Timed 15-foot walking test"
            },
            {
                "label": "D.",
                "text": "Colonoscopy"
            },
            {
                "label": "E.",
                "text": "Electromyography"
            }
        ],
        "correct_answer": "Timed 15-foot walking test",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in this patient’s pre-transplant evaluation is to perform a timed 15-foot walking test.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient currently endorses 3 components of the Fried frailty score: unintentional weight loss, low physical activity, and reduced grip strength on examination. Although there are other explanations for these symptoms, including depression, it is very likely that this patient meets diagnostic criteria for frailty. The final criterion is a slow walking speed over a 15-foot distance. Frailty is prevalent in 12%–20% of kidney transplant candidates and is associated with increased rates of delayed graft function, length of hospital stay, incidence of risk-adjusted graft loss, and mortality. A multicenter, prospective cohort study of &gt;7000 kidney transplant candidates between 2009 and 2018 showed that the chance of listing frail patients at 6 months, 1 year, and 3 years is 33%, 41%, and 46%, respectively. Frailty is considered a modifiable barrier to transplantation, and by diagnosing frailty, patients can receive pre-transplant rehabilitation that may increase their chances of being listed for transplant and improve their subsequent outcomes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ANCA-associated vasculitis is not a contraindication to kidney transplant. Although relapses can occur in 9%–40% of patients, these episodes respond similarly to treatment of native disease. Transplant should be delayed if there is active disease, but this patient reports that he is in remission, and his erythrocyte sedimentation rate is normal, so checking ANCA serology would not be the next best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient had low- to intermediate-risk prostate cancer and has been in remission for &gt;5 years. Additionally, he has a negative prostate-specific antigen test. He would not need urologic evaluation prior to transplant listing. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient is anemic, hemoglobin is within the target range for patients with ESRD, and per KDIGO guidelines, colon cancer screening before kidney transplant should be done according to local guidelines. In this patient with a normal colonoscopy 4 years ago, there is no indication to repeat colonoscopy at this time.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s decreased grip strength is more likely due to frailty than a neurologic disease. Electromyography would not be an appropriate next step without other neurologic findings</p>\n</div>",
        "references": [
            "Al-Adra D, Hammel L, Roberts J, et al: Pretransplant solid organ malignancy and organ transplant candidacy: a consensus opinion statement.Am J Transplant21(2): 460–474, 2021",
            "Fried LP, Tangen CM, Walston J et al: Frailty in older adults: evidence for a phenotype.J Gerotol A Biol Sci Med Sci56(3): M146–156. 2001",
            "Chadban SJ, Ahn C, Axelrod D, et al: KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation.Transplantation104(4 Suppl 1): S11–S103, 2020",
            "Haugen CE, Chu NM, Ying H, et al: Frailty and access to kidney transplantation.Clin J Am Soc Nephrol14 (4): 576–582, 2019",
            "Haugen CE, Thomas AG, Chu NM, et al: Prevalence of frailty among kidney transplant candidates and recipients in the United States: estimates from a National Registry and multicenter cohort study.Am J Transplant20(4): 1170–1180, 2020",
            "Jorgenson M, Descourouez J, Singh T, Astor BC, Panzer SE: Malignancy in renal transplant recipients exposed to cyclophosphamide prior to transplantation for the treatment of native glomerular disease.Pharmacotherapy38(1): 51–57, 2018",
            "Oniscu G, Brown H, Forsythe J: How old is old for transplantation?Am J Transplant4(12): 2067–2074, 2004"
        ]
    },
    "26": {
        "question": "<div class=\"qtext\"><p>A 37-year-old woman presents to the emergency department with 3 months of generalized weakness, muscle aches, cramping, and increasingly dark urine. Symptoms have worsened over the last 2 weeks, during which time the patient began training for a marathon, running up to 6 miles daily and increasing her water and sports drink intake. Her past medical history includes hyperlipidemia and Sjögren syndrome. Her medications include simvastatin and hydroxychloroquine.</p>\n<p>On examination, her BP is 132/80 mm Hg, her heart rate is 76/min, and her respiratory rate is 18/min. She is afebrile. Other than dry oral mucosa and some deep tenderness of the large muscles, her examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>133 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5 </p>\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatine kinase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13,000 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30–135</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.8</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0 </p>\n<p> </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the most likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Distal renal tubular acidosis"
            },
            {
                "label": "B.",
                "text": "Excessive exercise"
            },
            {
                "label": "C.",
                "text": "Hypokalemic periodic paralysis"
            },
            {
                "label": "D.",
                "text": "Simvastatin toxicity"
            },
            {
                "label": "E.",
                "text": "Surreptitious diuretic use"
            }
        ],
        "correct_answer": "Distal renal tubular acidosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this young patient with Sjögren syndrome, marked hypokalemia, and a non–anion gap metabolic acidosis, the most likely diagnosis is rhabdomyolysis attributable to hypokalemia induced by her distal (type 1) renal tubular acidosis (RTA). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Some patients with Sjögren syndrome (up to 25%) have been found to lack the H<sup>+</sup> ATPase on the luminal membrane of the α-intercalated cells of the distal nephron. Some patients may also generate antibodies against carbonic anhydrase in these cells, preventing generation of H<sup>+</sup> and regeneration of HCO<sub>3</sub><sup>-</sup>. These defects lead to both impaired hydrogen ion secretion and potassium reabsorption. The resulting metabolic acidosis also leads to increased distal tubular sodium delivery, as the decreased filtered load of bicarbonate leads to less sodium-bicarbonate reabsorption in the proximal tubule with increased distal sodium delivery, further enhancing urinary potassium losses. Urine pH is relatively alkaline due to impaired distal H<sup>+</sup> secretion. Severe hypokalemia, occasionally with paralysis and respiratory arrest, has been reported as the initial presentation in some cases of Sjögren syndrome. Normally, relative hyperkalemia in exercising muscle leads to the release of vasodilatory factors and increased blood flow. In hypokalemia, this response is impaired, which can lead to skeletal muscle ischemia and myocyte necrosis, and ultimately rhabdomyolysis.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hypokalemia is a potential complication of diuretic use, patients usually present with a normal acid-base status or metabolic alkalosis if sufficient chloride is lost. Hypokalemic periodic paralysis (HPP) is frequently associated with positive family history (familial HPP) or hyperthyroidism (thyrotoxic HPP) and is not associated with a non–anion gap metabolic acidosis. Rhabdomyolysis from statin toxicity is associated with normal or high levels of serum potassium. This patient’s weakness predated her marathon training, so traumatic rhabdomyolysis is less likely.</p>\n</div>",
        "references": [
            "Cherif E, Ben Hassine L, Kechaou I, Khalfallah N: Hypokalemic rhabdomyolysis: an unusual presentation of Sjogren's syndrome.BMJ Case Rep2013 Oct 28;2013:bcr2013201345",
            "Aronson PS, Giebisch G: Effects of pH on potassium: new explanations for old observations.J Am Soc Nephrol22(11): 1981–1989, 2011",
            "Jain VV, Gupta OP, Jajoo SU, Khiangate B: Hypokalemia induced rhabdomyolysis.Indian J Nephrol21(1): 66, 2011",
            "Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury.N Engl J Med361(1): 62–72, 2009",
            "Pertovaara M, Bootorabi F, Kuuslahti M, Pasternack A, Parkkila S: Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 50(8): 1453–1457, 2011"
        ]
    },
    "27": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman presents to clinic for routine follow-up after kidney transplant. She received a preemptive living-related donor kidney transplant 5 years ago for CKD stage 5 due to vesicoureteral reflux. She has had an unremarkable post-transplant\n    course with no episodes of rejection or development of donor-specific antibodies. Her maintenance immunosuppression is tacrolimus and mycophenolate. Since her last visit, she has married and is interested in conception.</p>\n<p>On examination, BP is 115/70 mm Hg and heart rate is 72/min. Her allograft site is non-tender without bruit, and she has no peripheral edema. The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>26 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Tacrolimus, whole blood trough</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.0 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.0–10.0 (&gt;3 months post transplantation)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine albumin-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 mg/g</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>˂30 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong> Which ONE of the following is the MOST common risk associated with pregnancy in kidney transplant recipients?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acute graft rejection"
            },
            {
                "label": "B.",
                "text": "Preterm delivery"
            },
            {
                "label": "C.",
                "text": "Decreased graft survival"
            },
            {
                "label": "D.",
                "text": "Gestational diabetes mellitus"
            },
            {
                "label": "E.",
                "text": "Birth defects"
            }
        ],
        "correct_answer": "Preterm delivery",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This otherwise healthy kidney transplant recipient is most at risk for preterm delivery if she becomes pregnant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pregnancy outcomes in kidney transplant recipients are generally excellent, although recipients have a higher risk of hypertension, preeclampsia, preterm birth, and cesarean section. A meta-analysis of studies of pregnancy-related outcomes of kidney transplant recipients between 2000 and 2010 reported the incidence of cesarian section to be 56.9% and preterm delivery to be 45.6% versus 31.9% and 12.5% in the general population, respectively.</p>\n<p>Acute transplant rejection is not common during pregnancy (2%–4%). A 2009 review of 40 years of pregnancy outcomes in transplant recipients found an equivalent 20-year graft survival rate between nulliparous and first child-bearing kidney transplant recipients. Kidney transplant recipients with a serum creatinine &lt;1.4 mg/dL were more likely to have a successful pregnancy, and those with a creatinine &gt;1.4 mg/dL had a greater risk for future graft loss. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The Transplant Pregnancy Registry International (formerly the National Transplantation Pregnancy Registry) reported in 2014 that 4.4% of babies born to kidney transplant recipients had birth defects; this rate is similar to that of the general population. Note that mycophenolate should be changed to azathioprine when conception is planned to minimize the risk of birth defects. Similarly, the risk of gestational diabetes has been reported at 5.7%–8% in kidney transplant recipients compared with 9.2% in the general population. </p>\n</div>",
        "references": [
            "Ong SC, Kumar V: Pregnancy in a kidney transplant patient.Clin J Am Soc Nephrol15(1): 120–122, 2020",
            "Deshpande NA, James NT, Kucirka LM, et al: Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis.Am J Transplant11(11): 2388–2404, 2011",
            "Levidiotis V, Chang S, McDonald S: Pregnancy and maternal outcomes among kidney transplant recipients.J Am Soc Nephrol20(11): 2433–2440, 2009",
            "Hou S: Pregnancy in renal transplant recipients.Adv Chronic Kidney Dis20(3): 253–259, 2013"
        ]
    },
    "28": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman with ESRD due to lupus nephritis and treated with CCPD presents to the dialysis clinic with one day of red PD effluent. Her CCPD prescription is 5 cycles of 1.8 L of either 1.5% or 2.5% dextrose, with a last fill of 1.5 L of 7.5% icodextrin. She feels well, without any mucosal bleeding or melena. Her last menstrual period was 15 days ago. She recently underwent a tooth extraction without any complications. Her medications include hydroxychloroquine and darbepoetin. She is not prescribed aspirin or other anticoagulants and does not take any over-the-counter medications or herbal supplements.</p>\n<p>On examination, her BP is 130/70 mm Hg with a pulse of 85/min. There is no abdominal tenderness, and the PD catheter and exit site are unremarkable.</p>\n<p>Hemoglobin is 9.2 g/dL (reference range, 12–16), which has been stable for 2 months, and platelet count is normal.</p>\n<p><strong>Which ONE of the following is the BEST next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Rapid exchanges with heparinized dialysate"
            },
            {
                "label": "B.",
                "text": "PD dialysate cell count, differential, and culture"
            },
            {
                "label": "C.",
                "text": "CT angiography of the abdomen and pelvis"
            },
            {
                "label": "D.",
                "text": "Temporary transition to HD"
            },
            {
                "label": "E.",
                "text": "Hematology referral"
            }
        ],
        "correct_answer": "Rapid exchanges with heparinized dialysate",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this young woman with hemoperitoneum, the next step should be to flush the peritoneum with heparinized dialysate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common causes of hemoperitoneum in young women are retrograde menstruation, ovulation, and endometriosis, and hemoperitoneum may be reported in &gt;50% of menstruating women receiving PD. Given the timing of the hemoperitoneum 2 weeks after her last menstrual period, the hemoperitoneum in this case is likely due to ovulation. Management in suspected ovulation- or menstruation-related hemoperitoneum is rapid flushes of the peritoneum with heparinized dialysate until the fluid clears to confirm the cessation of bleeding. Heparin is used to prevent the peritoneal blood from clotting and obstructing the PD catheter. The use of room temperature (rather than body temperature) dialysate has been advocated due to the potential vasoconstrictive effect of colder dialysate that may stop active bleeding.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A fluid cell count, differential, and culture are not necessary in this scenario, in which there is a much more likely explanation for the clinical presentation than peritonitis. It is rare for peritonitis to present with hemoperitoneum, and the patient has not reported abdominal pain, which is typical of peritonitis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Similarly, abdominal imaging would be indicated if the cause of bleeding were not suggested by the presentation or failed to resolve with conservative management. Efforts to locate active bleeding are not needed given the stability of the hemoglobin and the clinical stability of the patient. If the clinical scenario raised concerns for intra-abdominal pathology, a CT scan would be the imaging modality of choice, but it would not be the next best step in management in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Temporary transition to HD is not necessary in this case of benign hemoperitoneum. Referral to hematology to evaluate for bleeding disorders would not be appropriate given the patient’s stable hemoglobin, normal platelet count, and recent well-tolerated oral surgery.</p>\n</div>",
        "references": [
            "Holley JL, Schiff M, Schmidt RJ, Bender FH, Dumler F: Hemoperitoneum occurs in over half of menstruating women on peritoneal dialysis.Perit Dial Int16(6): 650, 1996",
            "Harnett JD, Gill D, Corbett L, Parfrey PS, Gault H: Recurrent hemoperitoneum in women receiving continuous ambulatory peritoneal dialysis.Ann Intern Med107(3): 341–343, 1987",
            "Dimitriadis CA, Bargman JM: Gynecologic issues in peritoneal dialysis.Adv Perit Dial27: 101–105, 2011",
            "Goodkin DA, Benning MG: An outpatient maneuver to treat bloody effluent during continuous ambulatory peritoneal dialysis (CAPD).Perit Dial Int10(3): 227–229, 1990"
        ]
    },
    "29": {
        "question": "<div class=\"qtext\"><p>A 66-year-old woman who is 2 years status post simultaneous liver and kidney transplant presents to clinic for routine follow-up. Her past medical history includes primary biliary cirrhosis, which resulted in end-stage liver disease, and ESRD caused by hepatorenal syndrome. She was treated for BK virus nephropathy 1 year ago with reduction of immunosuppression. Her medication regimen includes tacrolimus, everolimus, and prednisone.</p>\n<p>BP is 142/80 mm Hg, and heart rate is 72/min. On examination, she is thin and cachectic, with a body mass index (BMI) of 18 kg/m<sup>2</sup>. She has normal heart and lung examinations and trace peripheral edema. Her abdomen has a well-healed incision.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;top; width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;top; width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;top; width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5100/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.8 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelet count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>119,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>130 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.2 mg/dL (at baseline)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Lactate dehydrogenase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>215 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>80–225</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Haptoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>122 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>83–267</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Tacrolimus, whole blood, trough</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.7 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.0–10.0 (&gt;3 months post<br/> transplantation)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Everolimus, whole blood, trough</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.1 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–8.0</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urine is clear, with 2+ protein and 0‒2 isomorphic RBC/HPF. Her 24-hour urine collection shows 1890 mg of protein (reference range, &lt;100 mg).</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Obtain kidney allograft biopsy"
            },
            {
                "label": "B.",
                "text": "Measure serum BK virus DNA"
            },
            {
                "label": "C.",
                "text": "Change everolimus to mycophenolate"
            },
            {
                "label": "D.",
                "text": "Prescribe furosemide"
            },
            {
                "label": "E.",
                "text": "Check peripheral blood smear"
            }
        ],
        "correct_answer": "Change everolimus to mycophenolate",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management for this liver-kidney transplant recipient with proteinuria and associated volume overload is to change everolimus to mycophenolate mofetil.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Everolimus is a mammalian target of rapamycin (mTOR) inhibitor; this class of drugs is frequently used as an immunosuppressant in both liver and kidney transplants. Side effects include proteinuria in up to 50% of patients, including nephrotic syndrome, and preexisting proteinuria may be exacerbated after switching a calcineurin inhibitor to an mTOR inhibitor. In the absence of contraindications, and in conjunction with the transplant hepatology team, changing everolimus to mycophenolate would be the next best step to prevent progression of proteinuria. Unfortunately, withdrawal of mTOR inhibitors is not always associated with improvement in proteinuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">mTOR inhibitors have been associated with thrombotic microangiopathy (TMA). In this case, although the patient has anemia and thrombocytopenia, the normal potassium, haptoglobin, and lactate dehydrogenase make TMA less likely, so peripheral blood smear would be unlikely to assist with diagnosis or management. mTOR inhibitors can cause bone marrow suppression, leading to anemia, thrombocytopenia, and leukopenia. Mechanisms underlying this phenomenon are not known, but hematologic toxicities are some of the most common in patients prescribed mTOR inhibitors.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Biopsy of the allograft could be considered if this patient develops AKI or proteinuria fails to improve or progresses after withdrawal of everolimus, but would not be the next best step in management. Histopathology in cases of mTOR inhibitor–associated proteinuria would be expected to show podocyte injury and focal segmental glomerulosclerosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BK virus nephropathy is associated with AKI, hemorrhagic cystitis, and interstitial nephritis, but not usually isolated proteinuria as in this case, so measuring serum BK virus PCR would not be the next best step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Furosemide would likely improve this patient’s mildly volume-overloaded state but would not address the significant proteinuria. Loop diuretic prescription may eventually be required if hypervolemia worsens and becomes symptomatic.</p>\n</div>",
        "references": [
            "Wiseman AC, McCague K, Kim Y, et al: The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes.Am J Transplant13(2): 442‒449, 2013",
            "Diekmann F, Andrés A, Oppenheimer F: mTOR inhibitor-associated proteinuria in kidney transplant recipients.Transplant Rev (Orlando)26(1): 27‒29, 2012",
            "Arnau A, Ruiz JC, Rodrigo E, et al: Is proteinuria reversible, after withdrawal of mammalian target of rapamycin inhibitors?Transplant Proc43(6): 2194‒2195, 2011",
            "Letavernier E, Legendre C: mTOR inhibitors-induced proteinuria: mechanisms, significance, and management.Transplant Rev (Orlando)22(2): 125‒130, 2008"
        ]
    },
    "30": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with hepatosplenic T-cell lymphoma presents to the emergency department with 1 month of progressive fatigue and muscle weakness. For the last 3 months, he has been undergoing chemotherapy with ifosfamide, carboplatin, and etoposide.\n    His last treatment was 1 week ago, and since that time, he has had nausea, vomiting, diarrhea, and poor oral intake.</p>\n<p>On examination, BP is 104/58 mm Hg, and heart rate is 96/min. His lungs are clear, and there is no lower extremity edema. He has diminished strength in all extremities. The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>140 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>115 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>17 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Uric acid</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–7.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>81 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>45 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>85 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>40 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Uric acid</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>40 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> Trace</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely etiology of his electrolyte abnormalities?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ifosfamide"
            },
            {
                "label": "B.",
                "text": "Malnutrition"
            },
            {
                "label": "C.",
                "text": "Etoposide"
            },
            {
                "label": "D.",
                "text": "Carboplatin"
            },
            {
                "label": "E.",
                "text": "Diarrhea"
            }
        ],
        "correct_answer": "Ifosfamide",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypokalemia, hypophosphatemia, hypouricemia, and non-anion gap metabolic acidosis most likely has generalized proximal tubule dysfunction from ifosfamide toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Electrolyte abnormalities are common complications of chemotherapy. Ifosfamide may adversely affect kidney function in several ways, including AKI due to acute tubular injury, CKD, and proximal tubulopathy (Fanconi syndrome). Ifosfamide is transported via the apical organic cation transporter OCT-2 from the urinary filtrate into proximal tubule cells. Inside the cell, the drug is metabolized into chloroacetaldehyde, where it can accumulate and disrupt oxidative phosphorylation. AKI occurs in up to 60% of patients receiving ifosfamide, and up to 30% progress to CKD. Risk factors include cumulative dose, concurrent cisplatin therapy, and nephrectomy. Manifestations of Fanconi syndrome include hypokalemia, hypophosphatemia, hypouricemia, aminoaciduria, non-anion gap metabolic acidosis, and normoglycemic glycosuria. The diagnosis of Fanconi syndrome can be confirmed calculating the fractional excretion of each electrolyte, which will be elevated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although malnutrition may lead to hypophosphatemia and hypokalemia in patients with underlying malignancy, especially in those with refeeding syndrome, the renal electrolyte wasting seen here would be unexpected. Vomiting may lead to hypokalemia but typically causes concurrent metabolic alkalosis, which is not present in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Carboplatin is less nephrotoxic than cisplatin because it circulates bound to plasma proteins and is less likely to be filtered and reabsorbed into proximal tubule cells. The generalized proximal tubulopathy seen in this case would be more characteristic of ifosfamide exposure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Etoposide may cause metabolic acidosis and other electrolyte abnormalities due to diarrhea and impaired gastrointestinal absorption. Again, renal wasting of these electrolytes would not be consistent with this diagnosis.</p>\n</div>",
        "references": [
            "Sprangers B, Lapman S: The growing pains of ifosfamide.Clin Kidney J13(4): 500–503, 2020",
            "Ensergueix G, Pallet N, Joly D, et al: Ifosfamide nephrotoxicity in adult patients.Clin Kidney J13(4): 660–665, 2019",
            "Nissim I, Horyn O, Daikhin Y, et al: Ifosfamide-induced nephrotoxicity: mechanism and prevention.Cancer Res66(15): 7824–7831, 2006",
            "Oronsky B, Caroen S, Oronsky A et al: Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.Cancer Chemother Pharmacol80(5): 895–907, 2017"
        ]
    },
    "31": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with metastatic cholangiocarcinoma and type 2 diabetes presents to the emergency department with syncope and polyuria. He reports decreased appetite but no diarrhea or vomiting. He has lost 4 kg over the last 2 weeks, and reports dizziness\n    and lightheadedness when standing. He was diagnosed with cholangiocarcinoma 1 year ago and has received cisplatin and gemcitabine since diagnosis, most recently 1 week ago. He reports that he has not been taking his insulin for the last 4 days. Over\n    the last 24 hours, his fluid intake was 1 L, and his urine output was 3.2 L.</p>\n<p>His vital signs are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>BP</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Heart Rate</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Supine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>105/72 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>99/min</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sitting</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90/68</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>115</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Standing</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>85/60</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>135</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>On examination, he has dry skin, with decreased turgor, sunken and icteric eyes, and tachycardia. He does not have an elevated jugular venous pressure or edema.</p>\n<p> Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>127 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>1.8 mg/dL (baseline, 1.4)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>240 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>70­–99, fasting </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>35 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>257 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>275–295 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>125 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>85 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>     Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>360 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 15px; vertical-align: top;\">\n<p>38–1400 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>A CT scan of the head is unremarkable.</p>\n<p><strong>Which ONE of the following is the MOST likely etiology of his hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Glycosuria-mediated osmotic diuresis"
            },
            {
                "label": "B.",
                "text": "Syndrome of inappropriate antidiuretic hormone (SIADH)"
            },
            {
                "label": "C.",
                "text": "Low solute intake"
            },
            {
                "label": "D.",
                "text": "Pseudohyponatremia"
            },
            {
                "label": "E.",
                "text": "Renal salt wasting"
            }
        ],
        "correct_answer": "Renal salt wasting",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypovolemic hyponatremia and polyuria most likely has renal salt wasting attributable to cisplatin toxicity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with syncope due to orthostatic hypotension, polyuria, AKI, and hyponatremia. The urine is hypertonic compared with serum, and the urine sodium concentration is elevated despite evidence of volume depletion. Specifically, this hypovolemic patient is losing (125 mEq/L × 3.2 L/day =) 400 mEq/day or 9.2 g/day of sodium in the urine. These findings suggest inappropriate urinary salt wasting. Cisplatin has been associated with renal salt wasting, attributed to several mechanisms. Cisplatin concentrates in proximal tubular cells via the organic cation transporter-2, directly damaging proximal tubular cells and preventing sodium reabsorption. Furthermore, cisplatin binds to and inhibits the basolateral Na<sup>+</sup>-K<sup>+</sup>-ATPase and may weakly inhibit the distal sodium epithelial channel, further reducing sodium reabsorption. Low mean arterial pressure leads to secretion of antidiuretic hormone (ADH) with consequent hyponatremia. The treatment of choice is to replete volume with isotonic saline and to maintain a high sodium diet while polyuria persists.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Osmotic diuresis from non-reabsorbed solute, such as glucose, in the urinary filtrate can cause polyuria and volume depletion. Osmotic diuresis is usually diagnosed when urine osmolality &gt;300 mOsm/kg H<sub>2</sub>O and total daily urine osmolal excretion &gt;1000 mOsm/day, both of which are present in this case (daily osmolal excretion = urine osmolality × urine output = 360 mOsm/kg H<sub>2</sub>O × 3.2 L/day = 1152 mOsm/day). However, despite the serum hyperglycemia, most of the urine osmolality is accounted for by sodium and its associated anions (daily sodium and anion excretion = 125 mOsm/kg H<sub>2</sub>O × 2 × 3.2 L/day = 800 mOsm/day).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although SIADH is almost always in the differential diagnosis with renal salt wasting, SIADH is not consistent with inappropriate urinary sodium loss, polyuria, and hypovolemia. Patients with SIADH tend to be euvolemic with relatively low urine output.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Low solute intake, that is, “tea and toast” diet or beer potomania, presents with a low urinary sodium and osmolality, which is not the case here.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient does not have paraproteinemia or hyperlipidemia, and low serum osmolality rules out pseudohyponatremia.</p>\n</div>",
        "references": [
            "Pabla N, Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.Kidney Int73(9): 994–1007, 2008",
            "Soares AG, Mironova E, Archer CR, et al: Cisplatin decreases ENaC activity contributing to renal salt wasting syndrome.Cancers (Basel)12(8): 2140, 2020",
            "Latcha S, Jaimes EA, Patil S, et al: Long-term renal outcomes after cisplatin treatment.Clin J Am Soc Nephrol11(7): 1173–1179, 2016",
            "Russo C, Ma L, Johnson WR, Singaraju R: Cisplatin-induced acute kidney injury and renal salt wasting syndrome.Fed Pract38(12): 606–611a, 2021"
        ]
    },
    "32": {
        "question": "<div class=\"qtext\"><p>A 31-year-old woman is referred to the nephrology clinic for kidney cysts. One month ago, she underwent a CT scan to evaluate new abdominal pain; the scan revealed kidney cysts and cholelithiasis. No cysts were seen in her liver. Her past medical history includes obesity, pre-diabetes, and hypertension. She is adopted and does not know her family history. Her only medication is amlodipine.</p>\n<p>Her BP is 129/73 mm Hg. The remainder of her examination is normal, without masses palpated in her flanks.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.05 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>eGFR</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>74 mL/min/1.73 m<sup>2</sup></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≥60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.2 mg/mg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for protein, glucose, blood, and leukocyte esterase.</p>\n<p>Kidney ultrasound shows a 12-cm right kidney, with one simple cyst in the upper pole measuring 3.4 cm at its largest diameter, and an 11.3-cm left kidney, with two simple cysts in the lower pole measuring 2.3 cm and 1.9 cm at their largest diameter.</p>\n<p>The patient and her husband are planning pregnancy within the next year and are interested to know whether she has ADPKD.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Genetic screening"
            },
            {
                "label": "B.",
                "text": "Prescribe lisinopril"
            },
            {
                "label": "C.",
                "text": "Prescribe tolvaptan"
            },
            {
                "label": "D.",
                "text": "No additional management"
            },
            {
                "label": "E.",
                "text": "MRI with kidney volume\n calculation"
            }
        ],
        "correct_answer": "Genetic screening",
        "abim_content_category": "Tubular, Interstitial and Cystic disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with an unknown family history and a higher-than-expected number of kidney cysts, genetic screening for <em>PKD </em>mutations may provide a definitive diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The revised Ravine criteria (also called the Pei-Ravine criteria) for ADPKD uses ultrasound findings to diagnose ADPKD in individuals with a family history of ADPKD. These criteria include the presence of ≥3 unilateral or bilateral kidney cysts in those aged 15–39 years, ≥2 cysts in each kidney in those aged 40–59 years, ≥4 cysts in each kidney in those aged ≥60 years. Studies have shown 10%–25% of those with ADPKD do not have an apparent positive family history. For those without a clear family history of ADPKD, the presence of ≥10 cysts in each kidney has been used to diagnose ADPKD.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This case highlights the challenge of applying ultrasound criteria when family history is uncertain or unknown. In these cases, comparing cyst number to the prevalence in the general population can be used for risk stratification. A 1993 study of kidney ultrasound results from 729 people with normal kidney function determined the prevalence of at least one kidney cyst to be 0% among patients 15–29 years, 1.7% in those 30–49 years, 11.5% in those 50–69 years, and 22.1% in those ≥70 years of age. The prevalence of bilateral cysts (at least one cyst in each kidney) by age was 1% in patients 30–49 years, 4% in patients 50–69 years, and 9% in patients ≥70 years of age. A second study of potential kidney donors without cystic kidney disease reported that in subjects who were 19–49 years old, 39% had a cortical or medullary cyst ≥2 mm in diameter, 22% had a cyst ≥5 mm in diameter, 7.9% had a cyst ≥10 mm in diameter, and 1.6% had a cyst ≥20 mm in diameter. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Therefore, although our patient does not meet the Pei-Ravine ultrasound criteria for ADPKD, based on the estimated prevalence in the general population, she has a higher number of cysts than expected for her age. Therefore, given this patient’s interest in obtaining a diagnosis for family planning, further testing by genetic testing could be considered. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She does not meet criteria for ADPKD, so starting tolvaptan would be inappropriate. Similarly, in the HALT-PKD trial, lisinopril to lower BP to &lt;110/75 mm Hg improved several surrogate outcomes but would be inappropriate in this patient without a diagnosis; additionally, lisinopril would not be a good medication to initiate in a patient planning pregnancy. Reassurance without additional management would be appropriate if this patient had a known family history or if she had fewer kidney cysts than the general population prevalence for her age.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Volumetric MRI is used to determine risk of progression in patients with known ADPKD but would not be used to make the diagnosis.</p>\n</div>",
        "references": [
            "Pei Y, Obaji J, Dupuis A et al: Unified criteria for ultrasonographic diagnosis of ADPKD.J Am Soc Nephrol20(1): 205–212, 2009",
            "Rule AD, Sasiwimonphan K, Lieske JC, et al: Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors.Am J Kidney Dis59(5): 611–618, 2012",
            "Iliuta IA, Kalatharan V, Wang K, et al: Polycystic kidney disease without an apparent family history.J Am Soc Nephrol28(9): 2768–2776, 2017",
            "Cornec-Le Gall E, Audrézet MP, Chen JM, et al: Type of PKD1 mutation influences renal outcome in ADPKD.J Am Soc Nephrol24(6): 1006–1013, 2013",
            "Schrier RW, Abebe KZ, Perrone RD, et al: Blood pressure in early autosomal dominant polycystic kidney disease.N Engl J Med371(24): 2255–2266, 2014"
        ]
    },
    "33": {
        "question": "<div class=\"qtext\"><p>A 45-year-old woman presents to nephrology clinic for follow-up of hypertension and stage 3 CKD. Her hypertension has been well controlled for 3 years on a regimen containing lisinopril, chlorthalidone, and hydralazine. Today, she complains of 4 months of generalized malaise, low-grade fevers, and arthralgias. She does not take over-the-counter or herbal medications and has not been exposed to any sick contacts. </p>\n<p>On examination, her BP is 138/90 mm Hg, heart rate is 82/min, temperature is 38.2°C, and oxygen saturation is 99% while breathing room air. She appears tired but is in no acute distress. Her cardiac and pulmonary examinations are normal. She has generalized tenderness to palpation of her major muscle groups, but no erythema or edema of her joints or extremities. She has a faint maculopapular rash on her arms and torso. </p>\n<p>Laboratory data are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.4 mg/dL (2 years ago, 1.6)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C3</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>120 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100–233</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  C4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>39 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–48</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Antinuclear antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1:80</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤1:40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Antibodies to double-stranded DNA</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0 IU/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–7</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Antihistone antibodies</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1:32</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1:16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  p-ANCA (anti-myeloperoxidase antibodies)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3 U</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  c-ANCA (anti-proteinase-3 antibodies)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3 U</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Specific gravity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.020</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.002–1.030</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Blood</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the NEXT best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Obtain kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Prescribe methylprednisolone"
            },
            {
                "label": "C.",
                "text": "Discontinue hydralazine"
            },
            {
                "label": "D.",
                "text": "Obtain blood cultures"
            },
            {
                "label": "E.",
                "text": "Check creatine kinase level"
            }
        ],
        "correct_answer": "Discontinue hydralazine",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Discontinuing hydralazine is the next best step in this patient with evidence of drug-induced lupus (DIL).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">DIL is a type B hypersensitivity reaction leading to the development of true autoantibodies. Although the mechanism of autoimmunity is not clear, there is evidence for disruption of T-cell tolerance and direct T-cell activation by drug metabolites. Additionally, studies have shown that activated neutrophils can convert procainamide and hydralazine into cytotoxic products via a myeloperoxidase-dependent pathway. Several drugs have been implicated in DIL, but procainamide and hydralazine have the highest reported incidence. DIL can occur any time after initiation of treatment with the offending agent, although incidence is highest within the first year. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diagnosis requires the following:</p>\n<ol>\n<li>Continued exposure to the offending agent for &gt;1 month </li>\n<li>Symptoms consistent with SLE </li>\n<li>No prior history of SLE </li>\n<li>Quick resolution of symptoms upon discontinuation of the offending agent</li>\n</ol>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Symptoms commonly are mild and include rash, fever, myalgias, and polyarthritis. Common serologic abnormalities in hydralazine-induced DIL include positive ANA, ANCA, and anti-histone antibodies, but anti-double-stranded DNA antibodies are uncommon. Anemia and leukopenia are common. Organ-specific involvement, including pericarditis, pleuritis, and nephritis are possible but rare.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The first step in treatment is identification and withdrawal of the offending agent. Symptoms typically improve within days to weeks. If symptoms are severe or persistent, NSAIDs, antimalarials, and low-dose corticosteroids may be prescribed. Major organ involvement, however, requires immunosuppressive therapy with high-dose corticosteroids and alkylating or antiproliferative agents. Prognosis, especially in cases without major organ involvement, is favorable compared with SLE. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient has several positive autoantibodies, she has no evidence of AKI, proteinuria, or active sediment, and a biopsy would not be indicated. Treatment with methylprednisolone and other immunosuppressants may be indicated in SLE, but primary SLE has not been diagnosed. Her fever and leukopenia are more consistent with DIL than bacteremia, so obtaining blood cultures would not be the most appropriate next step. Similarly, her myalgias are likely due to DIL, so checking a creatine kinase level would not be diagnostic.</p>\n</div>",
        "references": [
            "Hogan JJ, Markowitz GS, Radhakrishnan J: Drug-induced glomerular disease: immune-mediated injury.Clin J Am Soc Nephrol10(7): 1300–1310, 2015",
            "Lee AYS: Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus [published online ahead of print April 6, 2022].Immunol Meddoi:10.1080/225785826.2022.2060168.",
            "Vaglio A, Grayson PC, Fenaroli P: Drug-induced lupus: traditional and new concepts.Autoimmun Rev17(9): 912–918, 2018",
            "Rubin RL, Haluptzok RF, Davila LM: Severe hydralazine-induced lupus presenting as systemic lupus erythematosus.Lupus29(5): 509–513, 2020"
        ]
    },
    "34": {
        "question": "<div class=\"qtext\"><p>A 70-year-old man with metastatic lung cancer is admitted to the hospital due to lethargy. He has a 2-week history of nausea, intermittent emesis, and poor oral intake. Over the last few days, he has had minimal fluid intake and has been sleeping most of the day, which prompted his family to bring him to the emergency department.</p>\n<p>On examination, his BP is 102/64 mm Hg with a heart rate of 108/min. He is in no respiratory distress. He appears cachectic and older than his stated age. Oral mucosa are dry. He has no peripheral edema. He is alert and oriented but slow to answer questions.</p>\n<p>Laboratory data are obtained and show that his serum sodium is 162 mEq/L (reference range, 136–145) and serum creatinine is 1.3 mg/dL (reference range, 0.7–1.3). His urine sodium is &lt;20 mEq/L, and urine osmolality is 835 mOsm/kg H<sub>2</sub>O (reference range, 38–1400).</p>\n<p>He is administered isotonic saline 1 L, and repeat BP is now 118/68 mm Hg, with a heart rate of 98/min. His repeat serum sodium is 161 mEq/L, and creatinine is 1.2 mg/dL.</p>\n<p><strong>Which ONE of the following is the BEST next step in management of this patient’s hypernatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Dextrose 5% in water,\nwith goal correction 4–6 mEq/L over 24 hours"
            },
            {
                "label": "B.",
                "text": "Isotonic saline, with\ngoal correction 10–12 mEq/L over 24 hours"
            },
            {
                "label": "C.",
                "text": "Isotonic saline, with\ngoal correction 4–6 mEq/L over 24 hours"
            },
            {
                "label": "D.",
                "text": "Dextrose 5% in water,\nwith goal correction 10–12 mEq/L over 24 hours"
            },
            {
                "label": "E.",
                "text": "Lactated Ringer’s\nsolution, with goal correction 10–12 mEq/L over 24 hours"
            }
        ],
        "correct_answer": "Dextrose 5% in water,\nwith goal correction 10–12 mEq/L over 24 hours",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The best next step in managing this patient’s hypernatremia is to start dextrose 5% in water (D5W) continuous IV infusion, with a goal correction rate of 10–12 mEq/L over the next 24 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with severe hypernatremia, which in this case is due to severe gastrointestinal losses without adequate water intake. His urine osmolality &gt;800 mOsm/kg H<sub>2</sub>O indicates appropriate renal water conservation, mediated by antidiuretic hormone acting on functional renal tubules, for the ongoing serum water deficit. Although hemodynamic stabilization appropriately takes precedence over serum sodium correction, the focus now should shift toward normalization of the serum tonicity. Isotonic saline or lactated Ringer’s solution would not provide additional water supplementation, so would not address the patient’s free water deficit or ongoing water losses. Thus, these isotonic fluids would not help ameliorate hypernatremia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In adult patients with acute hypernatremia, defined by a duration of 48 hours or less, the serum sodium may be corrected up to a rate of 1 mEq/L per hour to a normal sodium level within 24 hours. If the duration of the hypernatremia is &gt;48 hours or unknown, then it must be treated as chronic hypernatremia. In adult patients, the goal correction rate of 10–12 mEq/L over the first 24 hours is generally recommended, although adopted from the pediatric literature. A recent study of 122 patients with severe hypernatremia (serum sodium &gt;155 mEq/L) on admission and 327 patients who developed hospital-acquired hypernatremia failed to show a higher risk of mortality, seizure, altered consciousness, or cerebral edema in patients who had their serum sodium levels corrected faster than 0.5 mEq/L per hour. Thus, D5W infusion with a goal correction rate of 4–6 mEq/L would be unnecessarily slow and would likely prolong this patient’s hospitalization.</p>\n</div>",
        "references": [
            "Qian Q: Hypernatremia.Clin J Am Soc Nephrol14(3): 432–434, 2019",
            "Chauhan K, Pattharanitima P, Patel N, et al: Rate of correction of hypernatremia and health outcomes in critically ill patients.Clin J Am Soc Nephrol14(5): 656–663, 2019"
        ]
    },
    "35": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with a past medical history of hypertension and hyperlipidemia presents to his primary care physician to evaluate fatigue and low back pain. He was last seen two years ago. His home medications include atorvastatin, amlodipine, and chlorthalidone.\n    He has also been taking over-the-counter ibuprofen three times daily for the last month.</p>\n<p>On examination, his BP is 160/80 mm Hg with a heart rate of 80/min. He is in no acute distress and appears his stated age. There is no evidence of a cardiac murmur or rub. He has no peripheral edema. He has no point tenderness on palpation of his back and no\n    rashes or lesions noted.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>139 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.3 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98‒106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>33 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8‒20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.3 mg/dL (baseline 1.0)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>78 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70‒99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6‒10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.5‒9.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5‒5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total cholesterol</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>265 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;200, desirable</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Triglycerides</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>602 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;150, normal</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s low anion gap?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Paraproteinemia"
            },
            {
                "label": "B.",
                "text": "Hypertriglyceridemia"
            },
            {
                "label": "C.",
                "text": "Ibuprofen consumption"
            },
            {
                "label": "D.",
                "text": "Laboratory error"
            },
            {
                "label": "E.",
                "text": "Chlorthalidone"
            }
        ],
        "correct_answer": "Paraproteinemia",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely explanation for this patient’s low anion gap is unmeasured, cationic light chains (paraproteins) suggesting underlying multiple myeloma (MM).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The anion gap, calculated as serum Na – (Cl + HCO<sub>3</sub>), is most commonly used to evaluate for unmeasured anions to further characterize a metabolic acidosis. The normal anion gap varies by local laboratory but is usually in the range of 7–13 mEq/L, or approximately two to three times the albumin (normal, ~4) measured in g/dL. This patient’s serum anion gap is 139 – (110 + 28) = 1 mEq/L..</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with symptoms and laboratory findings concerning for MM, including fatigue, back pain, worsening kidney function, hypercalcemia, and an elevated protein gap (total protein – albumin &gt;4 g/dL), which suggests unmeasured serum proteins such as paraproteins. Patients with plasma cell dyscrasias may accumulate monoclonal immunoglobulins that are typically cationic and occur in the serum as chloride salts, causing elevated serum chloride and a low or even negative anion gap.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most frequent cause of a low anion gap is laboratory error, which is less likely in this case given the high suspicion for MM. Once error has been excluded, other causes of low anion gap should be sought. A common cause of low anion gap is low serum albumin. Other causes include the accumulation of unmeasured cations such as lithium or substances that interfere with and activate the chloride electrode, such as bromide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertriglyceridemia is a cause of pseudohyponatremia, which may be accompanied by falsely low measurement of other serum electrolytes and, possibly, a falsely low anion gap. In this case, the normal serum sodium argues against hypertriglyceridemia as a cause of low anion gap.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ibuprofen and chlorthalidone are not associated with low or negative serum anion gap.</p>\n</div>",
        "references": [
            "Emmett M: Approach to the patient with a negative anion gap.Am J Kidney Dis67(1): 143‒150, 2016",
            "Kraut JA, Madias NE: Serum anion gap: its uses and limitations in clinical medicine.Clin J Am Soc Nephrol2(1): 162‒174, 2007"
        ]
    },
    "36": {
        "question": "<div class=\"qtext\"><p>A 24-year-old man with newly diagnosed hypertension is referred to the outpatient nephrology clinic for evaluation. He presented for a routine health screening visit and was to have BP of 160/90 mm Hg. He is otherwise healthy and denies any symptoms.\n    He denies the use of over-the-counter supplements, illicit drugs, or NSAIDs. He reports that he was not born prematurely. He has a history of childhood urinary tract infections that have required twice yearly antibiotic treatments since age 5. He has\n    no family history of kidney disease, vision problems, or hearing loss.</p>\n<p>On examination, his BP is 150/90 mm Hg with a heart rate of 80/min. He appears well. Physical examination is normal with no peripheral edema. </p>\n<p>Laboratory data reveal serum creatinine 1.2 mg/dL (reference range, 0.7‒1.3), potassium 4.0 mEq/L (reference range, 3.5‒5.0), and total CO<sub>2</sub> 24 mEq/L (reference range, 23‒28). His urinalysis shows 1+ protein. Serum aldosterone and renin levels are normal. A kidney ultrasound reveals that the right kidney is 13.5 cm long without hydronephrosis, but the left kidney is severely atrophic.</p>\n<p><strong>Which ONE of the following is the MOST likely explanation for this patient’s ultrasound findings? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypertensive nephrosclerosis"
            },
            {
                "label": "B.",
                "text": "Reflux nephropathy"
            },
            {
                "label": "C.",
                "text": "Renal artery stenosis"
            },
            {
                "label": "D.",
                "text": "Chronic interstitial\nnephritis"
            },
            {
                "label": "E.",
                "text": "Glomerulonephritis"
            }
        ],
        "correct_answer": "Reflux nephropathy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely explanation for this patient’s ultrasound findings is chronic reflux nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The ultrasound shows evidence of unilateral renal atrophy, which falls into the constellation of findings termed congenital abnormalities of the kidney and urinary tract (CAKUT). Chronic reflux nephropathy may be attributed to vesicoureteral reflux, posterior urethral valves, or ureteropelvic junction obstruction and may predispose to recurrent urinary tract infections, including pyelonephritis, and unilateral or bilateral kidney hypodysplasia because of increased pressure in the collecting system during kidney development. Genetic mutations account for ~16% of cases of CAKUT, and manifestations are protean. Notable genetic disorders include renal-coloboma syndrome (renal hypoplasia and optic nerve coloboma) and branchio-oto-renal syndrome (neck cysts or fistulae, pinna malformations, and renal hypoplasia). In the absence of family history, parental consanguinity, or systemic syndrome manifestations, there is no well-defined role for genetic screening in CAKUT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Unilateral renal artery stenosis (RAS) may cause persistent ischemia and eventual kidney atrophy. In older patients, atherosclerosis is the most common cause of proximal RAS and may present with unilateral atrophy. In younger patients, fibromuscular dysplasia is a more likely cause of RAS and presents with more distal obstruction; unilateral kidney atrophy is uncommon. In either case, impaired renal artery perfusion causes increased renin and aldosterone production, which in turn results in hypertension, frequently with hypokalemia and metabolic alkalosis. The normal laboratory parameters in this case make RAS unlikely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic interstitial nephritis may occur in the setting of long-term exposure to toxins or drugs, including antibiotics. Exposure would affect both kidneys, however, and the normal urinalysis and unilateral atrophy make this diagnosis less likely.</p>\n<p>Hypertension is frequently invoked as a cause of CKD, but the precise relationship between elevated BP and CKD is unknown and may vary by genetic predisposition. Regardless, neither hypertension-associated CKD nor chronic glomerulonephritis manifest as unilateral kidney atrophy, and the latter would most likely present with an active urinary sediment.</p>\n</div>",
        "references": [
            "Kerecuk L, Schreuder MF, Woolf AS: Renal tract malformations: perspectives for nephrologists.Nat Clin Pract Nephrol4(6): 312‒325, 2008",
            "Weber S, Moriniere V, Knuppel T et al: Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study.Clin J Am Soc Nephrol17(10): 2864‒2870, 2006",
            "Kagan M, Pleniceanu O, Vivante A: The genetic basis of congenital abnormalities of the kidney and urinary tract.Pediatr Nephrol37(10): 2231‒2243, 2022",
            "Alexander SE, Arlen AM, Storm DW et al: Bladder volume at onset of vesicoureteral reflux is an independent risk factor for breakthrough febrile urinary tract infection.J Urol193(4): 1342‒1346, 2015"
        ]
    },
    "37": {
        "question": "<div class=\"qtext\"><p>A 63-year-old woman with ESRD due to IgA nephropathy, who is 4 years status post deceased donor kidney transplant, presents to kidney transplant clinic for routine follow-up. She feels well, with no changes to her diet or urine output, and is adherent to all her medications. Her medication regimen includes tacrolimus, mycophenolate mofetil, low-dose prednisone, lisinopril, and atorvastatin. Her BP is 132/88 mm Hg.</p>\n<p>Her laboratory results are notable for a serum creatinine of 1.2 mg/dL (reference range, 0.5–1.1), which is her baseline. Her urinalysis shows microscopic hematuria, and her urine protein-to-creatinine ratio has increased from 0.1 mg/mg 3 months ago to 0.7 mg/mg currently (reference range, &lt;0.2) </p>\n<p>An ultrasound of her kidney transplant demonstrates no hydronephrosis, normal echogenicity, and no masses. A CT urogram reveals bilateral benign native kidney cysts with no other abnormalities. Cystoscopy reveals no masses or evidence of inflammation.</p>\n<p>Her transplant kidney biopsy reports increased mesangial matrix deposition with mesangial hypercellularity and no crescents on light microscopy. Immunofluorescence shows 3+ mesangial IgA and 2+ mesangial C3.</p>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase prednisone"
            },
            {
                "label": "B.",
                "text": "Prescribe cyclophosphamide"
            },
            {
                "label": "C.",
                "text": "Prescribe budesonide"
            },
            {
                "label": "D.",
                "text": "Continue current regimen"
            },
            {
                "label": "E.",
                "text": "Prescribe losartan"
            }
        ],
        "correct_answer": "Continue current regimen",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No change in the medication regimen is the next best step in the management of this patient with subclinical, recurrent IgA nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IgA nephropathy is the most common cause of glomerulonephritis worldwide and recurs in approximately 33% of patients following kidney transplant. Recurrent IgA nephropathy typically presents as asymptomatic microscopic hematuria with or without proteinuria. IgA nephropathy may recur immediately after kidney transplant, but the average time of diagnosis is approximately 3 years after transplantation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recurrence of IgA nephropathy seems to have no effect on short-term graft survival (&lt;10 years), and therefore the management of recurrent IgA nephropathy following kidney transplant is to maintain the immunosuppressive regimen, unless there are compelling indications to modify it. There is some evidence that long-term graft survival (~15 years) may be reduced in patients with recurrent IgA nephropathy. No specific therapy for recurrent IgA nephropathy is currently available, although ACEIs and ARBs are reasonable treatment options.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The combination of an ARB with an ACEI is not recommended due to an increased risk of adverse events. Budesonide has been shown to be of possible benefit in preventing the progression of IgA nephropathy, although has not been studied in kidney transplant recipients. Cyclophosphamide is reserved for patients with rapidly progressive disease (such as those with crescentic glomerulonephritis).</p>\n</div>",
        "references": [
            "Uffing A, Hullekes F, Riella LV, Hogan JJ: Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas.Clin J Am Soc Nephrol16(11): 1730‒1742, 2021",
            "Uffing A, Pérez-Saéz MJ, Jouve T, et al: Recurrence of IgA nephropathy after kidney transplantation in adults.Clin J Am Soc Nephrol16(8): 1247‒1255, 2021",
            "Ponticelli C, Glassock RJ: Posttransplant recurrence of primary glomerulonephritis.Clin J Am Soc Nephrol5(12): 2363‒2372, 2010",
            "O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC: Patient characteristics and outcomes by GN subtype in ESRD.Clin J Am Soc Nephrol10(7): 1170‒1178, 2015"
        ]
    },
    "38": {
        "question": "<div class=\"qtext\"><p>A 53-year-old man who underwent deceased donor kidney transplantation 1 year ago calls the transplant clinic to seek advice after being diagnosed with COVID-19. His post-transplant course was previously complicated by an episode of acute cellular rejection, which was managed with high-dose corticosteroids. He has subsequently done well, and his kidney allograft function has recently been normal. He now reports two days of rhinorrhea and mild throat soreness in the setting of his infection. He is otherwise asymptomatic. He has been fully vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is following recommendations regarding the timing of booster shots. His current immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. </p>\n<p><strong>Which ONE of the following is MOST likely to reduce the risk of severe illness?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue tacrolimus"
            },
            {
                "label": "B.",
                "text": "Discontinue all immunosuppression"
            },
            {
                "label": "C.",
                "text": "Dexamethazone"
            },
            {
                "label": "D.",
                "text": "Anti-SARS-CoV-2 monoclonal antibodies"
            },
            {
                "label": "E.",
                "text": "Tocilizumab"
            }
        ],
        "correct_answer": "Anti-SARS-CoV-2 monoclonal antibodies",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a solid organ transplant and COVID-19 infection should be treated with anti-SARS-CoV-2 monoclonal antibodies.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The management approach for COVID-19 in solid organ transplant recipients is largely analogous to that recommended for the general population. Due to the higher risk of severe illness in solid organ transplant recipients, however, a lower threshold for antiviral treatment, such as the administration of monoclonal antibodies, is recommended. Such treatment should be provided as soon as possible after symptom onset. Monoclonal antibody treatment is currently only approved for outpatient management of patients with COVID-19.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is currently only mildly symptomatic and is neither hospitalized nor requiring supplemental oxygen. He does therefore not meet criteria for initiation of treatment with either dexamethasone or tocilizumab, an interleukin-6 receptor inhibitor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Complete discontinuation of immunosuppression will increase the risk of kidney allograft rejection and is not a recommended strategy for preventing severe illness due to COVID-19. Although the dose of mycophenolate mofetil is commonly reduced or fully discontinued in solid organ transplant recipients with COVID-19 infection, particularly in the setting of severe illness and when neutropenia is present, such decisions are made on an individualized basis. Evidence that discontinuing or decreasing doses of any component of the immunosuppressive regimen improves outcomes as a routine approach to mild COVID-19 infection is currently lacking.</p>\n</div>",
        "references": [
            "Kates OS, Haydel BM, Florman SS, et al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study.Clin Infect Dis73(11): e4090–e4099, 2021",
            "COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed February 6, 2022",
            "Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management. Accessed February 6, 2022",
            "Catalano C, Servais S, Bonvoisin C, et al: Preemptive antibody therapy for vaccine breakthrough SARS-CoV-2 infection in immunocompromised patients.Transplantation105(12): e282, 2021",
            "Del Bello A, Marion O, Vellas C, et al: Anti-SARS-CoV-2 monoclonal antibodies in solid-organ transplant patients.Transplantation105(10): e146–147, 2021",
            "Fernandes G, Devresse A, Scohy A, et al: Monoclonal antibody therapy for SARS-CoV-2 infection in kidney transplant recipients: a case series from Belgium.Transplantation106(1): e107–e108, 2022"
        ]
    },
    "39": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man is referred to the nephrology clinic to evaluate resistant hypertension. He reports excellent adherence to his medication regimen and started the Dietary Approaches to Stop Hypertension (DASH) diet and 30 minutes of aerobic exercise daily 6 months\n    ago. He feels well, without dyspnea, chest pain, palpitations, sweating, or headache. He does not have a history of smoking, alcohol use, or drug use. His medication regimen includes valsartan, amlodipine, hydrochlorothiazide, and potassium chloride. </p>\n<p>On examination, BP is 157/90 mm Hg in his right arm and 158/88 mm Hg in his left arm. Heart rate is 80/min. His body mass index (BMI) is 23 kg/m<sup>2</sup>, and neck circumference is 38 cm. His cardiac and pulmonary examinations are unremarkable, and he has\n    no carotid or abdominal bruits. There is no edema in the lower extremities bilaterally. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Reference Range</strong> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>139 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.4 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>108 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.9 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Urine albumin-to-creatinine ratio </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4 mg/g</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;30</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound shows each kidney 10–10.2 cm in length with no obstruction but mildly increased echogenicity.</p>\n<p><strong>Which ONE of the following is the BEST next step in diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Renal artery Doppler ultrasound"
            },
            {
                "label": "B.",
                "text": "Polysomnography"
            },
            {
                "label": "C.",
                "text": "Plasma renin and aldosterone"
            },
            {
                "label": "D.",
                "text": "Thyroid-stimulating hormone"
            },
            {
                "label": "E.",
                "text": "24-hour urine metanephrines and normetanephrines"
            }
        ],
        "correct_answer": "Plasma renin and aldosterone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with resistant hypertension and mild hypokalemia despite potassium supplementation, the next best step in management is to obtain a morning plasma aldosterone-to-renin ratio.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Resistant hypertension is defined as a BP of &gt;130/80 mm Hg while on maximal doses of at least three antihypertensive medications, including a diuretic. Patients with apparent resistant hypertension should first be assessed for adherence to their medical regimen and then should be evaluated for secondary causes of hypertension, including hyperaldosteronism, renal artery stenosis, and obstructive sleep apnea. In a patient with mild hypokalemia and/or metabolic alkalosis, despite use of an ARB and PO potassium supplementation, evaluation for hyperaldosteronism is warranted. In a study of ~1600 patients with resistant hypertension, 11% had primary aldosteronism. However, of these patients, only 46% had hypokalemia. Thus, the absence of hypokalemia should not preclude testing for primary hyperaldosteronism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary aldosteronism may be diagnosed by measuring a simultaneous, morning (8:00 am) plasma renin activity (PRA) or renin concentration (PRC) and aldosterone concentration (PAC). In patients with primary aldosteronism, PRA and PRC will be low and PAC will be elevated. There is some evidence that the PAC/PRA ratio is relatively insensitive compared with a 24-hour urine aldosterone measurement following two days of sodium loading. Moreover, there has been a national trend for laboratories to replace measuring PRA with PRC; as there is no ready conversion between enzyme activity and enzyme concentration, it is uncertain how to apply previously derived absolute values and ratios for renin activity to diagnose primary aldosteronism in the modern era.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Traditionally, diagnostic thresholds for diagnosing primary aldosteronism include undetectable PRA with PAC &gt;10 ng/dL or PAC/PRA ratio &gt;20. Some experts recommend dividing the PRC by 4‒5 to calculate the approximate equivalent PRA. Alternatively, a PAC/PRC ratio &gt;3.7 is concerning for primary aldosteronism. Although many medications may affect the PRA, PAC, and PAC/PRA ratio, calculations remain valid as long as a patient has not taken a mineralocorticoid receptor antagonist for the preceding 6‒8 weeks. Measurements must be made under standard conditions: in the morning &gt;2 hours after awakening, seated after 5‒15 minutes, with normal dietary salt intake and normal potassium levels. In this case, potassium would optimally be supplemented further to increase serum levels into the normal range before measuring the PAC/PRA ratio.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Renal artery duplex Doppler ultrasound is a commonly used initial test to evaluate for renovascular hypertension (RVHT). Patients with renal artery stenosis have secondary hyperaldosteronism and can be profoundly hypokalemic. However, patients with RVHT typically have evidence of CKD (from ischemic nephropathy) or discrepancy in their kidney sizes in the case of unilateral renal artery stenosis. Moreover, measuring PRA and PRC may suggest RVHT, as both parameters would be expected to be elevated. Last, the value of diagnosing renal artery stenosis as a cause of secondary hypertension is questionable, as there is usually no indication for other management besides medical control of BP.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Polysomnography is used to evaluate for sleep apnea as a cause of resistant hypertension. However, this patient has a normal BMI and neck circumference and no evidence of daytime sleepiness. Additionally, recent evidence suggests that primary aldosteronism is common and unrecognized in patients with obstructive sleep apnea, suggesting that such screening should be done irrespective of the presence of sleep apnea risk factors.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypothyroidism and hyperthyroidism may cause resistant hypertension. Diastolic pressures &gt;90 mm Hg were common in about 40% of patients who became hypothyroid after radioiodine therapy for thyrotoxicosis. As this patient does not have symptoms of thyroid disease, measuring thyroid-stimulating hormone would not be the best initial screening test for secondary hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pheochromocytoma is a rare cause of resistant hypertension, usually suspected when there are paroxysmal changes in BP resulting in palpitations, sweating, and headache. Checking 24-hour urine metanephrines and normetanephrines would not be the next best step in evaluating the most likely cause of resistant hypertension in this patient.</p>\n</div>",
        "references": [
            "Galati SJ, Hopkins SM, Cheesman KC, Zhuk RA, Levine AC: Primary aldosteronism: emerging trends.Trends Endocrinol Metab24(9): 421‒430, 2013",
            "Berta E, Lengyel I, Halmi S, et al: Hypertension in thyroid disorders.Front Endocrinol (Lausanne)10: 482, 2019",
            "Douillard C, Houillier P, Nussberger J, Girerd X: SFE/SFHTA/AFCE consensus on primary aldosteronism, part 2: first diagnostic steps.Ann Endocrinol (Paris)77(3): 192‒201, 2016",
            "Brown JM, Siddiqui M, Calhoun DA, et al: The unrecognized prevalence of primary aldosteronism: a cross-sectional study.Ann Intern Med173(1): 10‒20, 2020",
            "Conroy PC, Hernandez S, Graves CE, et al: Screening for primary aldosteronism is underutilized in patients with obstructive sleep apnea.Am J Med135(1): 60‒66, 2022",
            "Leung AA, Orton DJ, Chin A, et al: Novel approach to establishing an aldosterone:renin ratio cutoff for primary aldosteronism.Hypertension69(3): 450‒456, 2017"
        ]
    },
    "40": {
        "question": "<div class=\"qtext\"><p>A 23-year-old man with ESRD secondary to focal segmental glomerulosclerosis who undergoes HD through a left upper arm arteriovenous fistula was admitted 3 days ago for uncontrolled hypertension. He presented with systolic BP of 220–260 mm Hg associated with headache, chest pain, and shortness of breath. He did not miss any HD sessions and said he was adherent to maximum oral doses of nifedipine, carvedilol, lisinopril, doxazosin, clonidine, and isosorbide. Dry weight reported from the outpatient dialysis center is 82 kg. Urine output has been 100–200 mL daily for the last 2 years. Review of systems is positive for long-standing snoring and daytime somnolence. Initial management included changing carvedilol and nifedipine PO to labetalol and nicardipine IV, respectively, and daily ultrafiltration sessions.</p>\n<p>Current vital signs include BP of 172/110 mm Hg, heart rate of 96/min, weight of 84 kg, and body mass index of 34 kg/m<sup>2</sup>. Jugular venous pressure is increased. Heart examination reveals a regular rhythm with an S4 gallop, and lung examination reveals bilateral fine crackles. There is 1+ peripheral edema.</p>\n<p>Laboratory data are within acceptable ranges for a patient with ESRD. Chest x-ray shows mild pulmonary edema. Echocardiogram reveals left ventricular hypertrophy, mild tricuspid regurgitation, increased pulmonary artery systolic pressure, and a small pericardial effusion.</p>\n<p><strong>Which of the following is the NEXT BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Continue daily\nultrafiltration"
            },
            {
                "label": "B.",
                "text": "Prescribe\nfurosemide"
            },
            {
                "label": "C.",
                "text": "Obtain\nsleep study"
            },
            {
                "label": "D.",
                "text": "Change\nclonidine to transdermal delivery"
            },
            {
                "label": "E.",
                "text": "Prescribe minoxidil"
            }
        ],
        "correct_answer": "Continue daily\nultrafiltration",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with ESRD and hypertensive urgency has evidence of ongoing volume overload, with some improvement with ultrafiltration over the last few days, and should continue daily ultrafiltration to achieve or reestablish his dry weight.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypertension in patients receiving HD is multifactorial and includes persistent hypervolemia and increased peripheral vascular resistance. Numerous clinical trials show that intensive, frequent HD improves BP and decreases the need for oral antihypertensive medications. This patient is compliant with HD sessions and antihypertensive medications but is nonetheless volume-overloaded despite ongoing ultrafiltration during this hospital admission. His BP has improved somewhat with current management, so further ultrafiltration would be expected to further improve BP and associated signs and symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics are useful for patients with ESRD who continue to make a significant amount of urine. Prescription of loop diuretics is associated with decreased rates of hospitalization, intradialytic hypotension, and interdialytic weight gain. This patient, however, is oligoanuric at baseline, so would not be expected to respond significantly to furosemide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sleep disturbances are common in ESRD, and sleep apnea may be central or obstructive in etiology. This patient has symptoms of sleep apnea and increased body mass index, so polysomnography and continuous positive airway pressure may ultimately be indicated to improve his pulmonary hypertension. However, these measures would not help improve his severe hypertension over the short term. Additionally, there is evidence that ultrafiltration to decrease volume overload may help manage sleep apnea symptoms, and the interpretation of a sleep study could be confounded if it is undertaken when the patient is above his dry weight. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The clonidine patch is a convenient way to administer clonidine, especially in patients with nonadherence, requiring changing every 72 hours instead of every 8 hours as with oral dosing. However, the maximal daily dose available with the patch is less than with the oral formulation, and this patient does not have evidence of nonadherence, especially during hospitalization. This change would be unlikely to significantly improve BP.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Minoxidil is a potassium-channel opener that decreases BP by causing vasodilation. Adding a fourth vasodilator after nifedipine, lisinopril, and doxazosin in this patient with a heart rate of 96/min could worsen reflex tachycardia. Additionally, minoxidil has been reported to cause or exacerbate pericardial effusion, which is already present on this patient’s echocardiogram. Thus, adding minoxidil would not be the next best step in management.</p>\n</div>",
        "references": [
            "Bakris GL, Burkart JM, Weinhandl ED, et al: Intensive hemodialysis, blood pressure, and antihypertensive medication use.Am J Kidney Dis68(5S1): S15–S23, 2016",
            "Nongnuch A, Campbell N, Stern E, El-Kateb S, Fuentes L, Davenport A: Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients.Kidney Int87(2): 452–457, 2015",
            "Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM, Flythe J: Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes.Clin J Am Soc Nephrol14(1): 95–102, 2019",
            "Diaz S, Abad K, Patel SR, Unruh ML: Emerging treatments for insomnia, sleep apnea, and restless legs syndrome among dialysis patients.Semin Nephrol41(6): 526–533, 2021"
        ]
    },
    "41": {
        "question": "<div class=\"qtext\"><p>A 64-year-old man with a history of diabetes mellitus, hypertension, and benign prostatic hypertrophy is admitted to the ICU for septic shock secondary to pneumonia. His hospital course has been complicated by AKI requiring renal replacement therapy. His hemodynamics improve over the next few days.</p>\n<p>The patient now complains of the urge to urinate and worsening pain in the suprapubic area. He has an indwelling urinary catheter with no documented urine output. The catheter was exchanged one day before, prior to which he was making approximately 250–300 mL of urine daily.</p>\n<p>A point-of-care ultrasound (POCUS) examination of the bladder is performed (shown below).</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2b1q26a.jpg\" width=\"75%\"/>\n</figure>\n<p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p><strong>Which of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Abdominal and pelvic ascites"
            },
            {
                "label": "B.",
                "text": "Obstructed urinary catheter in the bladder"
            },
            {
                "label": "C.",
                "text": "Neoplasm in the bladder"
            },
            {
                "label": "D.",
                "text": "Stone in the bladder"
            },
            {
                "label": "E.",
                "text": "Misplaced urinary catheter in the prostatic urethra"
            }
        ],
        "correct_answer": "Misplaced urinary catheter in the prostatic urethra",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with AKI, the urge to urinate, and worsening suprapubic pain has a urinary catheter that has been misplaced in the prostatic urethra.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"255\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2b1q26b.jpg\" width=\"566\"/></figure>\n<p><em>Images courtesy of Dr. Abhilash Koratala, Medical College of Wisconsin</em></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ultrasound images demonstrate an inflated urinary catheter balloon (anechoic, cyst-like structure) in the prostatic urethra, leading to bladder outlet obstruction and pain. The balloon should be positioned within the urinary bladder. While performing bladder POCUS, it is important to fan the transducer adequately to search for potential causes of urinary obstruction within and outside the bladder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The large, well-defined anechoic structure seen is more likely to be the distended urinary bladder than abdominal or pelvic ascites, which typically has irregular margins due to interspersed bowl loops. Moreover, this patient’s clinical history and hospital course would not suggest the presence of ascites.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A correctly placed urinary catheter can sometimes be obstructed due to debris or clotted blood. However, in such cases, the catheter balloon would be seen within the distended bladder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the images shown, no intravesical structure such as a tumor or stone is visualized.</p>\n</div>",
        "references": [
            "Renal Fellow Network:Holy Moly! What’s Up with the Foley?https://www.renalfellow.org/2019/02/27/holy-moly-whats-up-with-the-foley/. Accessed February 28, 2022",
            "Koratala A, Bhattacharya D, Kazory A: Point of care renal ultrasonography for the busy nephrologist: a pictorial review.World J Nephrol8(3): 44–58, 2019",
            "Koratala A, Vangapalli A, Bhattacharya D, Lee Loy J: Bladder stone: \"must know\" ultrasonographic signs.Clin Case Rep7(3): 573–574, 2019"
        ]
    },
    "42": {
        "question": "<div class=\"qtext\"><p>A 53-year-old man with ESRD due to diabetic nephropathy is evaluated in the emergency department for arm pain. Two days ago he fell onto his left arm and now reports pain, swelling, and redness in the arm near his arteriovenous graft (AVG). He has no fever or chills. His most recent urea reduction ratio is 57%.</p>\n<p>On examination, temperature is 37.8°C, BP is 182/72 mm Hg, and heart rate is 80/min. His left arm has 1+ edema throughout, with erythema, warmth, and tenderness to light palpation over the distal portion of a C-shaped, upper arm AVG. There is a small amount of exudate seen at a prior cannulation site. He has bibasilar rales. He has 2+ radial pulses, and fingers are equally warm in both hands.</p>\n<p>His laboratory results show potassium 5.8 mEq/L (reference range, 3.5–5.5) and BUN 60 mg/dL (reference range, 8–20).</p>\n<p>Blood cultures are drawn from the AVG and peripherally, and empiric vancomycin and cefepime are prescribed.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "AVG angioplasty"
            },
            {
                "label": "B.",
                "text": "No additional management"
            },
            {
                "label": "C.",
                "text": "HD catheter insertion"
            },
            {
                "label": "D.",
                "text": "Indium-labeled WBC scan"
            },
            {
                "label": "E.",
                "text": "Upper arm x-ray"
            }
        ],
        "correct_answer": "HD catheter insertion",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with evidence of an infected AVG should be referred for HD catheter placement, which should be used for dialysis, pending blood culture results and a surgical evaluation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Accessing an infected AV access should be avoided, if possible, as seeding of the synthetic graft material can lead to graft breakdown and catastrophic bleeding. KDOQI guidelines state that decisions about surgical management should be based on the individual circumstances of a patient, considering the infecting organism, the extent of infection, and future access plans. The patient should be dialyzed through an HD catheter until the infection is either confirmed or resolved, and definitive surgical management can be determined once the speciation and extent of infection is known. Removal of the infected AVG is the preferred option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although outflow obstruction could present with a swollen, erythematous, and tender arm, outflow obstruction would not cause an exudate over the cannulation site. Additionally, it is important to rule out infection prior to angioplasty to prevent embolization of bacteria during the angioplasty procedure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If infection is ruled out, it may be reasonable to dialyze through the AVG with no additional management. However, given the high suspicion for AVG infection, and the severe tenderness on examination, it would be inappropriate to continue to use the AVG for dialysis without further investigation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An indium-labeled WBC scan can be a helpful diagnostic test to confirm the AVG is the source of bacteremia of unknown source. In this patient, in whom bacteremia has not yet been established, it would not be the optimal first step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An x-ray of the arm would not be a useful diagnostic test to evaluate for AVG infection. An ultrasound can potentially diagnose a peri-graft fluid collection, such as an abscess, but x-ray is not sufficiently sensitive to evaluate for this possibility.</p>\n</div>",
        "references": [
            "Lok CE, Huber TS, Lee T, et al: KDOQI clinical practice guideline for vascular access: 2019 update.Am J Kidney Dis75(4 Suppl 2): S1–S164, 2020",
            "Shemesh D, Goldin I, Verstandig A, et al: Upper limb grafts for hemodialysis access.J Vasc Access16(Suppl 9): S34–S39, 2015",
            "Achinger SG, Ayus JC: When the source of inflammation is hiding in plain sight: failed kidney transplants, clotted arteriovenous grafts, and central venous catheters.Semin Dial32(1): 15–21, 2019"
        ]
    },
    "43": {
        "question": "<div class=\"qtext\"><p>A 30-year-old man is brought to the emergency department for evaluation of altered mental status. He has no known past medical history. On examination, the patient is lethargic and unresponsive to verbal and tactile stimuli. BP is 100/80 mm Hg, heart\n    rate is 70/min, respiratory rate is 12/min, and temperature is 37°C. He has a fruity breath odor and miotic pupils on examination.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>137 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>103 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.0 mg/dL (baseline 0.9)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>325 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>275–295</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Lactate </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.6 mmol/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–2.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Ketones</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Positive</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>pH, arterial</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.41</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>pCO<sub>2, </sub>arterial</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>40 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is positive for ketones but negative blood and protein, and no cells or casts are observed on microscopy.</p>\n<p>The toxicology screen is pending.</p><strong>\n\nWhich ONE of the following is MOST likely contributing to this patient’s presentation?</strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Isopropyl alcohol"
            },
            {
                "label": "B.",
                "text": "Methanol"
            },
            {
                "label": "C.",
                "text": "Ethylene glycol"
            },
            {
                "label": "D.",
                "text": "Aspirin"
            },
            {
                "label": "E.",
                "text": "Acetaminophen"
            }
        ],
        "correct_answer": "Isopropyl alcohol",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The normal pH, normal anion gap, hyperosmolality with osmolal gap, and positive ketones in an intoxicated patient suggests isopropyl alcohol ingestion as the cause of this patient’s altered mental status.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Isopropyl alcohol is commonly found in hand sanitizers and disinfectants and is the most common toxic alcohol ingestion reported to poison control in the United States. Isopropyl alcohol poisoning presents similarly to ethanol intoxication and can manifest with varying degrees of central nervous system depression, including dizziness, intoxication, miotic pupils, stupor, and coma. Symptoms usually peak between 30 minutes and 3 hours after ingestion. Massive ingestion can result in hemorrhagic gastritis from irritation of the gastric epithelium, hypotension, hypothermia, and, rarely, cardiovascular collapse. Accumulation of this alcohol causes increased osmolality and osmolal gap. Unlike other alcohols, isopropyl alcohol ingestion does not result in anion gap metabolic acidosis, because it is metabolized into acetone, an uncharged molecule. However, the accumulated volatile acetone causes ketonemia, ketonuria, and characteristic fruity-odored breath. Measurement of isopropyl alcohol levels can confirm the diagnosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients may present with a “pseudo-AKI” due to acetone interference in the Jaffe reaction, used in some laboratories to measure serum creatinine. An elevated creatinine with a normal BUN can suggest acetone interference. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mortality is rare compared with methanol and ethylene glycol intoxication, and management is often supportive. In contrast to other alcohols, alcohol dehydrogenase inhibitors such as fomepizole should be avoided, as they prolong the elimination half-life of the parent compound isopropyl alcohol. HD may be considered if the patient has signs of cardiovascular collapse or if the serum isopropyl alcohol level is &gt;500 mg/dL.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Methanol is commonly found in windshield wiper fluid and “moonshine.” Symptoms of intoxication include visual disturbances, such as decreased visual acuity, photophobia, blurred vision, and occasionally blindness. Toxicity is due to formic acid produced by methanol metabolism. Methanol ingestion is typically associated with high anion gap metabolic acidosis and an increased osmolal gap. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ethylene glycol is commonly found in antifreeze. Patients can initially present with confusion and stupor and later develop pulmonary or cardiac dysfunction AKI. Ethylene glycol is metabolized to glycolic acid and oxalic acid, responsible for calcium oxalate crystalluria. As with methanol, intoxicated patients present with increased osmolal gap and high anion gap metabolic acidosis. Lactic acidosis may be diagnosed erroneously, as ethylene glycol metabolites may react with the assay for lactate (“pseudo-lactic acidosis”).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Salicylate acute overdose often presents with tinnitus, vertigo, nausea, vomiting, and fever. Severe ingestion can lead to hallucinations, seizures, cerebral edema, coma, noncardiogenic pulmonary edema, and shock. Patients usually present with respiratory alkalosis and anion gap metabolic acidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Clinical manifestations of acetaminophen toxicity may range from nausea, vomiting, and lethargy to acute liver injury and AKI depending on the acetaminophen levels and time since ingestion. Measurement of acetaminophen and salicylate levels in the blood can confirm the diagnosis. Although salicylate and acetaminophen toxicity can cause an anion gap metabolic acidosis, these ingestions do not cause an elevated osmolal gap.</p>\n</div>",
        "references": [
            "Kraut JA, Mullins ME: Toxic alcohols.N Engl J Med378(3): 270‒280, 2018",
            "Kraut JA, Kurtz I: Toxic alcohol ingestions: clinical features, diagnosis and management.Clin J Am Soc Nephrol3(1): 208‒225, 2008",
            "Gallagher N, Edwards FJ: The diagnosis and management of toxic alcohol poisoning in the emergency department: a review article.Adv J Emerg Med3(3): e28, 2019",
            "Palmer BF, Clegg DJ: Salicylate toxicity.N Engl J Med382(26): 2544‒2555, 2020",
            "Yoon E, Babar A, Choudhary M, et al: Acetaminophen-induced hepatotoxicity: a comprehensive update.J Clin Transl Hepatol4(2): 131‒142, 2016",
            "Pernet P, Beneteau-Burnat B, Vaubourdolle M, et al: False elevation of blood lactate reveals ethylene glycol poisoning.Am J Emerg Med27(1): 132.e1‒132.e2, 2009"
        ]
    },
    "44": {
        "question": "<div class=\"qtext\"><p>A 38-year-old woman with a history of ESRD due to focal segmental glomerulosclerosis is seen in kidney transplant clinic 5 weeks after deceased donor kidney transplantation. She was sensitized pre-transplant but had no detectable donor-specific antibodies. Her post-transplant course was complicated by cellulitis at the surgical incision site, for which she received a course of amoxicillin/clavulanate. She now complains of weight gain and peripheral edema but otherwise feels well. She is prescribed tacrolimus, mycophenolic acid, prednisone, amlodipine, valganciclovir, trimethoprim/sulfamethoxazole, omeprazole, and magnesium oxide.</p>\n<p>BP is 122/68 mm Hg, and heart rate is 75/min. Her weight has increased by 3 kg over the last week. She has 2+ bilateral lower extremity edema. Her examination is otherwise unremarkable.</p>\n<p>Her laboratory data are as follows:\n</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td ;=\"\" style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: topwidth: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Blood\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11,400/µL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.07 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Tacrolimus, trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.7 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5–15 (0­–3 months after transplantation)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Donor-specific antibodies, anti-human leukocyte antigen\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine, random\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Blood\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     RBC\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;2/HPF\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     WBC\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0/HPF\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4360 mg/g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;30\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Focal segmental glomerulosclerosis"
            },
            {
                "label": "B.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "C.",
                "text": "Acute cellular rejection"
            },
            {
                "label": "D.",
                "text": "Antibody-mediated rejection"
            },
            {
                "label": "E.",
                "text": "Infection-associated glomerulonephritis"
            }
        ],
        "correct_answer": "Focal segmental glomerulosclerosis",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s development of nephrotic-range proteinuria and peripheral edema early after transplantation without accompanying azotemia, hematuria, or hypertension is most consistent with recurrent focal segmental glomerulosclerosis (FSGS). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary FSGS commonly recurs early after transplant. In a recent study of 176 transplant recipients with a history of idiopathic FSGS, the rate of recurrence was estimated to be 32% (95% confidence interval, 25%–39%). In the same study, recurrence occurred at a median of 1.5 (interquartile range, 0–11) months after transplant. Kidney allograft biopsies obtained early in the course of the disease after transplant may show minimal changes by light microscopy, as sclerotic glomerular lesions may not have had time to develop. Diffuse effacement of podocyte foot processes is, however, seen on electron microscopy. It has long been suspected that rapid recurrence of primary FSGS after transplantation may be caused by circulating pathogenic factors, providing a rationale for treatment with plasmapheresis. Patients with FSGS who are not anuric at the time of kidney transplantation may have continued albuminuria originating from their native kidneys. In those with good allograft function, nephrotic-range proteinuria would no longer be expected &gt;3 weeks after transplant.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute cellular or antibody-mediated rejection would be accompanied by worsening allograft function. Moreover, although proteinuria would be expected in the setting of rejection, rapid-onset nephrotic-range proteinuria with accompanying peripheral edema would be more likely to occur with recurrent FSGS. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Infection-associated glomerulonephritis and other forms of acute glomerulonephritis would typically be accompanied by worsening allograft function, hypertension, and hematuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis (AIN) would also be expected to lead to worsening graft function. Proteinuria in patients with AIN is usually modest with no significant albuminuria as podocytes are predominantly intact. Pyuria is often present, as may be fevers, rashes, or eosinophilia.</p>\n</div>",
        "references": [
            "Uffing A, Pérez-Sáez MJ, Mazzali M, et al: Recurrence of FSGS after kidney transplantation in adults.Clin J Am Soc Nephrol15(2): 247–256, 2020",
            "Alasfar S, Matar D, Montgomery RA, et al: Rituximab and therapeutic plasma exchange in recurrent focal segmental glomerulosclerosis postkidney transplantation.Transplantation102(3): e115–e120, 2018",
            "Watts AJB, Keller KH, Lerner G, et al: Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology.J Am Soc Nephrol33(1): 238–252, 2022",
            "Cooper JE: Evaluation and treatment of acute rejection in kidney allografts.Clin J Am Soc Nephrol15(3): 430–438, 2020",
            "Myslak M, Amer H, Morales P, et al: Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant.Am J Transplant6(7): 1660–1665, 2006"
        ]
    },
    "45": {
        "question": "<div class=\"qtext\"><p>A 59-year-old man with no known medical history is brought to the emergency department with fever, headache, and confusion. He is diagnosed with HIV and cryptococcal meningitis. He has a prolonged hospitalization that is complicated by seizures, hypertension,\n    diarrhea, and urinary tract obstruction from benign prostatic hyperplasia. His current medications include amphotericin B, tenofovir, emtricitabine, bictegravir, carbamazepine, topiramate, lisinopril, and tamsulosin.</p>\n<p>After 4 weeks, he develops acidemia and electrolyte disturbances, for which he receives sodium bicarbonate IV.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Initial</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>After Sodium Bicarbonate </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Blood</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>137 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>143</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>114 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>112</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>20</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.84 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.75</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>88 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH, arterial</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.28</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.36</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.2</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Fractional excretion of bicarbonate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.5%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.4%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Ammonium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s acidosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Tenofovir"
            },
            {
                "label": "B.",
                "text": "Amphotericin B"
            },
            {
                "label": "C.",
                "text": "Diarrhea"
            },
            {
                "label": "D.",
                "text": "Topiramate"
            },
            {
                "label": "E.",
                "text": "Urinary obstruction"
            }
        ],
        "correct_answer": "Amphotericin B",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely etiology of a normal anion gap acidosis with an inappropriately elevated urinary pH and decreased ammonium excretion is distal renal tubular acidosis (RTA), in this case caused by amphotericin B.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A normal anion gap acidosis is caused by non-renal loss of bicarbonate, impaired renal acid excretion, or dilution of the blood by administration of IV fluids that do not contain bicarbonate (or potential bicarbonate). In this patient with acidemia and a normal anion gap, the first step is to distinguish between gastrointestinal (GI) and renal etiologies. Urinary ammonium excretion increases in diarrhea-induced acidosis (up to 200–300 mEq/d), whereas a low value, as in this case, suggests an RTA. The urine anion gap, frequently used to estimate urinary ammonium excretion, has been shown in recent studies to be unreliable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has several potential reasons for an RTA. To determine the most likely etiology, it is necessary to distinguish between proximal RTA and distal RTA. In distal RTA, there is impaired acid excretion (defect in H<sup>+</sup> secretion) that results in an inability to reduce the urinary pH to &lt;5.5 in the setting of acidemia. In proximal RTA, there is defective bicarbonate<sup> </sup>reabsorption in the proximal tubule, but distal acidification remains intact. Thus, in the setting of acidemia, urinary pH will be appropriately low in proximal RTA. These relationships are only approximate in actual practice, as urine ammonium production and H<sup>+</sup> secretion rates may differ depending on the acuity of the acidosis, confusing the relationship between urine pH and urine ammonium production.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Infusion of sodium bicarbonate can aid with diagnosis of proximal versus distal RTA. In proximal RTA, infusion of sufficient sodium bicarbonate to raise the serum bicarbonate concentration level to 18–20 mEq/L will result in an increase in urine pH to above 7.5 (as the reabsorptive threshold for bicarbonate is exceeded), whereas urine pH will remain stable in distal RTA. Furthermore, the fractional excretion of bicarbonate will exceed 15%–20% in proximal RTA, whereas remaining &lt;3% for distal RTA. This patient’s urine pH is &gt;5.5 in the context of acidemia with little change after sodium bicarbonate infusion, leading to a diagnosis of distal RTA. Amphotericin B can cause an acquired distal RTA by increasing membrane permeability in the distal tubule, leading to back-diffusion of secreted H<sup>+</sup> ions from the lumen into the distal tubular cell and impairing urinary acidification.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tenofovir and topiramate cause predominantly proximal RTA and are therefore unlikely to be the cause of this patient’s acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diarrhea can cause a normal anion gap acidosis due to bicarbonate loss in the stool. In diarrhea, urine ammonium excretion will be increased, leading to an appropriately elevated urinary ammonium, which this patient does not have.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinary obstruction leads to a type 4 RTA, resulting in hyperkalemia in addition to mild metabolic acidosis.</p>\n</div>",
        "references": [
            "Rose BD, Post TW:Clinical Physiology of Acid-Base and Electrolyte Disorders, 5thEd, McGraw-Hill, New York, p. 612, 2001",
            "Soleimani M, Rastegar A: Pathophysiology of renal tubular acidosis: core curriculum 2016.Am J Kidney Dis68(3): 488–498, 2016",
            "Palmer BF, Clegg DJ: The use of selected urine chemistries in the diagnosis of kidney disorders.Clin J Am Soc Nephrol14(2): 306–316, 2019",
            "Batlle D, Haque SK: Genetic causes and mechanisms of distal renal tubular acidosis.Nephrol Dial Transplant27(10): 3691–704, 2012",
            "Brenes LG, Sanchez MI: Impaired urinary ammonium excretion in patients with isolated proximal renal tubular acidosis.J Am Soc Nephrol4(4): 1073–1078, 1993",
            "Carlisle EJF, Donnelly SM, Halperin ML: Renal tubular acidosis (RTA): recognize the ammonium defect and pHorget the urine pH.Pediatr Nephrol5: 242–248, 1991"
        ]
    },
    "46": {
        "question": "<div class=\"qtext\"><p>A 19-year-old woman with no past medical history is referred to the nephrology clinic for evaluation of proteinuria. At a routine gynecology appointment 2 weeks ago, proteinuria was found on urinalysis. She otherwise has no complaints; review of systems is negative, including no lower extremity edema, no excessive thirst or urination, and no foamy urine or hematuria. She runs for the university’s cross-country team and consumes a vegan diet. There is no family history of kidney disease. Medications include over-the-counter cholecalciferol, a multivitamin, and norethindrone.</p>\n<p>On examination, BP is 110/70 mm Hg, heart rate is 70/min, and body mass index (BMI) is 18 kg/m<sup>2</sup>. She has no edema, and the remainder of her examination is unremarkable. </p>\n<p>Urinalysis data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Results</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Reference Range </strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Appearance</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Clear</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Clear</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Specific gravity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.008</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.002–1.030 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.2</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Leukocyte esterase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Nitrites</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Blood</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Ketones</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Her urine albumin-to-creatinine ratio is 12 mg/g (reference range, &lt;30). Basic metabolic panel is within normal limits, including serum creatinine 0.7 mg/dL (reference range, 0.5–1.1).</p><br/>\n<p><strong>Which ONE of the following is the MOST likely cause of her dipstick-positive protein?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Vegan diet"
            },
            {
                "label": "B.",
                "text": "Low BMI"
            },
            {
                "label": "C.",
                "text": "Non-albumin proteinuria"
            },
            {
                "label": "D.",
                "text": "Norethindrone"
            },
            {
                "label": "E.",
                "text": "Cholecalciferol"
            }
        ],
        "correct_answer": "Vegan diet",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of her proteinuria on her urine dipstick is her vegan diet. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Alkaline urine (pH &gt;8) is a recognized cause of false-positive protein (albumin) results on urinalysis dipstick, at least with older tests, although a more recent study (Robinson et al., 2019) has called this effect into question. Vegan diets are more likely to result in an alkaline urine, as vegans have lower estimated net acid excretion compared with omnivores. Concentrated urine can also give a false-positive dipstick protein reading, whereas acidic and dilute urine can yield a false-negative result, although these findings have also been called into question recently by Robinson et al. The urine albumin-to-creatinine ratio is a quantitative spot measurement of albuminuria that corrects for the urinary concentration by comparing with the urine creatinine. The patient’s normal urine albumin-to-creatinine ratio confirms that the urine dipstick result is a false positive and should be the follow-up test performed when proteinuria is detected on urinalysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although high BMI has been correlated with proteinuria, frequently with obesity-related glomerulopathy or focal segmental glomerulosclerosis on histology, low BMI is not associated with increased proteinuria or false-positive urine dipstick results.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine dipsticks are sensitive to albumin and do not reliably detect low concentrations of other proteins such as gamma globulins or Bence-Jones proteins.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Progestin-only contraceptive pills such as norethindrone do not affect proteinuria or urine dipstick results. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Vitamin D analogues have been associated with a reduction in proteinuria and would not explain the false-positive dipstick result in this patient.</p>\n</div>",
        "references": [
            "Simerville JA, Maxted WC, Pahira JJ: Urinalysis: a comprehensive review.Am Fam Physician71(6): 1153–1162, 2005",
            "Robinson JL, Venner AA, Seiden-Long I: Urine protein detection by dipstick: no interference from alkalinity or specific gravity.Clin Biochem71: 77–80, 2019",
            "Ausman LM, Oliver LM, Goldin BR, et al: Estimated net acid excretion inversely correlates with urine pH in vegans, lacto-ovo vegatarians, and omnivores. J Renal Nutr 18(5): 456–465, 2008",
            "Gansevoort RT, Brinkman J, Bakker SJL, et al: Evaluation of measures of urinary albumin excretion.Am J Epidemiol164(8): 725–727, 2006",
            "Lucisano S, Buemi M, Passantino A, et al: New insights on the role of vitamin D in the progression of renal damage.Kidney Blood Press Res37(6): 667–678, 2013",
            "Shen W, Chen H, Chen H, et al: Obesity-related glomerulopathy: body mass index and proteinuria.Clin J Am Soc Nephrol5(8): 1401–1409, 2010",
            "Yoshida K, Yazawa M, Terashita M, et al: False-positive urine dipstick result for proteinuria in a severe case of alkalinuria.Clin Nephrol97(1): 57–59, 2022"
        ]
    },
    "47": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with a history of hypertension, abdominal aortic aneurysm, and peripheral vascular disease is referred to the nephrology clinic for evaluation of refractory hyperkalemia. </p>\n<p>One week ago, his primary care doctor ordered routine labs that showed a serum potassium of 5.5 mEq/L and a serum creatinine of 1.3 mg/dL. He was counseled to eat a low potassium diet, but repeat laboratory data 5 days later were essentially unchanged.</p>\n<p>He currently feels well without chest pain, shortness of breath, or palpitations. Medications include hydrochlorothiazide, carvedilol, aspirin, and atorvastatin.</p>\n<p>On examination, his BP is 144/84 mm Hg. He has normal heart sounds with clear lungs. The remainder of his examination is unremarkable. EKG shows normal sinus rhythm.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10,400/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11.3 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14‒18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>667,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>135 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.7 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>102 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98‒106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>17 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6‒10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>104 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70‒99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.1 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0‒4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Iron</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>90 µg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>50‒150</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Total iron-binding capacity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>356 µg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>250‒310</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Ferritin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>108 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24‒336</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals clear, yellow urine without blood or protein. Urine specific gravity is 1.009. EKG shows normal sinus rhythm. Kidney ultrasound shows no hydronephrosis.</p><br/>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Type 4 renal tubular acidosis"
            },
            {
                "label": "B.",
                "text": "Thrombocytosis"
            },
            {
                "label": "C.",
                "text": "Exogenous potassium supplementation"
            },
            {
                "label": "D.",
                "text": "Chronic kidney disease"
            },
            {
                "label": "E.",
                "text": "Adrenal insufficiency"
            }
        ],
        "correct_answer": "Thrombocytosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely explanation for elevated potassium in this patient is thrombocytosis (pseudohyperkalemia).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pseudohyperkalemia is an important cause of elevated potassium that must always be ruled out as a cause of hyperkalemia. It occurs when potassium shifts out of cells in vitro either from mechanical trauma during venipuncture or specimen processing.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the more common causes of pseudohyperkalemia are related to the technique of obtaining the blood draw (difficulty with venipuncture, tourniquet use, fist clenching, cold storage/transit temperatures, and contamination with potassium EDTA found in some sampling tubes), important pathologic causes include thrombocytosis (platelet count &gt;500,000/µL) and leukocytosis (WBC count &gt;70,000/µL), which may signify an underlying hematologic disorder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For pseudohyperkalemia due to thrombocytosis, the diagnosis can be confirmed by checking concurrent serum potassium and plasma or whole blood potassium levels, in which case the serum potassium concentration will often be &gt;0.5 mEq/L higher than the plasma or whole blood potassium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although type 4 renal tubular acidosis can cause hyperkalemia, this patient does not have a significant metabolic acidosis, and pseudohyperkalemia should be excluded first.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CKD can cause hyperkalemia due to impaired kidney clearance, but this patient’s hyperkalemia is out of proportion to the degree of kidney dysfunction, which should raise suspicion for spurious hyperkalemia. Likewise, more significant CKD would typically be required for exogenous potassium supplementation to cause significant hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"> Primary adrenal insufficiency can cause hyperkalemia, frequently in combination with hypotension and sometimes hyponatremia. High normal BP or hypertension would be unusual.</p>\n</div>",
        "references": [
            "Palmer BF: A physiologic-based approach to the evaluation of a patient with hyperkalemia.Am J Kid Dis56(2): 387‒393, 2010",
            "Smellie WSA: Spurious hyperkalaemia.BMJ334(7595): 693‒695, 2007",
            "Ranjitkar P, Greene DN, Baird GS, et al: Establishing evidence-based thresholds and laboratory practices to reduce inappropriate treatment of pseudohyperkalemia.Clin Biochem50(12): 663‒669, 2017"
        ]
    },
    "48": {
        "question": "<div class=\"qtext\"><p>A 60-year-old man with ESRD due to diabetic nephropathy and treated with HD for 2 years is evaluated in the HD unit for pre-dialysis hyperkalemia. For the last year, his pre-dialysis serum potassium level has ranged from 5.5 to 6.0 mEq/L (reference range, 3.5–5.0), with levels as high as 6.5 mEq/L after the long interdialytic period. He receives 4-hour treatments thrice weekly with a dialysate potassium concentration of 2 mEq/L and has not missed any treatments over the last 4 months. He is dialyzed via a brachiocephalic fistula that has been working well, with a normal fistulagram 2 months ago and no evidence of dialysis access recirculation on recent testing. His Kt/V has been &gt;1.4 (reference range, &gt;1.2) consistently. A detailed food diary recorded over the last 2 weeks has failed to reveal any high potassium-containing foods. Past medical history is notable for hypertension, type 2 diabetes, congestive heart failure, and ischemic colitis. His medications include lisinopril, amlodipine, insulin, sevelamer carbonate, epoetin alfa, and insulin.</p>\n<p><strong>Which ONE of the following is the next BEST step in management of the patient’s hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Lower dialysate potassium concentration"
            },
            {
                "label": "B.",
                "text": "Repeat dietary education with a dietician"
            },
            {
                "label": "C.",
                "text": "Prescribe sodium polystyrene sulfonate (SPS)"
            },
            {
                "label": "D.",
                "text": "Prescribe sodium zirconium cyclosilicate (SZC)"
            },
            {
                "label": "E.",
                "text": "Increase HD frequency to four times weekly"
            }
        ],
        "correct_answer": "Prescribe sodium zirconium cyclosilicate (SZC)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with pre-dialysis hyperkalemia despite adequate clearance and adherence to treatments and diet, the next best step is to prescribe SZC.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Multiple factors can contribute to hyperkalemia seen in patients receiving HD, including high dietary potassium intake, elevated dialysate potassium concentration, inadequate potassium clearance with dialysis due to shortened or missed dialysis sessions or dysfunctional dialysis access, medications, and hemolysis or rhabdomyolysis. Oral potassium binders such as SZC, patiromer, and sodium polystyrene sulfonate (SPS) offer additional treatment strategies for hyperkalemia once the above causes have been ruled out.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patiromer and SZC are newer agents that have been tested in patients with HD and whose use potentially allow for a more liberal diet and optimization of renin-angiotensin-aldosterone system (RAAS) inhibitor therapy in this population. Although patiromer has been tested and found to be effective in a real-world study, SZC has been tested in a randomized, double-blind, placebo-controlled study (DIALIZE) and helped significantly more patients to maintain pre-dialysis serum K<sup>+</sup> concentrations in the 4- to 5-mEq/L range. Either patiromer or SZC would be acceptable choices for this patient, and selection often depends on patient’s insurance coverage.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SPS is a cation-exchange resin that exchanges K<sup>+</sup> ions for Na<sup>+</sup> ions nonspecifically in the colon and has been used as a rescue therapy for hyperkalemia. However, its efficacy has not been proven in adequately-powered clinical trials, and it has an unfavorable safety profile, including serious gastrointestinal complications such as colonic necrosis. In this patient with a history of ischemic colitis, SPS would not be first-line therapy.   </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dialysate<sup> </sup>potassium concentrations of 1 mEq/L have been associated with higher mortality in patients receiving HD with serum potassium concentrations of <u>&gt;</u>5 mEq/L and are not recommended in routine practice.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although dietary potassium restriction is an essential facet of hyperkalemia management in patients receiving HD, this patient’s food diary has not revealed any patterns suggesting that further dietary education would be beneficial.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Adequate K<sup>+</sup> removal via dialysis is critical for maintaining normokalemia in patients receiving HD. In this case, the patient is adequately dialyzed, as indicated by his adequacy testing and good adherence with his HD therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are conflicting data showing that ACEIs and ARBs may cause hyperkalemia in patients with ESRD receiving HD. However, for patients with congestive heart failure, the mortality benefit conferred with ACE inhibition may prompt some clinicians to consider a trial of an effective potassium binder before discontinuing lisinopril.  </p>\n</div>",
        "references": [
            "Bansal S, Pergola PE: Current management of hyperkalemia in patients on dialysis.Kidney Int Rep5(6): 779–789, 2020",
            "Palmer BF: Potassium binders for hyperkalemia in chronic kidney disease—diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis.Mayo Clin Proc95(2): 339–354, 2020",
            "Ferrey A, You AS, Kovesdy CP, et al: Dialysate potassium and mortality in a prospective hemodialysis cohort.Am J Nephrol47(6): 415–423, 2018",
            "Fishbane S, Ford M, Fukagawa M, et al: A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia.J Am Soc Nephrol30(9): 1723–1733, 2019",
            "Kovesdy CP, Rowan CG, Conrad A, et al: Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients.Kidney Int Rep4(2): 301–309, 2018",
            "Bushinsky DA, Rossignol P, Spiegel DM, et al: Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis.Am J Nephrol44(5): 404–410, 2016",
            "Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.Am J Med112(2): 110–114, 2002",
            "Harel Z, Harel S, Shah PS, et al: Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review.Am J Med126(3): 264.e9–24, 2013"
        ]
    },
    "49": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man is referred to the nephrology clinic to evaluate hypertension. He is currently prescribed maximal doses of fosinopril, amlodipine, and chlorthalidone. His office BP, when checked after 5 minutes of quiet rest with a calibrated device, is 142/80 mm Hg. His average home BP over the last 7 days has been 145/85 mm Hg. He denies dyspnea, palpitations, headaches, over-the-counter medication use, or recreational drug use. </p>\n<p>On physical examination, he appears well. Lungs are clear, and there is no peripheral edema. He has no cardiac murmur or abdominal or carotid bruits. </p>\n<p>Laboratory evaluation shows serum creatinine 0.8 mg/dL (reference range, 0.7–1.3), serum potassium 3.9 mEq/L (reference range, 3.5–5.0), and urine sodium 80 mEq/24 hours.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Measure plasma aldosterone concentration and renin activity"
            },
            {
                "label": "B.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "C.",
                "text": "Evaluate for anti-hypertensive medication adherence"
            },
            {
                "label": "D.",
                "text": "Recommend dietary sodium reduction"
            },
            {
                "label": "E.",
                "text": "Prescribe labetalol"
            }
        ],
        "correct_answer": "Evaluate for anti-hypertensive medication adherence",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Assessing for medication adherence is the next best step in the management of this patient with apparent treatment-resistant hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Resistant hypertension (RH) is defined as a clinic BP of ≥130/80 mm Hg in a patient taking at least three anti-hypertensive agents, including a diuretic, at maximal or maximally tolerated doses. The diagnosis of RH requires the exclusion of pseudo-resistance by verifying uncontrolled hypertension with out-of-office BP measurement and confirmation of adherence to the prescribed medication regimen. Suboptimal adherence is a common cause of uncontrolled hypertension. A 2017 meta-analysis reported a pooled prevalence of nonadherence in patients with apparent treatment-resistant hypertension to be 31.2%. Identification of patients with inadequate adherence can avoid inappropriate intensification of the medication regimen and ensure patients receive the maximum benefit from therapy. Strategies to assess for adherence include patient self-report medication adherence assessment tools, nonthreatening direct questioning, review of pharmacy databases for medication possession and refills, witnessed drug intake, and urine or blood measurement of drug metabolites.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Measurement of plasma aldosterone concentration and plasma renin activity with calculation of the aldosterone-to-renin ratio is a commonly used screening test for primary aldosteronism (PA). Screening for PA is recommended in all patients with true RH once medication adherence has been confirmed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mineralocorticoid receptor antagonists such as spironolactone are an effective fourth drug in patients with resistant hypertension. The PATHWAY-2 trial showed that spironolactone was the most effective add-on drug for the treatment of resistant hypertension compared with bisoprolol and doxazosin across a wide range of plasma renin concentrations. Combined α- and β-adrenergic blockers such as labetalol are effective anti-hypertensive agents as well, but medication nonadherence should first be excluded before intensifying the treatment regimen.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dietary sodium reduction is a well-established intervention for BP reduction, including patients with RH. It is currently recommended that dietary sodium intake be reduced to &lt;2.3 g/day. This patient’s 24-hour urine sodium suggests a daily sodium intake of (80 mEq/day × 23.1 mg/mEq =) 1.8 g/day, which is below this threshold. </p>\n</div>",
        "references": [
            "Carey RM, Calhoun DA, Bakris GL, et al: Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association.Hypertension72: e53‒e90, 2018",
            "Durand H, Hayes P, Morrissey EC, et al: Medication adherence among patents with apparent treatment-resistant hypertension: systematic review and meta-analysis.J Hypertens35(12): 2346‒2357, 2017",
            "Vaidya A, Carey RM: Evolution of the primary aldosteronism syndrome: updating the approach.J Clin Endocrinol Metab105(12): 3771‒3783, 2020",
            "Williams B, MacDonald TM, Morant S, et al: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet386(10008): 2059‒2068, 2015"
        ]
    },
    "50": {
        "question": "<div class=\"qtext\"><p>A 68-year-old woman with a history of heart failure with reduced ejection fraction (35%) and hypertension presents to the emergency department with altered mental status. She is noted to have AKI with serum creatinine 2.2 mg/dL (baseline, 1.1; reference range, 0.5–1.1). Urinalysis is significant for bacteriuria and pyuria. She is admitted to the hospital, and antibiotic therapy initiated for presumed urinary tract infection. Chart review reveals that her home dose of furosemide was recently increased to 40 mg twice daily from once daily. There is no known history of parenchymal lung disease or significant pulmonary hypertension. </p>\n<p>On examination, the patient is awake and in no distress. There is trace pedal edema but no appreciable jugular venous distension or lung crackles.</p>\n<p>Point-of-care ultrasound (POCUS) of the inferior vena cava (IVC) and lungs is performed. Representative images are shown below.</p>\n<p><em>Play video and click lower right hand corner button to expand viewing pane.</em></p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28968e388b_1-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28968e388b_1\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"ksapv8m2b1q25a.mp4\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28968e388b_1_html5_api\" role=\"application\" tabindex=\"-1\" title=\"ksapv8m2b1q25a.mp4\"><source src=\"https://education.asn-online.org/pluginfile.php/1/question/questiontext/74046/50/13379/ksapv8m2b1q25a.mp4\" type=\"video/mp4\"/>\n            https://education.asn-online.org/pluginfile.php/1/question/questiontext/74046/50/13379/ksapv8m2b1q25a.mp4\n        </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-27\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-28\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:05\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 47.86%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">47.86%</span></span><div data-end=\"2.401\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28968e388b_1_component_285\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28968e388b_1_component_285\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28968e388b_1_component_589_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28968e388b_1_component_589_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28968e388b_1_component_595_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28968e388b_1_component_595_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_622\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_622\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-White\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Black\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Red\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Green\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Blue\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Yellow\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Magenta\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595 captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Cyan\" id=\"captions-foreground-color-id_videojs_68a28968e388b_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_627\" id=\"captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_627\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595 captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e388b_1_component_595 captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595 captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28968e388b_1_component_595\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_637\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_637\"><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Black\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-White\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Red\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Green\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Blue\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Yellow\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Magenta\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595 captions-background-color-id_videojs_68a28968e388b_1_component_595-Cyan\" id=\"captions-background-color-id_videojs_68a28968e388b_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_642\" id=\"captions-background-opacity-id_videojs_68a28968e388b_1_component_595\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_642\"><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" id=\"captions-background-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595 captions-background-opacity-id_videojs_68a28968e388b_1_component_595-Transparent\" id=\"captions-background-opacity-id_videojs_68a28968e388b_1_component_595-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28968e388b_1_component_595\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_652\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_652\"><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Black\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-White\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Red\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Green\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Blue\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Yellow\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Magenta\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595 captions-window-color-id_videojs_68a28968e388b_1_component_595-Cyan\" id=\"captions-window-color-id_videojs_68a28968e388b_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_657\" id=\"captions-window-opacity-id_videojs_68a28968e388b_1_component_595\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_657\"><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595-Transparent\" id=\"captions-window-opacity-id_videojs_68a28968e388b_1_component_595-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28968e388b_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595 captions-window-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" id=\"captions-window-opacity-id_videojs_68a28968e388b_1_component_595-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28968e388b_1_component_595\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_672\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-673-50\" id=\"vjs-track-option-673-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-674-75\" id=\"vjs-track-option-674-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-675-100\" id=\"vjs-track-option-675-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-676-125\" id=\"vjs-track-option-676-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-677-150\" id=\"vjs-track-option-677-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-678-175\" id=\"vjs-track-option-678-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-679-200\" id=\"vjs-track-option-679-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-680-300\" id=\"vjs-track-option-680-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e388b_1_component_595 vjs-track-option-681-400\" id=\"vjs-track-option-681-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_691\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595 vjs-track-option-692-None\" id=\"vjs-track-option-692-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595 vjs-track-option-693-Raised\" id=\"vjs-track-option-693-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595 vjs-track-option-694-Depressed\" id=\"vjs-track-option-694-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595 vjs-track-option-695-Uniform\" id=\"vjs-track-option-695-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e388b_1_component_595 vjs-track-option-696-Dropshadow\" id=\"vjs-track-option-696-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28968e388b_1_component_595\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595\" id=\"vjs_select_706\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-707-ProportionalSansSerif\" id=\"vjs-track-option-707-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-708-MonospaceSansSerif\" id=\"vjs-track-option-708-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-709-ProportionalSerif\" id=\"vjs-track-option-709-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-710-MonospaceSerif\" id=\"vjs-track-option-710-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-711-Casual\" id=\"vjs-track-option-711-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-712-Script\" id=\"vjs-track-option-712-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e388b_1_component_595 vjs-track-option-713-SmallCaps\" id=\"vjs-track-option-713-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p><strong>Which of the following are MOST LIKELY demonstrated by ultrasound?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "High right atrial pressure, increased extravascular lung water"
            },
            {
                "label": "B.",
                "text": "Low right atrial pressure, increased extravascular lung water"
            },
            {
                "label": "C.",
                "text": "High right atrial pressure, normal extravascular lung water"
            },
            {
                "label": "D.",
                "text": "Low right atrial pressure, normal extravascular lung water"
            }
        ],
        "correct_answer": "High right atrial pressure, increased extravascular lung water",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">POCUS images from this patient demonstrate a plethoric IVC and B-lines on lung ultrasound, suggesting high right atrial pressure (RAP) and increased extravascular lung water, respectively.</p>\n<p><span style=\"align:left; font-size: 16px;\"><strong> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></strong></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><strong><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28968e3a76_2-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28968e3a76_2\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"ksapv8m2b1q25b.mp4\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28968e3a76_2_html5_api\" role=\"application\" tabindex=\"-1\" title=\"ksapv8m2b1q25b.mp4\"><source src=\"https://education.asn-online.org/pluginfile.php/1/question/generalfeedback/74046/50/13379/ksapv8m2b1q25b.mp4\" type=\"video/mp4\"/>\n                        https://education.asn-online.org/pluginfile.php/1/question/generalfeedback/74046/50/13379/ksapv8m2b1q25b.mp4</video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-778\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-779\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" style=\"inset-inline: 50px;\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:05\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 0%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">0.00%</span></span><div data-end=\"0\" data-start=\"0\" style=\"left: 0%; width: 0%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:05</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28968e3a76_2_component_1023\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28968e3a76_2_component_1023\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28968e3a76_2_component_1324_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28968e3a76_2_component_1324_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28968e3a76_2_component_1330_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28968e3a76_2_component_1330_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_1357\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1357\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-White\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Black\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Red\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Green\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" id=\"captions-foreground-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1362\" id=\"captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1362\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28968e3a76_2_component_1330\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_1372\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1372\"><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Black\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-White\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Red\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Green\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330 captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" id=\"captions-background-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1377\" id=\"captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1377\"><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" id=\"captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-Transparent\" id=\"captions-background-opacity-id_videojs_68a28968e3a76_2_component_1330-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28968e3a76_2_component_1330\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_1387\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1387\"><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Black\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-White\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Red\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Green\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330 captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" id=\"captions-window-color-id_videojs_68a28968e3a76_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1392\" id=\"captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1392\"><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-Transparent\" id=\"captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330 captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" id=\"captions-window-opacity-id_videojs_68a28968e3a76_2_component_1330-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1407\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1408-50\" id=\"vjs-track-option-1408-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1409-75\" id=\"vjs-track-option-1409-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1410-100\" id=\"vjs-track-option-1410-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1411-125\" id=\"vjs-track-option-1411-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1412-150\" id=\"vjs-track-option-1412-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1413-175\" id=\"vjs-track-option-1413-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1414-200\" id=\"vjs-track-option-1414-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1415-300\" id=\"vjs-track-option-1415-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1416-400\" id=\"vjs-track-option-1416-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1426\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1427-None\" id=\"vjs-track-option-1427-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1428-Raised\" id=\"vjs-track-option-1428-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1429-Depressed\" id=\"vjs-track-option-1429-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1430-Uniform\" id=\"vjs-track-option-1430-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1431-Dropshadow\" id=\"vjs-track-option-1431-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330\" id=\"vjs_select_1441\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1442-ProportionalSansSerif\" id=\"vjs-track-option-1442-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1443-MonospaceSansSerif\" id=\"vjs-track-option-1443-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1444-ProportionalSerif\" id=\"vjs-track-option-1444-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1445-MonospaceSerif\" id=\"vjs-track-option-1445-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1446-Casual\" id=\"vjs-track-option-1446-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1447-Script\" id=\"vjs-track-option-1447-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28968e3a76_2_component_1330 vjs-track-option-1448-SmallCaps\" id=\"vjs-track-option-1448-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></strong></div></div><strong> <br/></strong><p></p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em>\n<p><br/></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To facilitate standardized reporting, RAP is stratified as follows in spontaneously breathing patients. The patient is asked to “sniff,” allowing for a sudden emptying of the IVC into the right atrium. RAP is low/normal (0–5 mm Hg) if the IVC maximal diameter is &lt;2.1 cm and it collapses more than 50% with respiration (sniff). RAP is high (10–20 mm Hg) if the IVC maximal diameter is &gt;2.1 cm and it collapses &lt;50% with respiration. An intermediate RAP (5–10 mm Hg) is assigned when the IVC diameter and collapse do not fit this paradigm. As renal perfusion pressure is the difference between inflow pressure (mean arterial pressure) and outflow pressure (mean venous pressure, approximated by RAP), a high RAP might suggest venous congestion of the kidneys, possibly from heart failure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Normal lung ultrasound demonstrates A-lines, which are equidistant hyperechoic (bright) horizontal artifacts, as opposed to the vertical B-lines seen in this patient. B-lines provide a semiquantitative estimate of the amount of extravascular lung water and often precede the onset of symptoms and auscultatory findings. They can also be seen in conditions other than cardiogenic pulmonary edema, such as pulmonary fibrosis and pneumonia, so should be interpreted in the appropriate clinical context.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The absence of jugular venous distention, rales on pulmonary auscultation, or pedal edema does not exclude volume overload. For instance, in one study including 43 patients with advanced heart failure (mean ejection fraction, 18%), the combined sensitivity of these parameters was only 58%. On the other hand, another study found that the sensitivity of IVC ultrasound for predicting RAP &gt;10 mm Hg was 82% compared with 14% from jugular vein inspection.</p>\n</div>",
        "references": [
            "Lang RM, Badano LP, Mor-Avi V, et al: Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.J Am SocEchocardiogr28(1): 1–39, 2015",
            "Husain-Syed F, Gröne HJ, Assmus B, et al: Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives.ESC Heart Fail8(1): 183–203, 2021",
            "Argaiz ER, Koratala A, Reisinger N: Comprehensive assessment of fluid status by point-of-care ultrasonography.Kidney3602(8): 1326–1338, 2021",
            "Stevenson LW, Perloff JK: The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.JAMA261(6): 884–888, 1989",
            "Brennan JM, Blair JE, Goonewardena S, et al: A comparison by medicine residents of physical examination versus hand-carried ultrasound for estimation of right atrial pressure.Am J Cardiol99(11): 1614–1616, 2007",
            "De Backer D, Vincent JL: Should we measure the central venous pressure to guide fluid management? Ten answers to 10 questions.Crit Care23; 22(1): 43, 2018"
        ]
    },
    "51": {
        "question": "<div class=\"qtext\"><p>A 73-year-old man with a history of CKD, hypertension, and abdominal aortic aneurysm status post endovascular graft is evaluated for worsening hypertension and AKI. Three weeks ago, he was hospitalized for acute-onset shortness of breath. Clinical evaluation\n    and chest x-ray were consistent with acute pulmonary edema. Echocardiogram revealed mild, concentric left ventricular hypertrophy but was otherwise normal. Stress radionuclide myocardial perfusion imaging was unremarkable. He responded to medical\n    therapy and is currently asymptomatic. Current medications include lisinopril, amlodipine, carvedilol, bumetanide, and atorvastatin.</p>\n<p>On examination, BP is 177/68 mm Hg in both arms with pulse is 80/min. Jugular venous pressure is normal, lungs are clear, and cardiac examination is normal. There is a mid-epigastric systolic bruit. There is no peripheral edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25;\">\n<p><strong>3 Weeks Ago</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25;\">\n<p><strong>Today</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>139 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>140</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.3 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.2</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>55</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.7 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>A renal artery duplex Doppler ultrasound is performed, with the following results:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p><strong>Measurement</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Right</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Left</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Peak systolic velocity of main renal artery</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>159 cm/s</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>527 cm/s</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Renal artery/aorta velocity ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.75</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.8</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Intraparenchymal resistive index</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.87</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.48</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Kidney length</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.1 cm</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.7 cm</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>The patient is sent for renal arteriogram and is found to have near-occlusive stenosis of the ostial main left renal artery, as shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2b1q19.png\" width=\"40%\"/>\n<figcaption><em>Image courtesy of John Duch, MD, South Texas Veterans Health Care System</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Diagnostic cardiac catheterization"
            },
            {
                "label": "B.",
                "text": "Change bumetanide to chlorthalidone"
            },
            {
                "label": "C.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "D.",
                "text": "Percutaneous revascularization of the left renal artery"
            },
            {
                "label": "E.",
                "text": "Increase dose of lisinopril"
            }
        ],
        "correct_answer": "Percutaneous revascularization of the left renal artery",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with uncontrolled hypertension, “flash” pulmonary edema, and AKI should undergo percutaneous revascularization of the left renal artery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Several large, randomized, controlled trials have investigated the optimal management of stable renal artery stenosis (RAS). Revascularization with percutaneous transluminal renal angioplasty (PTRA), with or without stent placement, has not provided any incremental benefit beyond maximal medical therapy, including antihypertensive and statin prescription, for cardiovascular events, CKD progression, or mortality. BP management with PTRA has been equally disappointing; in the CORAL study, systolic BP was only 2 mm Hg lower in the PTRA group. However, these clinical trials did not include patients with high-risk RAS, such as resistant or accelerated hypertension, rapidly worsening kidney function, or episodes of pulmonary edema. In smaller studies where PTRA was triggered by such clinical indicators, there was evidence for improved cardiovascular morbidity and mortality with revascularization. Consequently, many nephrologists would consider revascularization in cases such as this one or if antihypertensive therapy is not tolerated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diagnostic cardiac catheterization is not indicated and would not address worsening hypertension and kidney function. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has no evidence of volume overload, so increasing the dose of bumetanide would have little obvious value to controlling BP. Although chlorthalidone was recently shown to have significant benefit for hypertension management even in CKD stage 4, accelerated hypertension and AKI would be best addressed by renal artery revascularization rather than medical management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Similarly, lisinopril and spironolactone are effective antihypertensive medications but would not substitute for PTRA in addressing refractory hypertension and AKI.</p>\n</div>",
        "references": [
            "Ritchie J, Green D, Chrysochou C, Chalmers N, Foley RN, Kalra PA: High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization.Am J Kidney Dis63(2): 186–197, 2014",
            "Textor S, Lerman L: Reality and renovascular disease: when does renal artery stenosis warrant revascularization? Am J Kidney Dis63(2): 175–177, 2014",
            "Cooper CJ, Murphy TP, Cutlip DE, et al: Stenting and medical therapy for atherosclerotic renal-artery stenosis.N Engl J Med370(1): 13–22, 2014",
            "Agarwal R, Sinha AD, Cramer AE, et al: Chlorthalidone for hypertension in advanced chronic kidney disease.N Engl J Med385(27): 2507–2519, 2021"
        ]
    },
    "52": {
        "question": "<div class=\"qtext\"><p>A 36-year-old man with recently diagnosed stage 3 seminoma with bulky retroperitoneal lymphadenopathy presents to the emergency department with abnormal outpatient labs prior to his first cycle of chemotherapy. One month ago, he underwent right radical orchiectomy and right ureteral stent placement. He reports 3 days of progressive malaise, fatigue, lower back pain, and vomiting. He also notes decreased urine output. Medications include pregabalin and ondansetron.</p>\n<p>On examination, BP is 154/88 mm Hg, and body mass index is 50 kg/m<sup>2</sup>. His heart has a regular rhythm without rubs, he has clear lungs, and his lower extremities have 1+ pitting edema. EKG shows sinus bradycardia, with a heart rate of 52/min, with peaked T waves and prolonged PR and QRS intervals.</p>\n<p>Laboratory data in the emergency department are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000‒11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.3 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14‒18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>154,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000‒450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>134 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136‒145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5‒5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98‒106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23‒28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>113 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>19.1 mg/dL (baseline 1.5)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7‒1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.4 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6‒10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>78 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70‒99, fasting</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0‒4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Uric acid</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0‒7.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Arterial blood gas</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.25</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38‒7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>39 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38‒44 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>88 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75‒100 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>A urinary catheter is inserted with immediate return of 200 mL of dark, yellow urine. Kidney ultrasound shows severe right hydronephrosis with a ureteral stent in the right renal pelvis and moderate left hydronephrosis.</p>\n<p>He is given calcium gluconate IV, regular insulin and dextrose IV, and normal saline 1 L IV, which leads to an additional 100 mL of urine output 1 hour later.</p>\n<p>Repeat laboratory data are notable for potassium 6.9 mEq/L and creatinine 19.5 mg/dL.</p>\n<p><strong>Which ONE of the following is the NEXT BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Bilateral nephrostomy tubes"
            },
            {
                "label": "B.",
                "text": "Furosemide IV"
            },
            {
                "label": "C.",
                "text": "Patiromer"
            },
            {
                "label": "D.",
                "text": "Rasburicase"
            },
            {
                "label": "E.",
                "text": "Acute hemodialysis"
            }
        ],
        "correct_answer": "Acute hemodialysis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in the management of this patient with severe, refractory hyperkalemia unresponsive to medical therapy is to place a HD catheter and arrange for urgent HD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has severe, life-threatening hyperkalemia with EKG changes and bradycardia in the setting of oliguric AKI. After temporizing measures, management should include urgent removal of potassium from the extracellular fluid. Administration of IV fluids did not lead to a substantial increase in urine output, and with persistent, severe hyperkalemia, urgent HD is indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bilateral nephrostomy tube placement is warranted for management of the obstructive nephropathy, but the patient’s severe hyperkalemia makes him too unstable to undergo this procedure, which if successful would allow for the gradual removal of potassium as kidney function recovers. He should receive urgent HD to correct life-threatening electrolyte abnormalities and then undergo bilateral nephrostomy tube placement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics can be used to increase urinary potassium excretion, but his severe AKI from obstructive nephropathy will likely make diuresis attempts ineffective to rapidly lower his serum potassium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patiromer is a nonabsorbed, organic polymer that exchanges potassium for calcium in the distal colon and is being increasingly used in the management of chronic hyperkalemia, but due to its delayed onset of action, its use is not recommended (nor is it US FDA-approved) for the management of acute, life-threatening hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Rasburicase can be used in the prevention and management of tumor lysis syndrome, particularly when uric acid levels are elevated, but spontaneous tumor lysis typically occurs in patients with aggressive lymphoma or leukemia, although there are rare reports in patients with solid tumors. Furthermore, the most life-threatening electrolyte abnormality in this patient is hyperkalemia, which would not be addressed by rasburicase.</p>\n</div>",
        "references": [
            "Weiner, ID, Linas SL, Wingo CS: Disorders of potassium metabolism. InComprehensive Clinical Nephrology,6th ed.,edited by Feehally J, et al, Edinburgh: Elsevier, 2019, pp 111‒123",
            "Shingarev R, Allon M: A physiologic-based approach to the treatment of acute hyperkalemia.Am J Kid Dis56(3): 578‒584, 2010",
            "Pitt B, Bakris GL: New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future.Hypertension66(4):731‒738, 2015"
        ]
    },
    "53": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man with CKD stage 3a presents to the emergency department with 3 days of worsening dyspnea, cough, and decreased mobility. He has had no fevers, sick contacts, decreased urine output, or hematuria. He reports orthopnea and an increase in his weight, as well as a recent upper respiratory infection, which was treated with 7 days of amoxicillin. Past medical history includes type 2 diabetes complicated by retinopathy and nephropathy, coronary artery disease, atrial fibrillation, poorly controlled hypertension, and severe ischemic cardiomyopathy. Medications include apixaban, metformin, carvedilol, lisinopril, aspirin, and furosemide. </p>\n<p>On examination, BP is 148/90 mm Hg, heart rate is 72/min, and temperature is 38°C. He has moist mucous membranes. His heart has an irregularly irregular rhythm but no murmurs. Lungs demonstrate decreased breath sounds at the bases and bilateral crackles. There is 1+ pitting edema of his lower extremities bilaterally.</p>\n<p>Chest x-ray reveals vascular congestion, interstitial prominence, and bilateral pleural effusions.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>140 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>100 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>26 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>42 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.9 mg/dL (baseline 1.4)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.7 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   B-type natriuretic peptide (BNP), plasma</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1200 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>˂100</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Color</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Yellow </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Yellow </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.0</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.5–8.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Specific gravity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.018 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.002–1.030 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Blood</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1+</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Ketone</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Leukocyte esterase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Nitrite</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Urobilinogen</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Negative </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   WBC</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2/HPF</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–4</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   RBC</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10/HPF</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–4</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Squamous epithelial cells</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2/LPF</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0–4</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Urine protein-to-creatinine ratio</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.4 mg/mg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;0.2 </p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>The urine sediment is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2q53.jpg\" width=\"75%\"/>\n<figure><br/>\n<figcaption><em>Image courtesy of Wikimedia Commons (<a href=\"https://commons.wikimedia.org/w/index.php?curid=5652416\" target=\"_blank\">https://commons.wikimedia.org/w/index.php?curid=5652416</a>, accessed 9/2/22).\n\n            </em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the MOST appropriate treatment for this patient?</strong></p>\n</figure></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase furosemide"
            },
            {
                "label": "B.",
                "text": "Prescribe prednisone"
            },
            {
                "label": "C.",
                "text": "Prescribe bortezomib"
            },
            {
                "label": "D.",
                "text": "Obtain kidney biopsy"
            },
            {
                "label": "E.",
                "text": "Discontinue apixaban"
            }
        ],
        "correct_answer": "Increase furosemide",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with evidence of worsening volume overload and heart failure, increasing the furosemide dose is the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing diuresis would be indicated for this patient with known cardiomyopathy and atrial fibrillation, who has pulmonary edema as suggested by physical examination (high BP, decreased breath sounds, rales, and edema), elevated BNP, and a chest x-ray consistent with pulmonary edema. AKI is likely attributable to venous congestion with intact tubular function, as suggested by the high BUN-to-creatinine ratio and high urine specific gravity. Urine sediment shows no casts, and although RBCs are present, they appear to be monomorphic. In the absence of significant proteinuria, monomorphic RBCs are more likely attributable to urologic hematuria, possibly attributable to anticoagulation with apixaban. Increasing diuresis would treat congestive heart failure and would likely improve the hemodynamically mediated AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient’s presentation of dyspnea and microscopic hematuria appears to mimic a pulmonary-renal syndrome (i.e., anti-GBM disease, ANCA-associated vasculitis, or lupus nephritis), the urine sediment shows non-dysmorphic RBCs. His low-grade proteinuria is likely attributable to long-standing diabetic nephropathy. Thus, neither empiric prednisone nor kidney biopsy for vasculitis would be indicated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment with bortezomib for multiple myeloma would not be indicated at present, as further evaluation would be required. Urine dipstick analysis shows 30 mg/dL protein, consistent with his urine protein quantification (urine protein-to-creatinine ratio) and suggesting that proteinuria is largely albumin rather than light chains.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Discontinuing apixaban would not improve this patient’s AKI or pulmonary symptoms. Although some of the microscopic hematuria may be attributable to apixaban use, discontinuing anticoagulation is not required in the absence of significant bleeding and could expose this patient to an increased risk of thromboembolism. </p>\n</div>",
        "references": [
            "Rangaswami J, Bhalla V, Blair JEA, et al: Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.Circulation139(16): e840–e878, 2019",
            "Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J: Acute kidney injury.Nat Rev Dis Primers7(1): 52, 2021",
            "Geetha D, Jefferson JA: ANCA-associated vasculitis: core curriculum 2020.Am J Kidney Dis75(1): 124–137, 2020",
            "ANCA-associated vasculitis.Nat Rev Dis Primers6(1): 72, 2020",
            "Microhematuria.https://commons.wikimedia.org/w/index.php?curid=5652416. Accessed September 2, 2022"
        ]
    },
    "54": {
        "question": "<div class=\"qtext\"><p>A 53-year-old woman with ESRD due to ADPKD who is 5 months status post deceased donor kidney transplant presents to the emergency department with 10 days of severe headaches, nonproductive cough, papular rash, and malaise. Her medication regimen includes tacrolimus, mycophenolate mofetil, prednisone, nifedipine, valganciclovir, and aspirin.</p>\n<p>On examination, BP is 100/50 mm Hg, heart rate is 100/min, respiratory rate is 22/min, and oxygen saturation is 93% while breathing room air. She appears in mild acute distress and has rhonchi on auscultation and violaceous nodular lesions on her face, trunk, and extremities. Her kidney allograft site is well healed, without erythema or purulence.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>13.6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>33 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.5 mg/dL (baseline)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Chest x-ray reveals a right lower lobe opacity. A CT scan of the head reveals no intracranial abnormalities. A lumbar puncture is obtained with an opening pressure of 40 cm H<sub>2</sub>O noted.</p>\n<p><strong>Which ONE of the following pathogens is the MOST likely cause of this patient’s clinical presentation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cryptococcus"
            },
            {
                "label": "B.",
                "text": "Histoplasma"
            },
            {
                "label": "C.",
                "text": "Toxoplasma"
            },
            {
                "label": "D.",
                "text": "Epstein-Barr virus"
            },
            {
                "label": "E.",
                "text": "Cytomegalovirus"
            }
        ],
        "correct_answer": "Cryptococcus",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s symptoms is <em>Cryptococcus </em><em>neoformans </em>infection.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><em>Cryptococcus</em> is an opportunistic pathogen that may cause symptomatic infection in kidney transplant recipients, most commonly during the first year after transplant as immunosuppression is most intense during this period. Manifestations of disseminated <em>Cryptococcus</em> infection include meningoencephalitis, pneumonia, and skin lesions. In patients with neurologic symptoms, diagnosis requires a lumbar puncture with measurement of opening pressures (usually &gt;25 cm H<sub>2</sub>O) and India ink staining of cerebrospinal fluid (CSF) for encapsulated yeast. CSF cryptococcal antigen is another useful diagnostic tool, with sensitivity and specificity ranging from 93% to 100% and 93% to 98%, respectively. Treatment typically includes liposomal amphotericin B induction therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Histoplasmosis is a fungal infection, usually endemic to the American Midwest, that occurs after exposure to soil contaminated with bat or bird droppings and primarily presents as pneumonia. Toxoplasmosis is a protozoal infection that occurs after exposure to cat litter and may cause seizures or focal neurologic symptoms in immunocompromised patients; typically, a head CT scan would show multiple hypoattenuating lesions. EBV and CMV are herpesviruses that cause post-transplant lymphoproliferative disease and pneumonia, respectively, in kidney transplant recipients, among other diseases. None of these organisms would be expected to cause both pulmonary and neurologic symptoms as in this case.</p>\n</div>",
        "references": [
            "Akintilo L, Femia A: Disseminated cryptococcosis.N Engl J Med385(18): 1699, 2021",
            "Agrawal A, Ison MG, Danzinger-Isakov L: Long-term infectious complications of kidney transplantation.Clin J Am Soc Nephrol17(2):286–295, 2022",
            "Vilchez RA, Fung J, Kusne S: Cryptococcosis in organ transplant recipients: an overview.Am J Transplant2(7): 575–580, 2002"
        ]
    },
    "55": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man is admitted to the ICU for decompensated cirrhosis and AKI. Serum creatinine is 3.74 mg/dL from a baseline value of 0.8 mg/dL (reference range, 0.7–1.3). The patient’s nurse mentions that the automated portable bladder scanner recorded a urine volume of 420 mL, but bladder catheterization did not return any urine. The patient does not report any urge to urinate. A point-of-care ultrasound (POCUS) evaluation of the kidneys and urinary bladder is shown below.</p>\n<p><em>Play video and click lower right hand corner button to expand viewing pane.</em></p>\n<p> </p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a289810153d_1-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a289810153d_1\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"ksapv8m2b1q24a.mp4\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a289810153d_1_html5_api\" role=\"application\" tabindex=\"-1\" title=\"ksapv8m2b1q24a.mp4\"><source src=\"https://education.asn-online.org/pluginfile.php/1/question/questiontext/74046/55/13384/ksapv8m2b1q24a.mp4?time=1654783989438\" type=\"video/mp4\"/>\n        https://education.asn-online.org/pluginfile.php/1/question/questiontext/74046/55/13384/ksapv8m2b1q24a.mp4?time=1654783989438\n    </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-27\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-28\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\"></span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\"></span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">0%</span></span></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\"></span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a289810153d_1_component_285\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a289810153d_1_component_285\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">captions and subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"true\" class=\"vjs-picture-in-picture-control vjs-hidden vjs-control vjs-button vjs-disabled\" disabled=\"disabled\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a289810153d_1_component_589_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a289810153d_1_component_589_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a289810153d_1_component_595_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a289810153d_1_component_595_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a289810153d_1_component_595\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_622\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_622\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-White\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Black\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Red\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Green\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Blue\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Yellow\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Magenta\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595 captions-foreground-color-id_videojs_68a289810153d_1_component_595-Cyan\" id=\"captions-foreground-color-id_videojs_68a289810153d_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_627\" id=\"captions-foreground-opacity-id_videojs_68a289810153d_1_component_595\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-opacity-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_627\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-opacity-id_videojs_68a289810153d_1_component_595 captions-foreground-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a289810153d_1_component_595 captions-foreground-opacity-id_videojs_68a289810153d_1_component_595 captions-foreground-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a289810153d_1_component_595\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_637\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_637\"><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Black\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-White\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Red\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Green\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Blue\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Yellow\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Magenta\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595 captions-background-color-id_videojs_68a289810153d_1_component_595-Cyan\" id=\"captions-background-color-id_videojs_68a289810153d_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_642\" id=\"captions-background-opacity-id_videojs_68a289810153d_1_component_595\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_642\"><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" id=\"captions-background-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595 captions-background-opacity-id_videojs_68a289810153d_1_component_595-Transparent\" id=\"captions-background-opacity-id_videojs_68a289810153d_1_component_595-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a289810153d_1_component_595\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_652\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_652\"><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Black\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-White\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Red\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Green\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Blue\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Yellow\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Magenta\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595 captions-window-color-id_videojs_68a289810153d_1_component_595-Cyan\" id=\"captions-window-color-id_videojs_68a289810153d_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_657\" id=\"captions-window-opacity-id_videojs_68a289810153d_1_component_595\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_657\"><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595-Transparent\" id=\"captions-window-opacity-id_videojs_68a289810153d_1_component_595-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a289810153d_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595 captions-window-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" id=\"captions-window-opacity-id_videojs_68a289810153d_1_component_595-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a289810153d_1_component_595\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_672\"><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-673-50\" id=\"vjs-track-option-673-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-674-75\" id=\"vjs-track-option-674-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-675-100\" id=\"vjs-track-option-675-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-676-125\" id=\"vjs-track-option-676-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-677-150\" id=\"vjs-track-option-677-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-678-175\" id=\"vjs-track-option-678-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-679-200\" id=\"vjs-track-option-679-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-680-300\" id=\"vjs-track-option-680-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a289810153d_1_component_595 vjs-track-option-681-400\" id=\"vjs-track-option-681-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a289810153d_1_component_595\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_691\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595 vjs-track-option-692-None\" id=\"vjs-track-option-692-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595 vjs-track-option-693-Raised\" id=\"vjs-track-option-693-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595 vjs-track-option-694-Depressed\" id=\"vjs-track-option-694-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595 vjs-track-option-695-Uniform\" id=\"vjs-track-option-695-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a289810153d_1_component_595 vjs-track-option-696-Dropshadow\" id=\"vjs-track-option-696-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a289810153d_1_component_595\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595\" id=\"vjs_select_706\"><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-707-ProportionalSansSerif\" id=\"vjs-track-option-707-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-708-MonospaceSansSerif\" id=\"vjs-track-option-708-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-709-ProportionalSerif\" id=\"vjs-track-option-709-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-710-MonospaceSerif\" id=\"vjs-track-option-710-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-711-Casual\" id=\"vjs-track-option-711-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-712-Script\" id=\"vjs-track-option-712-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a289810153d_1_component_595 vjs-track-option-713-SmallCaps\" id=\"vjs-track-option-713-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div>\n<p></p><p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin\n    </em>\n</p>\n<p><strong>Which of the following is demonstrated by the POCUS images?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Distended urinary bladder"
            },
            {
                "label": "B.",
                "text": "Hydronephrosis"
            },
            {
                "label": "C.",
                "text": "Obstructed urinary catheter"
            },
            {
                "label": "D.",
                "text": "Pelvic ascites"
            },
            {
                "label": "E.",
                "text": "Enlarged prostate"
            }
        ],
        "correct_answer": "Pelvic ascites",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with decompensated cirrhosis and AKI has pelvic ascites on ultrasound.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pelvic ascites may be confused with the urinary bladder on ultrasound, as both urine and ascites are anechoic (appear black). Pelvic ascites typically shows irregular margins and contains bowel loops. In addition, ascites is more likely demonstrable in hepatorenal and splenorenal spaces. Automated bladder scanners cannot differentiate urine in the bladder from other pelvic fluid collections, and their reading should be interpreted with caution. The urine volume documented in this case likely represents ascites. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The urinary bladder is not seen on the POCUS images, which indicates that it is decompressed by the urinary catheter. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hydronephrosis appears as a branching, interconnected anechoic area in the renal pelvis. Here, the kidney ultrasound images do not demonstrate hydronephrosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">POCUS images do not demonstrate the balloon of the urinary catheter, which otherwise appears as an anechoic cyst-like structure in the decompressed bladder. When the catheter is obstructed due to debris or blood clots, the urinary bladder is distended despite the presence of the catheter balloon.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An enlarged prostate gland is seen as a rounded tissue protruding into the distended urinary bladder. No such structure is seen here, and the bladder is likely decompressed.</p>\n<p><span style=\"font-size: 16px;\"><strong></strong></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><strong><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a2898101a6a_2-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a2898101a6a_2\" lang=\"en-gb\" preload=\"auto\" role=\"region\" tabindex=\"-1\" title=\"ksapv8m2b1q24b.mp4\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a2898101a6a_2_html5_api\" preload=\"auto\" role=\"application\" tabindex=\"-1\" title=\"ksapv8m2b1q24b.mp4\"><source src=\"https://education.asn-online.org/pluginfile.php/1/question/generalfeedback/74046/55/13384/ksapv8m2b1q24b.mp4\" type=\"video/mp4\"/><a class=\"mediafallbacklink vjs-hidden\" hidden=\"hidden\" href=\"https://education.asn-online.org/pluginfile.php/1/question/generalfeedback/74046/55/13384/ksapv8m2b1q24b.mp4\">ksapv8m2b1q24b.mp4</a></video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-778\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-779\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\"></span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\"></span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">0%</span></span></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\"></span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a2898101a6a_2_component_1023\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a2898101a6a_2_component_1023\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">captions and subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"true\" class=\"vjs-picture-in-picture-control vjs-hidden vjs-control vjs-button vjs-disabled\" disabled=\"disabled\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a2898101a6a_2_component_1324_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a2898101a6a_2_component_1324_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a2898101a6a_2_component_1330_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a2898101a6a_2_component_1330_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_1357\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1357\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-White\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Black\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Red\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Green\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" id=\"captions-foreground-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1362\" id=\"captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1362\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a2898101a6a_2_component_1330\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_1372\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1372\"><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Black\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-White\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Red\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Green\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330 captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" id=\"captions-background-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1377\" id=\"captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1377\"><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" id=\"captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-Transparent\" id=\"captions-background-opacity-id_videojs_68a2898101a6a_2_component_1330-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a2898101a6a_2_component_1330\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_1387\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1387\"><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Black\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-White\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Red\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Green\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330 captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" id=\"captions-window-color-id_videojs_68a2898101a6a_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1392\" id=\"captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1392\"><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-Transparent\" id=\"captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330 captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" id=\"captions-window-opacity-id_videojs_68a2898101a6a_2_component_1330-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1407\"><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1408-50\" id=\"vjs-track-option-1408-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1409-75\" id=\"vjs-track-option-1409-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1410-100\" id=\"vjs-track-option-1410-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1411-125\" id=\"vjs-track-option-1411-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1412-150\" id=\"vjs-track-option-1412-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1413-175\" id=\"vjs-track-option-1413-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1414-200\" id=\"vjs-track-option-1414-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1415-300\" id=\"vjs-track-option-1415-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1416-400\" id=\"vjs-track-option-1416-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1426\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1427-None\" id=\"vjs-track-option-1427-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1428-Raised\" id=\"vjs-track-option-1428-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1429-Depressed\" id=\"vjs-track-option-1429-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1430-Uniform\" id=\"vjs-track-option-1430-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1431-Dropshadow\" id=\"vjs-track-option-1431-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330\" id=\"vjs_select_1441\"><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1442-ProportionalSansSerif\" id=\"vjs-track-option-1442-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1443-MonospaceSansSerif\" id=\"vjs-track-option-1443-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1444-ProportionalSerif\" id=\"vjs-track-option-1444-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1445-MonospaceSerif\" id=\"vjs-track-option-1445-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1446-Casual\" id=\"vjs-track-option-1446-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1447-Script\" id=\"vjs-track-option-1447-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a2898101a6a_2_component_1330 vjs-track-option-1448-SmallCaps\" id=\"vjs-track-option-1448-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></strong></div></div><p></p>\n<p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n</div>",
        "references": [
            "Koratala A, Bhattacharya D, Kazory A: Point of care renal ultrasonography for the busy nephrologist: a pictorial review.World J Nephrol8(3): 44–58, 2019",
            "Bejjanki H, Koratala A: The TIE fighter sign on point of care ultrasonography.CEN Case Rep9(1): 91–93, 2020",
            "Prentice DM, Sona C, Wessman BT, et al: Discrepancies in measuring bladder volumes with bedside ultrasound and bladder scanning in the intensive care unit: a pilot study.J Intensive Care Soc19(2):122–126, 2018",
            "O'Neill WC: Renal relevant radiology: use of ultrasound in kidney disease and nephrology procedures.Clin J Am Soc Nephrol9(2): 373–81, 2014"
        ]
    },
    "56": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man\n    with a past medical history of hypertension, type 2 diabetes, and obstructive\n    sleep apnea is brought to the emergency department by his wife, who noted the\n    patient to have slurred speech 8 hours prior to presentation. MRI of the brain\n    shows an acute lacunar infarct. Home medications include lisinopril,\n    amlodipine, chlorthalidone, and doxazosin.</p>\n<p>Vital signs include BP of 188/106 mm Hg, heart rate of 92/min, and temperature of 36.3°C.</p>\n<br/><strong><b>Which ONE of the following is the MOST appropriate next step in BP management?</b></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Lisinopril PO"
            },
            {
                "label": "B.",
                "text": "Nicardipine IV infusion"
            },
            {
                "label": "C.",
                "text": "No intervention"
            },
            {
                "label": "D.",
                "text": "Nitroprusside IV infusion"
            },
            {
                "label": "E.",
                "text": "Labetalol IV infusion"
            }
        ],
        "correct_answer": "No intervention",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">No additional intervention is required in this patient with an acute, ischemic stroke (cerebrovascular accident [CVA]) who has systolic BP &lt;220 mm Hg and diastolic BP &lt;120 mm Hg.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In patients with acute CVA for whom tissue plasminogen activator is not given, treatment of hypertension is not recommended unless systolic BP &gt;220 mm Hg or diastolic BP &gt;120, or if the patient has a secondary condition that requires more aggressive antihypertensive treatment (i.e., active coronary artery disease, acute aortic dissection, eclampsia). Numerous randomized controlled trials and meta-analyses have shown no benefit to mortality or functional status with initiating antihypertensive treatment in the absence of these indications. Moreover, overly aggressive management of hypertension is discouraged to avoid exacerbating cerebral ischemia. Should worsening BP mandate therapy, the goal BP reduction is by 15% within the first 24 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is acceptable to resume home antihypertensive medications in patients with BP &gt;140/90 mm Hg who are stable from a neurologic perspective 24–48 hours after stroke onset. This patient’s CVA has not yet reached that time frame, and in the acute setting, IV therapies are usually preferred. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nicardipine and labetalol are considered first-line therapy for hypertension in ischemic stroke and would be excellent choices had therapy been indicated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nitroprusside is thought to increase intracranial pressure and affect platelet function and therefore is usually second-line therapy for management of hypertension in ischemic stroke. </p>\n</div>",
        "references": [
            "Powers WJ, Rabinstein AA, Ackerson T, et al: Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke50(12): e344–e418, 2019",
            "Gasecki D, Kwarciany M, Kowalczyk K, et al: Blood pressure management in acute ischemic stroke.Curr Hypertens Res23(1): 3, 2021",
            "National Collaborating Centre for Chronic Conditions (UK): Stroke: National clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack (TIA). Royal College of Physicians (UK), 2008"
        ]
    },
    "57": {
        "question": "<div class=\"qtext\"><p>A 40-year-old old woman is referred to the nephrology clinic for hypernatremia. She reports 3 months of frequent urination, including waking several times per night to urinate. She does not have dysuria, hematuria, or urgency and denies excessive thirst or polyphagia. Past medical history includes pre-diabetes, sarcoidosis, and a 20-year history of well-controlled bipolar disorder, which had previously been treated with lithium but is now managed with valproate. Other than valproate, she does not take any prescription or over-the-counter medications</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>334,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>152 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>18 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Glucose</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>204 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99 (fasting)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.0 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Hemoglobin A<sub>1C</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.1%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.0–5.6</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Volume</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.2 L/day</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>121 mOsm/Kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Osmolality after desmopressin 2 μg subcutaneously</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>704 mOsm/Kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Nephrogenic diabetes insipidus"
            },
            {
                "label": "B.",
                "text": "Osmotic diuresis"
            },
            {
                "label": "C.",
                "text": "Central diabetes insipidus"
            },
            {
                "label": "D.",
                "text": "Reset osmostat"
            },
            {
                "label": "E.",
                "text": "Psychogenic polydipsia"
            }
        ],
        "correct_answer": "Central diabetes insipidus",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with polyuria, dilute urine, hypernatremia without thirst, and a physiologic response to desmopressin most likely has adipsic central diabetes insipidus.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The normal physiologic response to hypernatremia is the release of antidiuretic hormone (ADH) with consequent production of a small volume of maximally concentrated urine. A urine osmolality &lt;800 mOsm/kg H<sub>2</sub>O despite hypernatremia confirms diabetes insipidus (DI), and a water deprivation test is not essential. Urinary response to the ADH analogue desmopressin can distinguish between central and nephrogenic DI; in central DI, administration of desmopressin leads to an increase in urine osmolality. In nephrogenic DI, desmopressin will not cause an increase in the osmolality. In this case, the &gt;50% increase in urine osmolality following desmopressin suggests a central cause of DI. Urine osmolality will often not increase to the normal maximal range of 800–1200 mOsm/kg H<sub>2</sub>O in response to desmopressin because chronic polyuria causes washout of the medullary concentration gradient. Common causes for central DI include septo-optic dysplasia, germinoma, craniopharyngioma, aneurysms of the anterior communicating artery, and central nervous system sarcoidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, central DI is also suggested by the patient’s lack of thirst (adipsia). This very rare condition is marked by severe hypernatremia without thirst or polydipsia. Commonly, patients with DI (central or nephrogenic) have normal or only slightly elevated serum sodium as long as they have access to fluids.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic lithium use can cause permanent nephrogenic DI. Patients with this condition have normal thirst and should not become hypernatremic if they have access to water. In this case, the substantial increase in urine osmolality following desmopressin administration is not consistent with nephrogenic DI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Osmotic diuresis is a consideration when spot urine osmolality is &gt;300 mOsm/kg H<sub>2</sub>O and total 24-hour urinary osmole excretion is &gt;1000 mOsm. However, in this case, the urine osmolality of 121 mOsm/kg H<sub>2</sub>O and urine volume of 3.2 L/day suggests a total osmolal excretion of (121 mOsm/kg H<sub>2</sub>O × 3.2 L/day =) 387 mOsm/day, which is not consistent with osmotic diuresis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reset osmostat is more commonly invoked as an explanation for mild, asymptomatic hyponatremia in conditions such as quadriplegia, tuberculosis, malnutrition, and pregnancy. Mild hypernatremia from primary aldosteronism has also been ascribed to reset osmostat. This patient, however, has more severe hypernatremia and evidence of central DI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary polydipsia will not cause hypernatremia, as patients excrete an appropriately dilute urine and usually have a normal or slightly low serum sodium.</p>\n</div>",
        "references": [
            "Qian Q: Hypernatremia.Clin J Am Soc Nephrol14(3): 432–434, 2019",
            "Dalan R, Chin H, Hoe J, et al: Adipsic diabetes insipidus—the challenging combination of polyuria and adipsia: a case report and review of literature.Front Endocrinol (Lausanne)10: 630, 2019",
            "Gregoire JR: Adjustment of the osmostat in primary aldosteronism.Mayo Clin Proc69(11): 1108–1110, 1994",
            "Grünfeld JP, Rossier BC: Lithium nephrotoxicity revisited.Nat Rev Nephrol5(5): 270–276, 2009"
        ]
    },
    "58": {
        "question": "<div class=\"qtext\"><p dir=\"ltr\" style=\"margin-bottom: 15px;\">A 52-year-old man with ESRD attributed to hypertension receives thrice weekly dialysis. His dialysis prescription is 3.5 hours with a dialysate containing a sodium concentration of 140 mEq/L. Past medical history includes hypertension and congestive heart failure. He urinates approximately 100 mL/day. He is inconsistently adherent to a sodium- and fluid-restricted diet. Medications include fosinopril, amlodipine, furosemide, carvedilol, sevelamer, and a multivitamin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His estimated dry weight is 70 kg and his pre-dialysis weight averages 76 kg; his usual pre-dialysis BP is 170/95 mm Hg and his post-dialysis BP averages 160/90 mm Hg. He does not experience intradialytic hypotension or cramping. He cannot be accommodated for a longer treatment time and has limited ability to attend extra sessions for treatment of fluid overload. He is not interested in home HD or PD. In accordance with his dialysis unit policy of a maximal ultrafiltration rate of 13 mL/kg per hour, his ultrafiltration goal is set to 3.1 L per treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">His examination is notable for a BP of 165/93 mm Hg, elevated jugular venous pressure, bibasilar crackles, and moderate pretibial edema.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pre-dialysis laboratory data are as follows:</p><br/>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>135 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.6 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following interventions is most likely to decrease his interdialytic weight gain (IDWG)?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decrease dialysate sodium"
            },
            {
                "label": "B.",
                "text": "Advise fluid and sodium restriction"
            },
            {
                "label": "C.",
                "text": "Prescribe metolazone"
            },
            {
                "label": "D.",
                "text": "Prescribe sodium modeling"
            },
            {
                "label": "E.",
                "text": "Change fosinopril\nto losartan"
            }
        ],
        "correct_answer": "Decrease dialysate sodium",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reducing the dialysate sodium concentration to equal the patient’s serum sodium concentration is the intervention most likely to reduce this patient’s interdialytic weight gain (IDWG).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reducing the dialysate sodium concentration to the patient’s sodium concentration has been shown to be effective in lowering BP and reducing IDWG, a phenomenon attributed to sodium and fluid loading following activation of thirst. IDWG increases by 0.17% of post-dialysis body weight per 2 mEq/L higher dialysate sodium concentration compared with the patient’s pre-dialysis level. Many HD units have initiated strict limitations on fluid removal rates because of evidence that chronic fluid removal rates &gt;13 mL/kg per hour are associated with increased mortality, limiting the ability for aggressive ultrafiltration in patients with large IDWG.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dietary counselling is standard of care but unlikely to be as helpful in controlling IDWG. Adherence to sodium restrictions was poor in the HEMO study even with meticulous clinical oversight, and a more restrictive dietary sodium prescription was associated with only a small change in ultrafiltration requirement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Diuretics may be effective in maintaining urine output in patients initiating dialysis and may improve clinical outcomes. There is a paucity of data concerning the initiation or augmentation of diuretic therapy in patients who are already receiving dialysis. Although distally acting diuretics such as metolazone are commonly used to augment diuresis in patients with advanced heart failure receiving loop diuretics, there are no data regarding their efficacy in ESRD. Moreover, augmented diuresis may not be very effective in this patient who remains oligoanuric despite taking furosemide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium modeling is a practice by which the dialysate sodium concentration is increased during treatment, causing water to shift from the intracellular to the extracellular space to mitigate intradialytic hypotension during ultrafiltration. Sodium modeling has not been shown to be useful in a patient who is consistently hypertensive and hypervolemic and, by generating hypertonicity, may actually increase thirst and IDWG.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Angiotensin II (AII) levels increase after dialysis and have been associated with increased thirst, and drugs that block the action or formation of AII may be useful in decreasing IDWG. ACEIs have been demonstrated to reduce thirst and IDWG in patients receiving HD, whereas ARBs have not.</p>\n</div>",
        "references": [
            "Hecking M, Karaboyas A, Saran R, et al: Dialysate sodium concentration and the association with interdialytic weight gain, hospitalization, and mortality.Clin J Am Soc Nephrol7(1): 92‒100, 2012",
            "Mc Causland FR, Waikar SS, Brunelli SM: The relevance of dietary sodium in hemodialysis.Nephrol Dial Transplant28(4): 797‒802, 2013",
            "Sibbel S, Walker AG, Colson C, et al: Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes.Clin J Am Soc Nephrol14(1): 95‒102, 2019",
            "Santos SF, Peixoto AJ: Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients.Clin J Am Soc Nephrol3(2): 522‒530, 2008",
            "Flythe JE, McCausland FR: Dialysate sodium: rationale for evolution over time.Semin Dial30(2): 99‒111, 2017",
            "Slomka T, Lennon ES, Akbar H, et al: Effects of renin-angiotensin-aldosterone system blockade in patients with end-stage renal disease.Am J Med Sci351(3): 309‒316, 2016",
            "Assimon MM, Wenger JB, Wang L, Flythe JE: Ultrafiltration rate and mortality in maintenance hemodialysis patients.Am J Kidney Dis68(6): 911‒922, 2016"
        ]
    },
    "59": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man was admitted to the medical ICU 1 week ago with hypoxemic respiratory failure from COVID-19 pneumonia. He was treated with corticosteroids, barcitinib, and isotonic saline. Therapeutic anticoagulation was initiated on day 1 for an acute left leg deep vein thrombosis; however, due to significant upper gastrointestinal bleeding from a perforated peptic ulcer, anticoagulation was stopped on hospital day 3. He developed oliguria on day 3, and on day 6, he received furosemide 80 mg IV, with an increase in urine output to 400 mL over the next 2 hours. His current medications include propofol, pantoprazole, and prednisone.</p>\n<p>On examination, mean arterial pressure (MAP) is 70 mm Hg, heart rate is 100/min, and oxygen saturation is 90% while intubated and breathing 50% oxygen. He weighs 80 kg (75 kg on admission). He is sedated, with bilateral rhonchi, elevated jugular venous pressure, and left lower extremity edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>133 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.5 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>105 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>18 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>110 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.8 mg/dL (baseline 0.8)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     Lactate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.2 mmol/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–2.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Arterial blood gas</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.32</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>36 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>     pO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75 mm Hg</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75–100</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urine sediment shows 10–12 granular casts/LPF, 1–2 renal tubular cells/HPF, 0–5 isomorphic RBC/HPF and 1–2 WBC/HPF.</p><br/>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer lactated Ringer’s solution"
            },
            {
                "label": "B.",
                "text": "Initiate intermittent hemodialysis"
            },
            {
                "label": "C.",
                "text": "Initiate continuous renal replacement therapy"
            },
            {
                "label": "D.",
                "text": "Prescribe furosemide"
            },
            {
                "label": "E.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            }
        ],
        "correct_answer": "Prescribe furosemide",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with oliguric AKI from acute tubular necrosis (ATN), with evidence of fluid overload and responsiveness to a diuretic challenge, the next best step in management is to prescribe furosemide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The furosemide stress test is a tool that can predict the development of stage 3 AKI. Two hours after administering furosemide at a dose of 1–1.5 mg/kg IV, a urine output of &gt;200 mL indicates responsiveness to diuretics. Failure to produce at least this amount of urine, coupled with appropriate biomarkers, predicts progression to stage 3 AKI, renal replacement therapy (RRT), and death. In this case, conservative therapy with loop diuretics would be a reasonable option to help reach euvolemia in the absence of any absolute indications to initiate RRT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has ATN in the setting of severe COVID-19 pneumonia, gastrointestinal bleeding, and venous thromboembolic disease. He has met parameters dictating end points of resuscitation and appears hypervolemic, making further isotonic fluid administration inadvisable.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The timing of RRT has been an intensely investigated topic of study, and in the absence of emergent indications such as medically resistant hyperkalemia, severe metabolic acidosis, toxic ingestion, or other indications, initiating RRT earlier in the course of AKI has not shown a significant improvement in overall outcomes in randomized, controlled studies. In the Standard versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury Trial, no difference in mortality was noted between patients who underwent early initiation of RRT (within 12 hours of identification of AKI) versus those who underwent late initiation (when indications for RRT developed). Patients in the early initiation group were more likely to remain on RRT when assessed at 90 days and had more adverse everts. Although a small number of other trials have reported conflicting data, in a recent systematic review and patient data meta-analysis of randomized, clinical trials comparing delayed versus early initiation of RRT for severe AKI, the timing of initiation did not affect survival.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Indications for RRT (either HD or CRRT) do not include an absolute value for BUN. This patient has multiple confounding factors besides AKI or uremia that can also increase BUN, including the use of corticosteroids and upper gastrointestinal bleeding. CRRT would not be indicated, given this patient’s excellent hemodynamic parameters and response to IV diuretics.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium zirconium cyclosilicate (ZS-9) is a potassium exchange resin that is approved for chronic (not acute) management of hyperkalemia. It is contraindicated in patients with bowel motility disorders. Additionally, there is concern for increased volume overload while taking the drug, due to absorption of sodium. Alhtough ZS-9 may be useful adjunctive therapy with diuretics, furosemide alone would be expected to improve both volume overload and hyperkalemia.</p>\n</div>",
        "references": [
            "STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; United Kingdom Critical Care Research Group; Canadian Nephrology Trials Network; Irish Critical Care Trials Group; Bagshaw SM, Wald R, Adhikari NKJ, et al: Timing of initiation of renal-replacement therapy in acute kidney injury.N Engl J Med383(3): 240–251, 2020",
            "Lumlertgul N, Peerapornratana S, Trakarnvanich T, et al: Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial).Crit Care22(1): 101, 2018",
            "Koyner JL, Davison DL, Brasha-Mitchell E, et al: Furosemide stress test and biomarkers for the prediction of AKI severity.J Am Soc Nephrol26(8): 2023–2031, 2015",
            "Gaudry S, Hajage D, Benichou N et al: Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials.Lancet395(10235): 1506–1515, 2020"
        ]
    },
    "60": {
        "question": "<div class=\"qtext\"><p>A 30-year-old woman presents to nephrology clinic for routine follow-up of stage 3 CKD due to lupus nephritis. Past medical history is significant for antiphospholipid antibody syndrome and hypertension. She feels well, without joint pain, rashes, or changes to her urinary output. Her medications include aspirin, nifedipine, labetalol, lisinopril, tacrolimus, and hydroxychloroquine. She is currently sexually active, but does not want to conceive at this time. She inquires about options for contraception.</p>\n<p>On examination, BP is 132/72 mm Hg. The remainder of her examination is unremarkable.</p>\n<p><strong>Which ONE of the following is the MOST appropriate recommendation for contraception?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Levonorgestrel-releasing intrauterine device"
            },
            {
                "label": "B.",
                "text": "Barrier contraceptive (e.g., cervical cap or diaphragm)"
            },
            {
                "label": "C.",
                "text": "No contraception needed due to impaired fertility"
            },
            {
                "label": "D.",
                "text": "Combined ethinyl estradiol-progestin oral contraceptive"
            },
            {
                "label": "E.",
                "text": "Tubal ligation"
            }
        ],
        "correct_answer": "Levonorgestrel-releasing intrauterine device",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate contraceptive option in this patient is a levonorgestrel-releasing intrauterine device (IUD).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pregnancy can occur in all stages of CKD and is associated with an increased risk of maternal and fetal complications, including worsening kidney function, proteinuria, hypertension, preterm birth, and fetal growth restriction. Birth control is important to prevent unplanned pregnancies, especially in patients who are taking teratogenic medications such as lisinopril.</p>\n<p>The preferred contraceptive methods in patients with CKD include progestin-only medications and IUDs. Long-acting reversible contraception with a levonorgestrel-impregnated IUD is one of the most effective means of pregnancy prevention (&gt;99%). The hormonal IUD may be left in place for 3–5 years. For women with ESRD, progestin-only contraception has the most favorable safety profile and includes the progestin-only pill (desogestrel), the levonorgestrel-releasing IUD, and the etonogestrel implant, although rates of implementation are low (5.3%).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Barrier methods of contraception have high failure rates (12%–21%) and should be avoided as the sole means of pregnancy prevention. Barrier forms of contraception include male and female internal condoms, diaphragms, cervical caps, vaginal sponges, and spermicide. Male condoms provide the added benefit of protecting against sexually-transmitted diseases.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Combined hormonal contraception contains an estrogen compound, and these methods (oral, transdermal, and vaginal rings) are relatively contraindicated in patients with CKD or ESRD, lupus, hyperlipidemia, hypertension, or diabetes because of the increased risk of venous thrombosis and cardiovascular disease. This patient’s additional history of anti-phospholipid antibody syndrome would make estrogen-containing contraceptives confer an unacceptably high risk of thrombosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Permanent solutions with tubal ligation or sterilization (salpingectomy) are highly effective but irreversible and would not be recommended for patients in whom future pregnancy may be desired.</p>\n</div>",
        "references": [
            "Ahmed SB, Vitek WS, Holley J: Fertility, contraception, and novel reproductive technologies in chronic kidney disease.Semin Nephrol37(4) :327–336, 2017",
            "Sachdeva M: Contraception in kidney disease.Adv Chronic Kidney Dis27(6): 499–505, 2020",
            "Shah S, Christianson AL, Thakar CV, et al: Contraceptive use among women with end-stage kidney disease on dialysis in the United States.Kidney Med2(6): 707–715, 2020"
        ]
    },
    "61": {
        "question": "<div class=\"qtext\"><p>A 47-year-old man with a history of hypertension and degenerative disk disease is evaluated for post-operative AKI. He was admitted to the hospital 2 days ago for an elective, multilevel, lumbar fusion surgery, done in the prone position. During his pre-operative visit 1 week ago, his potassium was 4.3 mEq/L, and his creatinine was 1.0 mg/dL. He is currently post-operative day 1 from a 6-hour uncomplicated surgery, under general anesthesia, without episodes of hypotension and estimated blood loss of 300 mL. He received 1.5 g of vancomycin pre-operatively. Urine output during the procedure was 150 mL.</p>\n<p>His current medications include prophylactic low-molecular-weight heparin, amlodipine, and ketorolac and oxycodone as needed.</p>\n<p>On physical examination, he is in no acute distress. He is afebrile with a BP of 135/79 mm Hg and a heart rate of 82/min. His body mass index is 40 kg/m<sup>2</sup>. Cardiac and lung examinations reveal a normal rhythm without murmurs and clear breath sounds, respectively. His abdomen is distended and tympanic. He has trace lower extremity edema bilaterally. There are no areas of ecchymosis or rash. He has normal strength and sensation in the lower extremities. Urine output is 0.8 L/day with clear, yellow urine draining from an indwelling urinary catheter.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Result</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14.1 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>137 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>102 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>50 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7-1.3</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is normal.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Urinary tract obstruction"
            },
            {
                "label": "B.",
                "text": "Rhabdomyolysis"
            },
            {
                "label": "C.",
                "text": "Ischemic acute tubular necrosis"
            },
            {
                "label": "D.",
                "text": "Intra-abdominal hypertension"
            },
            {
                "label": "E.",
                "text": "Acute\ninterstitial nephritis"
            }
        ],
        "correct_answer": "Intra-abdominal hypertension",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of AKI in this patient undergoing a prolonged spinal surgery in the prone position is increased intra-abdominal pressure (IAP), resulting in intra-abdominal hypertension (IAH) or abdominal compartment syndrome. IAH occurs at IAP &gt;12 mm Hg and abdominal compartment syndrome (ACS) at IAP &gt;20 mm Hg and are often unrecognized causes of AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IAH/ACS is postulated to cause AKI through a variety of mechanisms, including compression of the inferior vena cava, leading to decreased cardiac preload; cranial displacement of the diaphragm, which compresses the heart; increased afterload; and increased pressure in the renal veins. These changes decrease renal plasma flow and increase intra-glomerular pressure, leading to decreased GFR and urine output. AKI occurs in approximately 4% of patients undergoing spinal surgery and may be related to a variety of factors, including intraoperative hypotension, intraoperative blood loss, and prolonged time in the prone position. Depending on the type of operating table and ventilation settings used, IAP in patients undergoing prone spinal surgery may be as high as 15 mm Hg. This patient has multiple risk factors for AKI caused by increased IAP, including obesity, prone-position spinal surgery, and pre-existing hypertension. A fall in his urine output during surgery, despite normal BP and minimal bleeding, supports a diagnosis of IAH. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Both intraoperative hypotension and intraoperative blood loss may occur during spinal surgery and contribute to AKI, although there was no report of either during this patient’s surgery. Profound intraoperative hypertension and blood loss may result in acute tubular necrosis, although this diagnosis typically presents 24–48 hours after surgery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinary tract obstruction can cause AKI, but the most likely etiology of obstruction is bladder pathology, such as atony or obstruction from an enlarged prostate, and these are unlikely in the presence of a functioning indwelling urinary catheter. His low urine output during surgery is more likely related to IAH.</p>\n<p>Intraoperative rhabdomyolysis can occur when there is prolonged compression of muscles during the operative period, often due to surgical positioning. Flank or dorsal lithotomy are the positions most associated with intraoperative rhabdomyolysis. Risk factors include obesity, CKD, and substantial intraoperative blood loss. In this case, the lack of ecchymosis, the clear urine, and the congruent urinalysis and urine microscopy make rhabdomyolysis unlikely. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis (AIN) can be caused by medications, such as antibiotics and NSAIDs. However, AIN would be expected to cause leukocyturia, hematuria, or proteinuria, which are absent here.</p>\n</div>",
        "references": [
            "Jin S-J, Park Y-S, Kim S-H, et al: Effect of prone positional apparatus on the occurrence of acute kidney injury after spine surgery.World Neurosurg128: e597–e602, 2019",
            "Kim E, Kim H-C, Lim Y-J, et al: Comparison of intra-abdominal pressure among 3 prone positional apparatuses after changing from the supine to the prone position and applying positive end-expiratory pressure in healthy euvolemic patients: a prospective observational study.J Neurosurg Anesthesiol29(1): 14–20, 2017",
            "Mohmand H, Goldfarb S: Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome.J Am Soc Nephrol22(4): 615–621, 2011",
            "Farag E, Makarova N, Argalious M, et al: Vasopressor infusion during prone spine surgery and acute renal injury: a retrospective cohort analysis.Anesth Analg129(3): 896–904, 2019",
            "Pressman E, Osburn B, Vivas A, et al: Rhabdomyolysis after spinal fusion surgery: management schema and prevention of a catastrophic complication [published online ahead of print, January 7, 2021].Br J Neurosurgdoi:10.1080/02688697.2020.1866164"
        ]
    },
    "62": {
        "question": "<div class=\"qtext\"><p>A 68-year-old man is evaluated in the ICU for shortness of breath and malaise. He reports that his symptoms began 4 days ago with diarrhea and vomiting. He has a past medical history of heart failure with preserved ejection fraction, CKD stage G3b, hypertension, and type 2 diabetes mellitus. He has been adherent to his medications, which include torsemide, carvedilol, lisinopril, amlodipine, and atorvastatin.</p>\n<p>On physical examination, BP is 98/62 mm Hg, heart rate is 106/min, respiratory rate is 22/min, and oxygen saturation is 92% while breathing 3 L/min supplemental oxygen. His examination is notable for moist mucus membranes, fine crackles in both lung bases, and tachycardia with a regular rhythm. There is no jugular venous distention, hepatojugular reflex, or edema, and the abdomen is benign.</p>\n<strong><b>Which of the following tests\n        would MOST LIKELY indicate whether this patient’s hemodynamic parameters will\n        respond to IV fluid administration?</b></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Passive leg raise"
            },
            {
                "label": "B.",
                "text": "Chest x-ray"
            },
            {
                "label": "C.",
                "text": "Pulmonary capillary wedge pressure"
            },
            {
                "label": "D.",
                "text": "Central venous pressure"
            },
            {
                "label": "E.",
                "text": "Inferior vena cava diameter"
            }
        ],
        "correct_answer": "Passive leg raise",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with complex underlying pathophysiology, including heart failure with preserved ejection fraction and hypertension, with hypotension, tachycardia, and indeterminate volume status, the best test for predicting volume responsiveness is the passive leg raise. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dynamic markers of volume status have generally been found more accurate at predicting volume responsiveness than static measures. The passive leg raise test is performed by first placing the patient's head and torso at a 45° angle and measuring cardiac output (CO) using arterial pulse contour analysis, end-tidal CO<sub>2</sub> monitoring, echocardiography, or esophageal Doppler. Other dynamic markers include arterial pulse pressure variability or stroke volume variability. Then, the head of the bed is lowered to the supine position while raising the foot of the bed to 45° for 30–90 seconds. A change in CO by &gt;10% demonstrates fluid responsiveness, with a sensitivity and specificity of 97% and 94%, respectively. In contrast to other dynamic tests of volume responsiveness, the passive leg raise test may be used in patients with atrial fibrillation, spontaneous breathing, and low lung compliance, although not in those with abdominal compartment syndrome or amputations. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The other answer choices are static indicators of volume responsiveness. Chest x-ray, central venous pressure (CVP), and pulmonary artery occlusion or capillary wedge pressure (PCWP), not to mention physical examination, are poor predictors of volume responsiveness. Additionally, CVP and PCWP require placement of a central venous or pulmonary artery catheter, respectively, which increase the risk of complications from these invasive procedures.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bioimpedance is a noninvasive way to measure real-time static volume status. It uses Ohm’s law to correlate resistance to changes in voltage in a current, which may be translated to volume status and CO. This method is not yet in widespread use but shows promise for assessment of intravascular volume status. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inferior vena cava (IVC) diameter and changes in diameter with respiration have been touted as markers of intravascular volume status. However, IVC diameter and collapsibility or distensibility with respiration have not been reliably associated with fluid responsiveness. In a systematic review of 20 studies, the sensitivity and specificity of these parameters were only 71% and 75%, respectively.</p>\n</div>",
        "references": [
            "Kalantari K, Chang JN, Ronco C, Rosner MH: Assessment of intravascular volume status and volume responsiveness in critically ill patients.Kidney Int83(6): 1017–1028, 2013",
            "Monnet X, Teboul JL: Passive leg raising: Five rules, not a drop of fluid!Crit Care19(1): 18, 2015",
            "Bentzer P, Griesdale DE, Boyd J, et al: Will this hemodynamically unstable patient respond to a bolus of intravenous fluids?JAMA316(12): 1298–309, 2016",
            "Broyles MG, Subramanyam S, Barker AB, Tolwani AJ: Fluid responsiveness in the critically ill patient.Adv Chronic Kidney Dis28(1): 20–28, 2021"
        ]
    },
    "63": {
        "question": "<div class=\"qtext\"><p>A 58-year-old man with ESRD due to diabetic nephropathy is evaluated in the HD unit for hypotension during HD. Eight years ago, he received a deceased donor kidney transplant. Four months ago, he was diagnosed with antibody-mediated rejection and was treated with plasmapheresis, IV immunoglobulin, and multiple courses of steroids. His kidney function continued to decline, and he initiated HD via a tunneled dialysis catheter 1 week ago. Mycophenolate mofetil and prednisone were discontinued when he began HD, but he remains on tacrolimus. </p>\n<p>His average BP for the last 6 months has been 140/80 mm Hg. During his last HD treatment, ultrafiltration was limited by symptomatic intradialytic hypotension. His pre-HD BP today was 94/62 mm Hg.</p>\n<p>On examination, 90 minutes into treatment, his BP is 84/53 mm Hg, heart rate is 82/min, and temperature is 36.7°C. He has faint bibasilar crackles in his lungs and 1+ lower extremity edema bilaterally to the mid-shin. His allograft site is nontender. His HD catheter exit site has no discharge or erythema. </p>\n<p>A bedside cardiac ultrasound shows an ejection fraction of 63% and no other significant abnormalities.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Check morning cortisol level"
            },
            {
                "label": "B.",
                "text": "Check blood cultures"
            },
            {
                "label": "C.",
                "text": "Increase estimated dry weight"
            },
            {
                "label": "D.",
                "text": "Increase dialysate sodium concentration"
            },
            {
                "label": "E.",
                "text": "Check orthostatic vital signs"
            }
        ],
        "correct_answer": "Check morning cortisol level",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with new-onset hypotension after discontinuation of long-term glucocorticoids, the next best step is to check a morning serum cortisol level.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with chronic glucocorticoid use are at risk of adrenal insufficiency from suppression of the hypothalamic-pituitary-adrenal axis due to inhibition of corticotropin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH). Sudden discontinuation of steroids, especially after exposure to multiple courses of high-dose glucocorticoids, can lead to adrenal insufficiency, which often manifests as weakness and hypotension. Other symptoms include abdominal pain and low-grade fever.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although it is important to rule out sepsis due to a catheter-related bloodstream infection with blood cultures, this patient has no fever and a clean-appearing catheter site, which makes sepsis less likely.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Intradialytic hypotension commonly occurs if the patient’s estimated dry weight (EDW) is set at too low a value. However, this patient has evidence of volume overload, with mild crackles and edema, and thus increasing his EDW would not be appropriate. Increasing the dialysate sodium concentration may improve his intradialytic hypotension but is associated with higher interdialytic weight gain and would not be an appropriate solution for a patient who is already having difficulty achieving target ultrafiltration goals. Neither of these measures would address his underlying adrenal insufficiency.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Checking orthostatic vital signs would be reasonable, as this patient is at risk of autonomic neuropathy given his history of diabetes. However, autonomic neuropathy would not be the most likely cause of his new-onset hypotension, given normal BP within the last few months.</p>\n</div>",
        "references": [
            "Sagar R, Mackie S, Morgan AW, Stewart P, Abbas A: Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment.Clin Endocrinol94(3): 361–370, 2021",
            "Valentin A, Borresen SW, Rix M, et al Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study.Nephrol Dial Transplant35(12): 2191–2197, 2020",
            "Munoz Mendoza J, Arramreddy R, Schiller B: Dialysate sodium: choosing the optimal hemodialysis bath.Am J Kidney Dis66(4): 710–720, 2015"
        ]
    },
    "64": {
        "question": "<div class=\"qtext\"><p>A 25-year-old woman\n    was referred to the nephrology clinic to evaluate 2 weeks of leg edema and\n    nephrotic-range proteinuria (6 g/day). She reported no past medical history.\n    She subsequently underwent percutaneous left kidney biopsy using real-time ultrasound.\n    The patient developed frank hematuria 4 hours after the procedure and now\n    complains of pain at the biopsy site.</p>\n<p>On examination,\n        BP is 100/80 mm Hg, pulse is 105/min, and respiratory rate is 14/min. Flank\n        tenderness is noted on the left side.</p>\n<p>Laboratory data\n        are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: topwidth: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9,500/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000‒11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11 g/dL (baseline, 13.2)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12‒16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                220,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000‒450,000\n            </td>\n</tr>\n</tbody>\n</table>\n<p><span style=\"font-size: 0.9375rem;\"></span></p>\n<p>CT angiogram reveals\n    an intra-renal arteriovenous fistula in the left kidney.</p>\n<p>IV fluids are\n        initiated.</p><strong><b>Which of the following is the MOST appropriate next step in management?</b></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "No additional intervention"
            },
            {
                "label": "B.",
                "text": "Duplex Doppler kidney ultrasound"
            },
            {
                "label": "C.",
                "text": "Partial nephrectomy"
            },
            {
                "label": "D.",
                "text": "Packed RBC transfusion"
            },
            {
                "label": "E.",
                "text": "Coil embolization of the fistula"
            }
        ],
        "correct_answer": "Coil embolization of the fistula",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with an intra-renal arteriovenous (AV) fistula after kidney biopsy, with hematuria, flank pain, and acute anemia, should undergo coil embolization of the AV fistula.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy complications range from minimally symptomatic (pain, hematuria, hematoma) to critical (anemia requiring blood transfusion or surgical hemostasis or death). Although kidney biopsy complications have decreased with the advent of percutaneous biopsy techniques and real-time ultrasound, it is important to be aware of their management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The formation of an intra-renal AV fistula is a rare complication of kidney biopsy. The reported incidence rates are 0.3%–5.6% after native and 10%–16% after transplant kidney biopsy. Most AV fistulas resulting from biopsy are asymptomatic, resolve spontaneously within two years, and are often detected as incidental imaging findings. In some cases, AV fistulas can cause persistent hematuria, perinephric hematoma, hypertension, high-output heart failure, and CKD. Symptomatic patients, such as this one, require further evaluation and closure of the fistula.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Intra-renal AV fistula is diagnosed by duplex Doppler ultrasound, CT angiography, or digital subtraction angiography (DSA); DSA is usually reserved to confirm the diagnosis and provide definitive treatment. The treatment goal is to occlude the AV fistula while preserving kidney function. The specific intervention depends on renal vascular anatomy, such as the number and distribution of renal arteries and the size of the fistula. Coil embolization is the preferred embolization, as it is effective, minimally invasive, and does not tend to cause renal ischemia. Reported success rates are 88%–95%. Follow-up imaging studies can be performed a few days after the procedure to confirm successful occlusion of the AV fistula.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Monitoring for spontaneous resolution is appropriate in most patients who are asymptomatic. The patient in this vignette has active hematuria with evolving signs of hemodynamic instability, and occluding the fistula is prudent.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Duplex Doppler kidney ultrasound is a screening modality for diagnosing intra-renal AV fistula, which appears as a mosaic pattern with a speckling of perivascular soft tissue caused by tissue vibration on duplex ultrasound. Increased arterial velocity, decreased arterial resistance, and arterial waveforms in the renal vein can be observed. The patient in this vignette has already had a CT angiogram confirming the diagnosis and does not require more imaging.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Partial or total nephrectomy may be pursued in cases of uncontrollable hemorrhage that are not amenable to embolization. Vascular embolization would be the preferred initial step for this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although blood transfusion is critical in the resuscitation of patients with active hemorrhage and unresponsive to fluid replacement, the patient in this vignette is receiving IV fluids, and her hemoglobin level is higher than generally accepted thresholds (&lt;7–8 g/dL) for transfusion of packed RBCs. Correcting the cause of anemia is the most appropriate next step.</p>\n</div>",
        "references": [
            "Poggio ED, McClelland RL, Blank KN, et al: Systematic review and meta-analysis of native kidney biopsy complications.Clin J Am Soc Nephrol15(11): 1595‒1602, 2020",
            "Maruno M, Kiyosue H, Tanoue S, et al: Renal arteriovenous shunts: Clinical features, imaging appearance, and transcatheter embolization based on angioarchitecture.Radiographics36(2): 580‒595, 2016",
            "Laberge JM: Interventional management of renal transplant arteriovenous fistula.Semin Intervent Radiol21(4): 239‒246, 2004",
            "Lubomirova M, Krasteva R, Bogov B, Paskalev E: Incidence of A-V fistulas after renal biopsy of native and transplanted kidney: Two centers experience.Open Access Maced J Med Sci3(2): 241‒244, 2015",
            "Carson JL, Guyatt G, Heddle NM, et al: Clinical practice guidelines from the AABB: Red blood cell transfusion thresholds and storage.JAMA316(19): 2025‒2035, 2016"
        ]
    },
    "65": {
        "question": "<div class=\"qtext\"><p>A 75-year-old\n    man is referred to the outpatient nephrology clinic to evaluate labile\n    hypertension. The patient has long-standing diabetes mellitus complicated by retinopathy\n    and neuropathy. He has a 10-year history of hypertension, previously well\n    controlled on amlodipine and chlorthalidone, but his medications were\n    discontinued two months ago due to recurrent syncope requiring hospitalization.</p>\n<p>On physical examination, supine BP is 184/110 mm Hg, and pulse is 78/min. Standing BP after 3 minutes is 100/80 mm Hg, and pulse is 85/min and is accompanied by lightheadedness. Home BP readings confirm these findings. The patient has previously tried wearing compression stockings, an abdominal binder, and drinking cold water and crossing his legs before standing with little benefit.</p>\n<strong><b>Which of the following is the MOST appropriate medication for managing supine\n        hypertension in this patient?</b></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Chlorthalidone"
            },
            {
                "label": "B.",
                "text": "Amiloride"
            },
            {
                "label": "C.",
                "text": "Clonidine"
            },
            {
                "label": "D.",
                "text": "Amlodipine"
            },
            {
                "label": "E.",
                "text": "Spironolactone"
            }
        ],
        "correct_answer": "Clonidine",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Supine hypertension is common in patients with neurogenic orthostatic hypotension. In addition to lifestyle changes, short-acting drugs such as nitrates or clonidine can be administered, typically at bedtime, to control supine BP in patients with severe supine hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Orthostatic hypotension (OH) is defined as a sustained reduction of systolic BP (SBP) of at least 20 mm Hg or diastolic blood BP (DBP) of at least 10 mm Hg within 3 minutes of standing. The evaluation and management of OH entails removing or modifying offending drugs and excluding adrenal insufficiency and volume depletion secondary to gastrointestinal or renal fluid losses. Neurogenic causes should be suspected once drug- and volume-associated OH have been ruled out. Common causes of neurogenic OH include α-synucleopathies (i.e., Parkinson disease, Lewy body dementia, multisystem atrophy) or peripheral neuropathies (i.e., diabetes mellitus, amyloidosis, hereditary autonomic neuropathies, Guillain-Barre syndrome).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In normal subjects, on standing, about 800–1000 mL of blood pools in the lower body veins, and approximately 10% of the fluid shifts from the intravascular space to the interstitial space because of increased hydrostatic pressure. The decrease in venous return and subsequent reduction in stroke volume results in decreased baroreflex activation, leading to increased sympathetic tone and decreased parasympathetic tone. The sympathetic tone increases peripheral vascular resistance, and any disruption of these pathways (central or peripheral neurological disorders) may result in neurogenic OH. Management involves patient education, including strategies to mitigate OH and removing or modifying drugs that can worsen OH. Long-acting hypertensive medications should be discontinued in these patients, especially those who are symptomatic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Strategies to mitigate OH include (1) exercises to increase muscle tone (i.e., crossing the legs before standing), (2) avoiding parasympathetic triggers (i.e., large meals, hot baths), (3) increasing sodium intake to at least 150 mEq/day and water intake to at least 2 L/day to increase plasma volume, and (4) compression stockings and/or an abdominal binder. Medical therapy, such as midodrine or droxidopa to increase sympathetic tone and fludrocortisone to increase volume status, may also be effective.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Unfortunately, 40%–50% of patients with OH demonstrate supine hypertension, often defined as SBP ≥150 mm Hg or DBP ≥90 mm Hg. Strategies to mitigate supine hypertension include sleeping with the head of the bed elevated to decrease BP and nocturnal diuresis and snacking before bedtime to induce postprandial hypotension. Drugs such as fludrocortisone may need to be discontinued, as they can worsen supine hypertension. Treatment is often individualized, with most experts agreeing that patients with severe supine hypertension (SBP ≥180 mm Hg) should be treated. Generally, short-acting medications such as clonidine, a nitroglycerine patch (removing the patch in morning), captopril, and short-acting calcium channel blockers (nifedipine) may be given at bedtime to control supine BP overnight. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Generally, long-acting antihypertensive medications are discouraged, because their long action may exacerbate OH throughout the day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chlorthalidone, spironolactone, and amiloride are long-acting diuretics. In general, diuretics are not preferred agents for managing supine hypertension, as they can worsen nocturnal natriuresis and decrease plasma volume, worsening symptoms of OH. Moreover, it is not advisable to administer even short-acting diuretics at bedtime due to the increased risk of nocturia and falls. Amlodipine is a long-acting antihypertensive agent that can exacerbate symptoms of OH throughout the day. If a calcium channel blocker is desired, a short-acting calcium channel blocker such as nifedipine may be attempted.</p>\n</div>",
        "references": [
            "Freeman R, Abuzinadah AR, Gibbons C, et al: Orthostatic hypotension: JACC state-of-the-art review.J Am Coll Cardiol72(11): 1294‒1309, 2018",
            "Peixoto AJ: Evaluation and management of orthostatic hypotension: limited data, limitless opportunity.Cleve Clin J Med89(1): 36‒45, 2022",
            "Gibbons CH, Schmidt P, Biaggioni I, et al: The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.J Neurol264(8): 1567‒1582, 2017",
            "Joseph A, Wanono R, Flamant M, Vidal-Petiot E: Orthostatic hypotension: a review.Nephrol Ther13(Suppl 1): S55‒S67, 2017",
            "Shibao C, Gamboa A, Abraham R, et al: Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure.Hypertension47(3): 522‒526, 2006"
        ]
    },
    "66": {
        "question": "<div class=\"qtext\"><p>A 65-year-old woman with a history of ESRD, hypertension, coronary artery disease, peripheral vascular disease, and unipolar major depression is seen during routine HD. During a recent evaluation by her psychiatrist, she was diagnosed with a major depressive episode. She reports that over the last 6 weeks, she has been experiencing depressed mood. She feels hopeless and sad nearly every day, shares feelings of worthlessness, and finds very little interest or pleasure in activities that she used to enjoy. She also describes insomnia, unintentional weight gain, severe fatigue, and poor concentration, such that she no longer spends time with family or friends. </p>\n<p>On examination, she appears tearful, tired, and poorly attentive. BP is 104/80 mm Hg, and heart rate is 66/min.\n</p>\n<p>Laboratory results are notable for the\n    following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6,800/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.5 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>12–16</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>336,000/μL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>138 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.0 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>29 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Calcium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>9.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Phosphorus</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.6 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Intact PTH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>435 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>130–585, dialysis</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Aspartate aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>16 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Alanine aminotransferase</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22 U/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–40</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.8 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–1.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Which ONE of the following is the MOST\n    appropriate pharmacotherapy for this patient? </p>\n<p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Paroxetine"
            },
            {
                "label": "B.",
                "text": "Citalopram"
            },
            {
                "label": "C.",
                "text": "Escitalopram"
            },
            {
                "label": "D.",
                "text": "Imipramine"
            },
            {
                "label": "E.",
                "text": "Phenelzine"
            }
        ],
        "correct_answer": "Paroxetine",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with ESRD receiving HD and major depression should be prescribed a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For patients receiving maintenance HD and treatment for unipolar major depression, evidence is limited regarding the relative efficacy of combination psychotherapy plus pharmacotherapy (antidepressants); psychotherapy alone; or pharmacotherapy alone. Treatment options may be largely guided by patient preference and access to these resources. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SSRIs are generally recommended as first-line agents for patients receiving dialysis due to established efficacy and relatively favorable side effect profile. Sertraline, paroxetine, and fluoxetine have been well studied and are some of the most recommended SSRIs. Dosing adjustment for paroxetine is needed in patients with a creatinine clearance &lt;30 mL/min. Citalopram and escitalopram should be avoided in patients with ESRD due to the potential for QT prolongation and/or increased risk of sudden cardiac death. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Selective norepinephrine reuptake inhibitors (SNRIs) and atypical antidepressants (bupropion, mirtazapine) have also demonstrated efficacy for the treatment of depression in patients with ESRD and carry additional properties that may be helpful for concurrent therapy of neuropathic pain, sleep disorders, and appetite stimulation, respectively. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Other classes of antidepressants are usually not recommended for patients receiving dialysis due to unfavorable side effects and risks of adverse dialysis-associated complications. Tricyclic antidepressants (e.g., imipramine) can cause anticholinergic effects (increased sedation, dry mouth, weight gain), orthostatic hypotension, and possible QT prolongation. Similarly, monoamine oxidase inhibitors (e.g., phenelzine) may cause hypotension; they are also largely avoided due to severe drug-drug and drug-food interactions.</p>\n</div>",
        "references": [
            "Eyler RF, Unruh ML, Quinn DK, Vilay AM: Psychotherapeutic agents in end-stage renal disease.Semin Dial28(4): 417–426, 2015",
            "King-Wing Ma T, Kam-Tao Li P: Depression in dialysis patients.Nephrology (Carlton)21(8): 639–646, 2016",
            "Mehrotra R, Cukor D, Unruh M, Rue T, et al: Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis. A randomized clinical trial.Ann Intern Med170(6): 369–379, 2019",
            "Assimon MM, Brookhart MA, Flythe JE: Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis.J Am Soc Nephrol30(4): 611–623, 2019",
            "Gregg LP, Trombello JM, McAdams M, Hedayati SS: Diagnosis and management of depression in patients with kidney disease.Semin Nephrol41(6): 505–515, 2021"
        ]
    },
    "67": {
        "question": "<div class=\"qtext\"><p>A 29-year-old man is admitted to the ICU following a 5-minute, tonic-clonic seizure and hyponatremia. Past medical history includes depression, medulloblastoma status post surgical resection, and radiation, complicated by panhypopituitarism and stroke. He receives feeds and 875 mL of free water per day through a gastrostomy tube and has no oral intake, although he reports thirst. His medications include desmopressin, hydrocortisone, levothyroxine, and fluoxetine.</p>\n<p>On examination, BP is 110/55 mm Hg, and heart rate is 80/min. He has moist oral mucosa, and a normal heart and lung examination. There is no edema. He has dysarthria and right-sided hemiparesis.</p>\n<p>Desmopressin is discontinued, and PO and IV water restriction is initiated.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong> </strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Day 1</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Day 2</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>125 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>132</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.86 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.9</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>263 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>267</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>275–295</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>52 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>27</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>45 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Osmolality</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>750 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>83</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Volume</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>650 mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3950</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table><strong><strong>Which ONE of the following is the MOST likely cause of this patient’s hyponatremia?</strong></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Volume depletion"
            },
            {
                "label": "B.",
                "text": "Desmopressin"
            },
            {
                "label": "C.",
                "text": "Hypothyroidism"
            },
            {
                "label": "D.",
                "text": "Primary polydipsia"
            },
            {
                "label": "E.",
                "text": "Syndrome of inappropriate antidiuretic hormone"
            }
        ],
        "correct_answer": "Desmopressin",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hyponatremia and elevated urine osmolality, who improves with fluid restriction and discontinuation of desmopressin (ddAVP), most likely has iatrogenic hyponatremia from ddAVP use. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with panhypopituitarism and likely central diabetes insipidus, ddAVP and other hormone replacement therapy has been prescribed. ddAVP, a synthetic form of vasopressin (ADH), acts at the collecting duct to cause water reabsorption. If the dose of ddAVP is too high or is accompanied by excess water intake, hyponatremia may ensue. Once ddAVP is discontinued or the dose is decreased, the patient will be able to excrete a dilute urine and restore normal serum sodium levels. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In severe volume depletion, accompanied by a decrease in mean arterial pressure of &lt;10%, ADH is released to facilitate vasoconstriction. This physiologic response may cause hypovolemic hyponatremia. However, this patient does not have signs or symptoms of volume depletion, and there is no evidence of renal sodium avidity or AKI to suggest prerenal physiology.</p>\n<p>Hypothyroidism is an uncommon, or possibly even a fictional, cause of hyponatremia. Hyponatremia has been associated with severe hypothyroidism, including myxedema coma, but may have been attributable to other causes in 99% of cases. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary polydipsia may cause polyuria but would not cause hyponatremia in the absence of increased ADH, unless severe (15–20 L/day) or accompanied by inadequate solute intake, such as malnutrition. Patients with primary polydipsia normally present with urine osmolarity &lt;100 mOsm/kg H<sub>2</sub>O. This patient’s presentation is not consistent with primary polydipsia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The syndrome of inappropriate ADH secretion (SIADH) is a common cause of hyponatremia with inappropriately increased urine osmolality. In this case, however, urine osmolality rapidly decreased after ddAVP discontinuation to allow the excretion of free water. Fluoxetine and other selective serotonin reuptake inhibitors are commonly implicated causes of SIADH.</p>\n</div>",
        "references": [
            "Adrogue HJ, Madias NE: Hyponatremia.N Engl J Med342(21): 1581–1589, 2000",
            "Kim RJ, Malattia C, Allen M, et al: Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.Pediatr Endocrinol Rev2(Suppl 1): 115–123, 2004",
            "Achinger SG, Ayus JC: Use of desmopressin in hyponatremia: foe and friend.Kidney Med1(2): 65–70, 2019",
            "Wolf P, Beiglbock H, Smaijs S, et al: Hypothyroidism and hyponatremia: rather coincidence than causality.Thyroid27(5): 611–615, 2017"
        ]
    },
    "68": {
        "question": "<div class=\"qtext\"><p>A 51-year-old man with ESRD due to diabetic nephropathy undergoing thrice weekly HD presents with worsening exertional dyspnea and fatigue. He had undergone a deceased donor kidney transplant 2 years ago that failed because of antibody-mediated rejection. Six months after resuming HD, he developed gross hematuria that responded to a course of corticosteroids, and other than ongoing treatment for diabetic retinopathy with intravitreal bevacizumab, he has not had other recent significant events. Hematuria has not recurred. His hemoglobin has continued to decline, despite receiving the unit maximum weight-based dose of darbepoetin at 100 µg/wk (1.5 µg/kg per week) and 1 unit of packed RBCs last month for symptomatic anemia. He currently receives sodium ferric gluconate 125 mg IV weekly. Other medications include insulin and carvedilol. He denies hematochezia or melena. Colonoscopy prior to transplant did not show any abnormalities.</p>\n<p>BP is 132/78 mm\n    Hg, pulse is 82/min, and temperature is 36.2°C. Heart, lung, and abdomen are\n    unremarkable. There is a well-developed, right arm arteriovenous fistula with\n    palpable thrill. There is no edema.</p>\n<p>Laboratory data\n    reveal the following:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4200/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6.7 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Serum</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Iron</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>60 µg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>50–150</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Ferritin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1310 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>24–336</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Transferrin saturation</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25%</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>20–50</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Intact PTH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>350 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>130–585, dialysis</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    C-reactive protein</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≤0.8</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Single-pool Kt/V</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.4</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>≥1.2</p>\n</td>\n</tr>\n</tbody>\n</table>\n<strong><b>Which of the following is the next BEST STEP in management of his anemia?</b></strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase ferric gluconate to 1000 mg over the next eight HD sessions"
            },
            {
                "label": "B.",
                "text": "Refer for allograft nephrectomy"
            },
            {
                "label": "C.",
                "text": "Increase darbepoetin to 120 µg weekly"
            },
            {
                "label": "D.",
                "text": "Refer for subtotal parathyroidectomy"
            },
            {
                "label": "E.",
                "text": "Discontinue darbepoetin and enroll in a clinical trial with roxadustat"
            }
        ],
        "correct_answer": "Refer for allograft nephrectomy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, with erythropoiesis-stimulating agent (ESA) hyporesponsiveness attributable to chronic inflammation from his nonfunctional allograft, should be referred for transplant nephrectomy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ESA hyporesponsiveness or resistance describes a condition where the desired hemoglobin concentration is not achieved despite increasing ESA doses. This condition is associated with increased morbidity, and one observational study evaluating patients with escalating doses of ESA but hemoglobin values persistently &lt;9.5 g/dL showed greater mortality (hazard ratio, 1.32 versus control). Increasing this patient’s dose of ESA further above the accepted maximum dose would increase his risk of thromboembolic adverse events.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common cause of poor response to ESA is absolute or relative iron deficiency, as iron substrate is necessary to construct heme for incorporation into erythrocyte precursors. Failure to provide adequate iron will lead to apoptosis of these primed, immature cells. This patient has adequate iron stores, as measured by iron saturation and ferritin, and has had a recent colonoscopy to rule out malignancy or other cause of lower gastrointestinal bleeding. Thus, increasing the dose of IV iron would not be the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Secondary and tertiary hyperparathyroidism are associated with ESA hyporesponsiveness. The exact mechanism is in dispute but may involve suppressing endogenous erythropoietin production by PTH or bone marrow fibrosis, with subsequently decreased RBC production and survival. This patient’s PTH is within acceptable parameters.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitors (PHIs) such as roxadustat have undergone several phase 3 clinical trials and are used in Asia to treat anemia in CKD. These agents increase production of endogenous erythropoietin by allowing HIF-α and HIF-β to heterodimerize and bind to hypoxia-response elements, inducing gene transcription. Although several studies have shown non-inferiority of HIF-PHIs compared with ESAs, there is concern regarding safety and an increase in major adverse cardiac events in more recent trials. Additionally, HIF-PHIs are associated with worsening diabetic retinopathy, which may contraindicate their use in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic inflammation is a common occurrence in patients with ESA hyporesponsiveness. Cytokines such as interleukin-1β and -6 and tumor necrosis factor-α lead to an increase in hepcidin levels, which decrease iron absorption by binding to ferroportin, a transmembrane iron transporter, on enterocytes, macrophages, and hepatocytes. Increased C-reactive protein and ferritin are common markers of inflammation. Infection is a common cause of chronic inflammation, but there are no signs or symptoms of infection in this patient. Conversely, he has had evidence of chronic allograft rejection. Immunosuppression is typically tapered slowly to prevent symptoms associated with rejection, including abdominal pain and gross hematuria, but may not ameliorate ESA hyporesponsiveness. Allograft nephrectomy should be considered in patients who require high doses of ESAs and repeated transfusions, which may be associated with significant morbidity and/or mortality.</p>\n</div>",
        "references": [
            "Weir MR: Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents.Am J Nephrol52(6): 450–466, 2021",
            "Mehrotra A, Tan JA, Ames SA: “Out of sight, out of mind”: The failed renal allograft as a cause of ESA resistance.Semin Dial28(5): 530–532, 2015",
            "Roger SD, Coyne DW: HIF-prolyl hydroxylase inhibitors: Confirmed efficacy with uncertain safety.Am J Nephrol52(10–11): 894–898, 2021"
        ]
    },
    "69": {
        "question": "<div class=\"qtext\"><p>A 58-year-old man with B-cell acute lymphocytic leukemia (ALL) presents to the emergency department with 1 week of severe and throbbing headaches. His past medical history includes ALL, which was treated with an allogenic T cell–depleted stem cell transplant 8 months ago. His post-transplant course was complicated by acute graft-versus-host disease (GVHD) of the skin and liver, for which he was prescribed immunosuppressive medications. Two weeks ago, he was seen by his nephrologist for new-onset proteinuria and hypertension. His current medications include tacrolimus, prednisone, acyclovir, and olmesartan, which was started two weeks ago. He has been using intermittent acetaminophen and ibuprofen for his headaches without improvement.</p>\n<p>He was admitted to the hospital, and olmesartan was changed to labetalol, but his BP has continued to worsen.</p>\n<p>On examination, his BP is 202/109 mm Hg, and his HR is 98/min. He is a thin man with diffuse skin excoriations but no rashes. The remainder of his examination is unremarkable</p>\n<p>His laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Hospital Day 5</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5300/µL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6000 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                101,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                67,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                135 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                133 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL (8 months ago, 0.6)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.6 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Lactate dehydrogenase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                457 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                513\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Haptoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;8 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                83–267\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong><strong>, </strong><strong>random</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                68 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                33 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis shows 100 mg/dL protein and no RBCs or WBCs. Peripheral blood smear reveals moderate schistocytes.</p>\n<p>A kidney ultrasound with arterial Dopplers reveals both kidneys 10 cm in length, no hydronephrosis, and a resistive index &lt;0.7 (reference range, 0.5–0.7).</p>\n<p>His kidney biopsy histopathology is shown below (top: light microscopy, hematoxylin and eosin stain, 400× magnification; bottom: EM, 6000× magnification).</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2b2q12a.png\" width=\"75%\"/>\n</figure>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv8m2b2q12b.png\" width=\"75%\"/>\n</figure>\n<p><em>Images\n        courtesy of Dr. Surya Seshan, Weill Cornell Medicine</em>\n</p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Membranous nephropathy"
            },
            {
                "label": "B.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "C.",
                "text": "Minimal change disease"
            },
            {
                "label": "D.",
                "text": "Acute tubular necrosis"
            },
            {
                "label": "E.",
                "text": "Leukemic infiltration"
            }
        ],
        "correct_answer": "Thrombotic microangiopathy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis is thrombotic microangiopathy (TMA). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The reported incidence of TMA following stem cell transplantation (SCT) is as high as 63%. Clinically, TMA presents with microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ dysfunction. When the kidneys are affected, patients may present with AKI, proteinuria, and hypertension. Diagnosis is definitively made by kidney biopsy, but thrombocytopenia may preclude this procedure. Light microscopy findings consistent with TMA include microthrombi within the glomerular capillary lumens, trapping of fragmented RBCs, and vascular congestion. EM shows cellular interposition of new basement membrane or “double contouring” of the GBM. Laboratory findings include anemia, increased lactate dehydrogenase, and decreased haptoglobin levels, and schistocytes may be seen on peripheral blood smear. A direct Coombs test should be negative. Because TMA is a nonspecific pathologic pattern, careful attention must be paid to the history, laboratory data, and physical examination to diagnose the underlying etiology.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common types of TMA seen after SCT include thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). The inciting factor for TMA after SCT is thought to be endothelial damage, either related to engraftment itself or from a combination of factors including CNI exposure, total body irradiation, and GVHD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Membranous nephropathy and minimal change disease can be seen in patients after stem cell transplant with GVHD. They both present with nephrotic-range proteinuria. On light microscopy (LM), membranous nephropathy shows diffuse capillary and GBM thickening, and silver stain reveals spikes. EM shows subepithelial electron deposits. In minimal change disease, the LM is unremarkable, with diffuse foot process effacement noted on EM. The biopsy findings here are inconsistent with membranous nephropathy or minimal change disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In ATN, the kidney biopsy shows denudation of renal tubular cells with loss of the brush border. Kidney infiltration with leukemic cells is a rare cause of AKI in patients with ALL but would demonstrate large numbers of leukemic cells in the tubulointerstitium on histology. Again, this patient’s biopsy findings do not support either of these diagnoses. </p>\n</div>",
        "references": [
            "Yilmaz F, Kasinath V, Postalcioglu M, Ho VT, Abdi R. (2020). Thrombotic microangiopathy and kidney injury after hematopoietic stem cell transplantation. Handbook of Stem Cell Transplantation and Cellular Therapy Management.https://doi.org/10.1891/9780826139948.0013",
            "Nakamae H, Yamane T, Hasegawa T, et al: Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.Am J Hematol81(7): 525–531, 2006",
            "Young JA, Pallas CR, Knovich MA: Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.Bone Marrow Transplant56(8): 1805–1817, 2021",
            "Obut F, Kasinath V, Abdi R: Post-bone marrow transplant thrombotic microangiopathy.Bone Marrow Transplant51(7): 891–897, 2016",
            "Renner B, Klawitter J, Goldberg R, et al: Cyclosporine induces endothelial cell release of complement-activating microparticles.J Am Soc Nephrol24(11): 1849–1862, 2013",
            "Changsirikulchai S, Myerson D, Guthrie KA, et al: Renal thrombotic microangiopathy after hematopoietic cell transplant: Role of GVHD in pathogenesis.Clin J Am Soc Nephrol4(2): 345–353, 2009",
            "Kim SS, Patel M, Yum K, Keyzner A: Hematopoietic stem cell transplant-associated thrombotic microangiopathy: Review of pharmacologic treatment options.Transfusion55(2): 452–458, 2015",
            "Girsberger M, Halter JP, Hopfer H, et al: Kidney pathology after hematologic cell transplantation: A single-center observation study of indication biopsies and autopsies.Biol Blood Marrow Transplant24(3): 571–580, 2018"
        ]
    },
    "70": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with a history of alcohol use disorder and cirrhosis presents to the emergency department with fatigue and abdominal distention. Three days ago, she underwent large-volume paracentesis, draining 6 L of clear ascitic fluid. She drinks 5 glasses of wine per day. </p>\n<p>On examination, she is afebrile, BP is 87/63 mm Hg, and heart rate is 92/min. She has temporal wasting, jaundice, abdominal distention with shifting dullness and a fluid wave, and 2+ edema to her knees. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>126 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4.7 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Bicarbonate</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>18 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.5 mg/dL (baseline 1.1)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.6 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Total bilirubin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>16.2 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.3–1.0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine (random)</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;20 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies with intake</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>   Osmolarity</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>390 mOsm/kg H<sub>2</sub>O</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–1400</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is normal, and sediment is bland.</p>\n<p>Repeated labs after albumin challenge are unchanged. Intra-abdominal pressure is 10 mm Hg. Kidney ultrasound reveals normal kidneys bilaterally, without hydronephrosis.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Midodrine and octreotide"
            },
            {
                "label": "B.",
                "text": "Repeat albumin challenge"
            },
            {
                "label": "C.",
                "text": "Fluid restriction"
            },
            {
                "label": "D.",
                "text": "Liver transplant"
            },
            {
                "label": "E.",
                "text": "Repeat paracentesis"
            }
        ],
        "correct_answer": "Midodrine and octreotide",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with hepatorenal syndrome, the most appropriate therapy is midodrine and octreotide.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with decompensated cirrhosis and AKI after large-volume paracentesis (LVP). Hepatorenal syndrome (HRS) is a clinical diagnosis, requiring advanced liver disease and portal hypertension, AKI without another clear precipitant (obstruction, nephrotoxins, etc.), lack of response to withholding diuretics and plasma volume expansion with albumin, and urine without RBCs or proteinuria. HRS is commonly triggered by LVP or spontaneous bacterial peritonitis. Portal hypertension leads to splanchnic arteriolar vasodilation, resulting in a decrease in total peripheral resistance. The compensatory response leads to an increase in cardiac output and peripheral vasoconstriction, leading to decreased renal perfusion and HRS. Treatment consists of improving the hemodynamic abnormalities underlying the disease: expansion of the effective arterial blood volume with albumin, and systemic and splanchnic vasoconstriction with a vasopressor.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When HRS is suspected, the next step in management is to discontinue diuretics and provide a fluid challenge of 20%–25% albumin 1 g/kg per day IV (up to 100 g/d) for at least two days. If kidney function does not improve, HRS is diagnosed, and vasopressors are added.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Options for vasopressors include terlipressin, norepinephrine, and the combination of midodrine and octreotide. Terlipressin has recently been approved by the US FDA based on results from a clinical trial showing improved kidney function in the group treated with terlipressin compared with placebo, although mortality was ~50% in both groups and the terlipressin group experienced more adverse events, particularly respiratory failure. Norepinephrine and most other vasopressors require ICU admission, limiting their use. More commonly, midodrine and octreotide are prescribed. These drugs lead to a reduction in splanchnic vasodilation and an increase in mean arterial pressure (MAP), which decreases renal vasoconstriction and improves renal plasma flow. A small trial showed that the combination of midodrine and octreotide in patients with HRS leads to higher MAP, renal plasma flow, GFR, and urine sodium excretion. It has also been associated with lower mortality and higher rate of resolution of HRS.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A repeat albumin challenge would not be appropriate, as the patient has had no benefit from the initial challenge, and further volume expansion in the absence of AKI recovery would likely worsen volume overload. Fluid restriction may improve hyponatremia but would not treat the underlying hemodynamic changes leading to HRS. Definitive treatment of cirrhosis and persistent HRS is liver transplant but would not be an appropriate therapy in a patient who has not been treated for her alcohol use disorder and has not abstained from alcohol. Paracentesis may be beneficial if AKI is due to abdominal compartment syndrome, which is diagnosed when intra-abdominal pressure is &gt;20 mm Hg.</p>\n</div>",
        "references": [
            "Simonetto DA, Gines P, Kamath PS: Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ370: m2687, 2020",
            "Kalambokis G, Economou M, Fotopoulos A, et al: The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.Am J Gastroenterol100(4): 879–885, 2005",
            "Salerno F, Navickis RJ, Wilkes MM: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.BMC Gastroenterol15: 167, 2015",
            "Wong F, Pappas SC, Curry MP, et al; CONFIRM Study Investigators: Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.N Engl J Med384(9): 818–828, 2021",
            "Polanco NAP, Martin P, Carrion AF: Advances in the management of renal disfunction in patients with cirrhosis.Gastroenterol Hepatol (NY)17(5): 211–220, 2021"
        ]
    },
    "71": {
        "question": "<div class=\"qtext\"><p>A 61-year-old woman with a history of type 2 diabetes mellitus, hypertension, CKD stage 3, heart failure with reduced ejection fraction (40%), and myocardial infarction presents to the emergency department complaining of dyspnea. Her weight has increased by 3 kg over the last week. Medications include metoprolol, lisinopril, and insulin.</p>\n<p>BP is 155/78 mm Hg, heart rate is 89/min, respiratory rate is 25/min, and oxygen saturation is 88% while breathing room air. On examination, she is in mild distress. Lung examination demonstrates bibasilar crackles, and cardiac examination reveals an S3 gallop. She has 2+ pitting edema in the lower extremities.  </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: width: 30%;\">\n<p><strong>Value</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>5.2 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>22 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5 mg/dL (baseline 2.0)</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Magnesium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.7 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6–2.6</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Urine</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;20 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>    Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Varies</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Pharmacologic inhibition of which of the following transporters or channels is MOST LIKELY to reduce symptoms in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Sodium-potassium-chloride cotransporter (NKCC2)"
            },
            {
                "label": "B.",
                "text": "Sodium chloride cotransporter (NCC)"
            },
            {
                "label": "C.",
                "text": "Epithelial sodium channel (ENaC)"
            },
            {
                "label": "D.",
                "text": "Sodium-glucose cotransporter-2 (SGLT2)"
            },
            {
                "label": "E.",
                "text": "Renal outer medullary potassium channel (ROMK)"
            }
        ],
        "correct_answer": "Sodium-potassium-chloride cotransporter (NKCC2)",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inhibition of NKCC2, the loop diuretic-sensitive sodium-potassium-chloride cotransporter, is most likely to benefit this patient with cardiorenal syndrome (CRS).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has many signs and symptoms of CRS, as well as AKI with sodium avidity. CRS is defined in a 2019 paper as “disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other.” The pathophysiology of this syndrome is complex and involves multiple hemodynamic, hormonal, and inflammatory processes. One pathologic element of CRS that is increasingly recognized is venous congestion, such that diuresis to decrease renal venous pressure improves renal perfusion and helps to treat AKI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Loop diuretics are first-line therapy for the management of volume overload in patients with acute, decompensated heart failure with CRS. These powerful agents act by inhibiting the NKCC2 in the thick ascending limb of the loop of Henle, leading to natriuresis and volume loss in edematous states.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NCC is the major sodium transporter and limiting step for sodium reabsorption in the distal convoluted tubule and plays a role in BP regulation and in the kidney’s ability to excrete potassium, calcium, and hydrogen. Thiazide-type diuretics exert their effect via blockage of this channel and are considered a reasonable next step in therapy in conjunction with loop diuretics.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ENaC is a sodium-selective ion channel located on the apical surface of the principal cells in the collecting duct. ENaC mediates apical entry of sodium in the aldosterone-sensitive distal nephron. Amiloride blocks this channel, resulting in decreased sodium reabsorption, but is not considered first choice in the management of CRS. ENaC blockers classically cause hyperkalemia by decreasing voltage-sensitive potassium excretion. These drugs may be considered in patients with diuretic resistance. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inhibition of SGLT2 plays an important role in managing acute, decompensated heart failure, as well as diabetic and other kidney disease, and improves clinical outcomes such as heart failure hospitalization and cardiovascular morbidity and mortality. Although SGLT2 inhibitors are important adjuncts in managing congestive heart failure, they would not substitute for loop diuretics to provide prompt and effective decongestion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inhibition of ROMK channel results in diuresis and natriuresis in the absence of kaliuresis. Mutations conferring loss of ROMK function are thought to cause type 2 Bartter syndrome. There are no clinically available agents to inhibit ROMK.</p>\n</div>",
        "references": [
            "Rangaswami J, Bhalla V, Blair JEA, et al: Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association.Circulation139(16): e840–e878, 2019",
            "Novak JE, Ellison DH: Diuretics in states of volume overload: core curriculum 2022.Am J Kidney Dis80(2): 264–276, 2022",
            "Junho CVC, Trentin-Sonoda M, Panico K, et al: Cardiorenal syndrome: long road between kidney and heart [published online ahead of print February 8, 2022].Heart Fail Revdoi:10.1007/s10741-022-10218-w",
            "Grodin JL, Stevens SR, de Las Fuentes L, et al: Intensification of medical therapy for cardiorenal syndrome in acute decompensated heart failure.J Card Fail22(1): 26–32, 2016",
            "Kumar U, Wettersten N, Garimella PS: Cardiorenal syndrome: pathophysiology.Cardiol Clin37(3): 251–265, 2019"
        ]
    },
    "72": {
        "question": "<div class=\"qtext\"><p>A 23-year-old man with ESRD due to Alport syndrome presents to the transplantation clinic for a living donor kidney transplant evaluation. He has received HD for the last 2 years. He is otherwise healthy and is blood group A. He has two potential living donors, which include his coworker and his grandfather. His coworker is 35 years old with blood group B and a 2/6 human leukocyte antigen (HLA) mismatch. His grandfather is 62 years old with blood group A, also with 2/6 HLA mismatch. The patient has an HLA-DR donor-specific antibody against his grandfather’s blood with a high median fluorescence intensity on single HLA antigen bead assay. </p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong><p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Enroll in a kidney exchange program"
            },
            {
                "label": "B.",
                "text": "Proceed with kidney transplantation from grandfather"
            },
            {
                "label": "C.",
                "text": "Proceed with kidney transplantation from coworker"
            },
            {
                "label": "D.",
                "text": "Proceed with kidney transplantation from\n grandfather with desensitization"
            },
            {
                "label": "E.",
                "text": "List for deceased donor kidney transplantation"
            }
        ],
        "correct_answer": "Enroll in a kidney exchange program",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This young patient with ESRD should be listed in a kidney paired donation (KPD) program.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">KPD is the exchange of kidneys between living donor-recipient pairs who are either incompatible or quasi-compatible to optimize outcomes for recipients. Since first performed in South Korea in 1991, KPD has become part of the standard of care in transplantation in many countries. Two major indications for KPD includes ABO and HLA incompatibility, which greatly increase the risk of rejection after transplantation and require desensitization protocols. Patients can also be enrolled in KPD when there is age or size discrepancy between the donor and recipient that would shorten graft survival.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">KPD may be performed between two or more pair of donors, in which case the exchange is termed a chain. In chains of donors, an altruistic donor can give a kidney to the recipient of an incompatible pair and begin a string of simultaneous transplants that ends with the last living donor giving a kidney to a recipient on the deceased donor waitlist; this sequence of events is called “domino KPD.” Current protocols, including exchanges between institutions, shipment of donor kidneys, and non-simultaneous exchanges, have enhanced access to KPD.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s coworker would not be a donor candidate due to ABO incompatibility, despite other favorable characteristics such as young age. His grandfather is ABO compatible, but the presence of a strongly positive donor-specific antibody (DSA), which carries a high risk for antibody-mediated rejection, and the substantial difference between donor and recipient age make KPD a more favorable option. Although desensitization for a patient with pre-formed DSA against a donor is possible, significantly higher intensity immunosuppression is required, antibody-mediated rejection occurs in &gt;50% of patients, and long-term graft survival is reduced. Listing for deceased donor transplantation is not optimal because of the typically longer waiting times and worse graft outcomes compared with living donor transplantation.</p>\n</div>",
        "references": [
            "Ferrari P, Weimar W, Johnson RJ, et al: Kidney paired donation: principles, protocols and programs.Nephrol Dial Transplant30(8): 1276–1285, 2015",
            "Gentry SE, Montgomery RA, Swihart BJ, Segev DL: The roles of dominos and nonsimultaneous chains in kidney paired donation.Am J Transplant9(6): 1330–1336, 2009",
            "Lefaucheur C, Loupy A, Hill GS, et al: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.J Am Soc Nephrol21(8): 1398–1406, 2010",
            "Gerbase-DeLima M, de Marco R, Monteiro F, et al: Impact of combinations of donor and recipient ages and other factors on kidney graft outcomes.Front Immunol11: 954, 2020",
            "Miller AJ, Kiberd BA, Alwayn IP, et al: Donor-recipient weight and sex mismatch and the risk of graft loss in renal transplantation.Clin J Am Soc Nephrol12(4): 669–676, 2017",
            "Haririan A, Nogueira J, Kukuruga D et al: Positive cross‐match living donor kidney transplantation: longer‐term outcomes.Am J Transplant9(3): 536–542, 2009",
            "Hariharan S, Israni AK, Danovitch G: Long-term survival after kidney transplantation. N Engl J Med385(8): 729–743, 2021"
        ]
    },
    "73": {
        "question": "<div class=\"qtext\"><p>A 77-year-old man is admitted to the cardiac ICU for acute exacerbation of congestive heart failure (CHF). Past medical history is significant for ischemic cardiomyopathy with an ejection fraction of 35%, type 2 diabetes mellitus, hypertension, chronic gastritis, and depression. He has a 15-pack-year smoking history but quit 5 years ago. He drinks occasionally and has no history of recreational drug use. Home medications include insulin, amlodipine, bumetanide, lisinopril, and carvedilol.</p>\n<p>On physical examination, BP is 138/84 mm Hg, heart rate is 84/min, and temperature is 37°C. Jugular venous distension is noted 9 cm above the sternal angle. Lungs have coarse breath sounds and crackles bilaterally. Cardiac examination reveals an S3 gallop. Extremities have 2+ pitting edema and 1+ peripheral pulses.</p>\n<p>Bumetanide IV is prescribed, urine output increases, and symptoms of orthopnea improve over the next few days.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Day 1</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Day 4</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<p><strong>Reference Range</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>WBC count</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>6000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8000</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4000–11,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Hemoglobin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10.9 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11.8 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>14–18</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Platelets</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>189,000/µL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>200,000</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>150,000–450,000</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Serum</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Sodium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>142 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>140</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Potassium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.9 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.1 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.0</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Chloride</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>108 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>88 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Total CO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>28 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  BUN</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>20 mg/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Creatinine</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.4 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.6</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.7–1.3</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  Magnesium</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.8 mEq/L</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.6–2.6 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  B-type natriuretic peptide, plasma</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>800 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>450 </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>&lt;100 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p><strong>Arterial blood gas</strong></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  pH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.5</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>7.38–7.44</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  pCO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>50</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>38–42</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>  pO<sub>2</sub></p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>88</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>75–100</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next BEST step in managing this patient’s metabolic alkalosis? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Normal saline"
            },
            {
                "label": "B.",
                "text": "Spironolactone"
            },
            {
                "label": "C.",
                "text": "Discontinue bumetanide"
            },
            {
                "label": "D.",
                "text": "Ammonium chloride"
            },
            {
                "label": "E.",
                "text": "Acetazolamide"
            }
        ],
        "correct_answer": "Spironolactone",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in managing this patient with CHF, hypokalemia, and metabolic alkalosis is to prescribe spironolactone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary metabolic alkalosis secondary to aggressive use of diuretics commonly occurs in the treatment of CHF. The mechanism involves inhibition of NaCl absorption proximal to the cortical collecting duct (CCD), leading to enhanced distal delivery of Na<sup>+</sup> and water to the H<sup>+</sup>/K<sup>+</sup>-secreting segments of the distal nephron. Natriuresis and the resulting volume contraction result in secondary hyperaldosteronism. High luminal Na<sup>+</sup> concentrations and luminal flow rates in the cortical collecting duct (CCD), in the presence of high aldosterone levels, enhance H<sup>+</sup> and K<sup>+</sup> secretion. The net result is a metabolic alkalosis generated in the CCD and maintained by hypochloremia and volume contraction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone is an aldosterone antagonist, which causes a potassium-sparing diuresis and can improve the aldosterone-mediated metabolic alkalosis and hypokalemia while allowing ongoing diuresis. There are also data that spironolactone and eplerenone improve patient outcomes in the treatment of systolic heart failure, although this is a long-term effect, and benefit would not be expected to be conferred in the acute setting. Concerns about spironolactone include hyperkalemia and hypotension, which are less likely in this patient with relatively high BP and hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Normal saline is the treatment of choice for patients with metabolic alkalosis and hypovolemia but would not be a suitable option in this patient with decompensated CHF who requires decongestion.</p>\n<p>Ammonium chloride may be used for acid-loading in patients with refractory metabolic alkalosis by providing a source of H<sup>+</sup> to titrate excess serum bicarbonate. Although ammonium chloride may improve this patient’s metabolic alkalosis, spironolactone would be a better option by addressing hypokalemia and providing additional decongestion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Discontinuing bumetanide is not a feasible option in this patient who continues to have evidence of volume overload and hypoxia and requires ongoing diuresis.</p>\n<p>Acetazolamide can help mitigate metabolic alkalosis by blocking bicarbonate reabsorption in the proximal tubule and would provide additional diuresis. However, acetazolamide would worsen hypokalemia by increasing sodium delivery to the distal nephron. Prescribing acetazolamide plus potassium supplementation may be a reasonable second-choice option but would require using two medications and titrating the dose of potassium.</p>\n</div>",
        "references": [
            "Emmett M: Metabolic alkalosis: a brief pathophysiologic review.Clin J Am Soc Nephrol15(12): 1848‒1856, 2020",
            "Peixoto AJ, Alpern RJ: Treatment of severe metabolic alkalosis in a patient with congestive heart failure.Am J Kidney Dis61(5): 822‒827, 2013",
            "Novak JE, Ellison DH: Diuretics in states of volume overload: core curriculum 2022.Am J Kidney Dis80(2): 264‒276, 2022",
            "Ellison DH, Felker GM: Diuretic treatment in heart failure.N Engl J Med377(20): 1964‒1975, 2017"
        ]
    },
    "74": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with stage 3b CKD presents to clinic for follow-up of his CKD. His past medical history includes type 2 diabetes and hypertension, both of which have been well controlled. He reports new intermittent abdominal pain and muscle cramping. His pain is unrelated to eating and not accompanied by a change in appetite, nausea, or vomiting. His medications include insulin, lisinopril, hydrochlorothiazide, and sevelamer carbonate.</p>\n<p>BP is 120/75 mm Hg. On examination, his abdomen is soft and nontender, with normal bowel sounds. The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table>\n</table>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.1 mg/dL (at baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                34 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                170 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25-Hydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                31 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–60\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound shows bilateral nephrolithiasis without obstruction and increased echogenicity bilaterally.</p>\n<p><strong> Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Order nuclear parathyroid scan"
            },
            {
                "label": "B.",
                "text": "Discontinue sevelamer"
            },
            {
                "label": "C.",
                "text": "Prescribe calcitriol"
            },
            {
                "label": "D.",
                "text": "Discontinue hydrochlorothiazide"
            },
            {
                "label": "E.",
                "text": "Measure serum fibroblast growth factor (FGF)-23 level"
            }
        ],
        "correct_answer": "Order nuclear parathyroid scan",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with hypercalcemia and an elevated PTH, the most appropriate next step is to order a nuclear parathyroid or technetium (99mTc) sestamibi scan to evaluate for parathyroid adenoma.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperparathyroidism presents with an elevated PTH and hypercalcemia. Although this patient has CKD stage 3b, which may be associated with an elevated PTH level caused by secondary hyperparathyroidism, the hypercalcemia and low-normal serum phosphorus are inconsistent with this diagnosis and would be unusual with eGFR ≥30 mL/min/1.73 m<sup>2</sup>.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with more advanced CKD or ESRD may have hypercalcemia in the setting of tertiary hyperparathyroidism, which usually develops after prolonged secondary hyperparathyroidism, but this diagnosis is rare in patients with moderate CKD. Furthermore, this patient has a borderline low serum phosphorus level, which is consistent with primary hyperparathyroidism but is not expected in secondary or tertiary hyperparathyroidism from CKD, even in a patient prescribed a phosphorus binder. Discontinuing sevelamer would likely increase serum phosphorus but would not treat primary hyperparathyroidism or hypercalcemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient presented has a normal 25-hydroxyvitamin D level, so supplementation would not appropriate at this time. Calcitriol might lower the PTH level but would likely worsen hypercalcemia and therefore would not be the best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hydrochlorothiazide increases calcium reabsorption in the kidney, it is unlikely to cause such significant hypercalcemia. Discontinuing the drug may improve the hypercalcemia slightly but would not address the cause of increased PTH production.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s FGF-23 level will likely be elevated because of his moderate CKD, but measuring serum FGF-23 would not advance the diagnosis or management of primary hyperparathyroidism.</p>\n</div>",
        "references": [
            "Cai MM, McMahon LP, Smith ER, et al: Hyperparathyroidism in chronic kidney disease: complexities within the commonplace.Clin Med (Lond)12(4): 333‒337, 2012",
            "Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.Kidney Int71(1): 31–38, 2006",
            "Hyder R, Sprague SM: Secondary hyperparathyroidism in a patient with CKD.Clin J Am Soc Nephrol15(7): 1041–1043, 2020",
            "Lau WL, Obi Y, Kalantar-Zadeh K: Parathyroidectomy in the management of secondary hyperparathyroidism.Clin J Am Soc Nephrol13(6): 952–961, 2018"
        ]
    },
    "75": {
        "question": "<div class=\"qtext\"><p>A 65-year-old woman presents for evaluation of one year of polyuria and polydipsia. She has no past medical history and takes no prescription or over-the-counter medications. She reports a two-year history of chronic cough. She reports no risk factors for chronic mycobacterial or fungal infection. She has a 40-pack-year history of smoking, and family history is only positive for diabetes in her mother.</p>\n<p>She reports ongoing polyuria, including overnight. She drinks 4–5 L of water daily due to thirst. \n</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<p><strong>Result</strong> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;30%;\">\n<p><strong>Reference Range</strong> </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Sodium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>145 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>136–145 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Potassium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.8 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5 .0 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Chloride </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>111 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98–106 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Total CO<sub>2</sub> </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>17 mEq/L </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>23–28  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>BUN </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8–20 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Creatinine </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1.3 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>0.5–1.1</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Glucose </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>98 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>70–99, fasting  </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Calcium </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>11.8 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>8.6–10.2 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Phosphorus </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>2.6 mg/dL </p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.0–4.5 </p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>Albumin</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>4 g/dL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3.5–5.5</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>PTH</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>3 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>10–65</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>25-Hydroxyvitamin D</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>32 ng/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>30–60</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>1,25-Dihydroxyvitamin D</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>85 pg/mL</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>15–60</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Urine dipstick shows specific gravity of 1.006, pH 5, 2+ glucose, no blood, and no protein. Spot urine protein-to-creatinine ratio is 0.8 mg/mg (reference range, &lt;0.2).</p>\n<p><strong> Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Multiple myeloma"
            },
            {
                "label": "B.",
                "text": "Milk-alkali syndrome"
            },
            {
                "label": "C.",
                "text": "Sarcoidosis"
            },
            {
                "label": "D.",
                "text": "Primary hyperparathyroidism"
            },
            {
                "label": "E.",
                "text": "Squamous cell lung carcinoma"
            }
        ],
        "correct_answer": "Sarcoidosis",
        "abim_content_category": "Calcium, Phosphorus and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with hypercalcemia and an elevated 1,25-dihydroxyvitamin D level is sarcoidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common renal abnormality identified in patients with sarcoidosis is hypercalciuria (50% of cases). Hypercalciuria, which may be accompanied by hypercalcemia (10% of cases), occurs via overactivation of 1α-hydroxylase in macrophages, leading to hydroxylation of 25-hydroxyvitamin D to the active metabolite, 1,25-dihydroxyvitamin D or calcitriol. This leads to hypercalcemia via enhanced intestinal absorption and renal reabsorption of calcium. PTH levels will be low, as both calcitriol and hypercalcemia decrease PTH release. Consequences of the dysregulated calcium metabolism in patients with sarcoidosis may include AKI from vasoconstriction and calcium-mediated volume depletion, increased risk of nephrolithiasis, nephrogenic diabetes insipidus, and progressive CKD due to chronic tubulointerstitial damage and nephrocalcinosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although patients with elevated calcitriol levels can have hyperphosphatemia from increased gastrointestinal phosphorus absorption, this patient shows evidence of Fanconi syndrome, with hypophosphatemia, euglycemic glycosuria, and proximal renal tubular acidosis. Fanconi syndrome is a rare complication of sarcoidosis-mediated granulomatous interstitial nephritis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypercalcemia in multiple myeloma is mediated by bone breakdown, and although PTH levels would be low as in this case, calcitriol production would also be suppressed. Milk-alkali syndrome results from ingestion of calcium carbonate and sometimes vitamin D, causing AKI, hypercalcemia, metabolic alkalosis, and supratherapeutic 25-hydroxyvitamin D, the latter two of which are absent here. Primary hyperparathyroidism would present with high PTH levels, which result is inconsistent with the findings in this case. Last, hypercalcemia due to squamous cell lung cancer is typically mediated by PTH-related peptide, and the laboratory data would show low PTH, phosphorus, and calcitriol levels (caused by hypercalcemia-mediated inhibition of 1α-hydroxylase).</p>\n</div>",
        "references": [
            "Berliner AR, Haas M, Choi MJ: Sarcoidosis: the nephrologist’s perspective.Am J Kidney Dis48(5): 856‒870, 2006",
            "Dahl K, Canetta PA, D’Agati VD, Radhakrishnan J: A 56-year-old woman with sarcoidosis and acute renal failure.Kidney Int74(6): 817‒821, 2008",
            "Omura D, Hagiya H, Hanayama Y, et al: Successful treatment with glucocorticoid for secondary Fanconi symdrome caused by sarcoidosis.Mod Rheumatol27(3): 545‒547, 2017"
        ]
    }
}